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Abstract
The neuromodulator adenosine is involved in both physiological and patho-
logical activity, such as sleep, epilepsy and stroke. However, the complex
processes underlying the release, transport and clearance of adenosine from
the extracellular space and their interactions are still poorly quantified. In
this thesis I develop the first detailed model of the dynamics of adenosine in
neural tissue, including intracellular and extracellular metabolism, using pa-
rameters taken from an extensive search of the literature. This approach also
identifies physiological and metabolic parameters that have yet to be exper-
imentally measured. The model provides estimates of the range of influence
of adenosine, the distance where the extracellular concentration is greater
than that required for half of the maximum inhibition by the dominant type
of adenosine receptors in the cortex, and suggests that under physiological
conditions the adenosine signal will be highly localised. The model predicts
that adenosine concentration profiles are primarily determined by diffusion
and that neuronal transport and metabolism are the dominant clearance
mechanisms. The model can be used with either experimental or endoge-
nous sources of adenosine, and I apply it to the bath application of adenosine
to a tissue slice, (a method used extensively to study the effect of adeno-
sine on synaptic transmission). The model is used to predict the effective
dose response curve of bath applied adenosine and to compare the effects
of transporter blockers. I then turn to the modelling of biosensors, which
are used extensively to measure the concentration of various analytes in
tissue, including adenosine. Biosensors are often calibrated in a flow injec-
tion system with a known concentration of the analyte. Mathematical and
computational models are used to compare the response characteristics of
biosensors in this free environment with the tortuous environment in which
they are used. An estimated correction factor is obtained together with the
sensitivity of this factor to the characteristics of the biosensor. This work
provides a framework to move from qualitative studies of changes of adeno-
sine in the brain to quantitative analysis of the spatio-temporal dynamics
of adenosine signalling and its influence on networks of neurons.
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Chapter 1
Introduction
Since adenosine was first identified as a neuromodulator (Sattin and Rall
1970), it has been shown to play a prominent role in both physiological and
pathological brain function. Recent developments of electrochemical and
voltammetric biosensors allow adenosine concentrations to be observed at
high spatio-temporal resolutions either in vivo or in vitro (Llaudet et al.
2003; Swamy and Venton 2007). Adenosine signalling is complex with mul-
tiple sources and release sites that vary with brain region and stimulus.
Adensoine has different effects on cells depending on the class of receptor and
may also interact with the receptors for other neuromodulators. However,
there is little work on the diffusion and clearance of adenosine in the brain.
Here a detailed model of adenosine transport in neural tissue is constructed,
based on an extensive search of the literature and includes approximations
of extracellular and intracellular metabolism. A mathematical description
of biosensors themselves is then developed to estimate the concentration
necessary to produce the observed response, so that the predictions of the
model could be better compared and validated against experimental work.
1.1 Neurotransmitters and neuromodulators
The brain is principally composed of two cell classes; neurons which commu-
nicate with one another forming networks capable of processing information,
and glia which are traditionally viewed as having a supportive role, provid-
ing electrical insulation and metabolic support, but have also been shown to
play a role in signalling (Araque et al. 1999). The membrane potential of
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neurons is able to change rapidly, due to voltage-gated ion channels. Given
enough stimulation the membrane will rapidly depolarise in an action po-
tential or spike. This can be communicated to other neurons via electrical
or chemical synapses. In general a neuron is formed of three distinct parts;
dendrites, a branching structure that receives input from other cells, the
cell body, and an axon which communicates the signal to other cells and
can be insulated by myelin, produced by glia, to speed up conduction. The
membrane potential of the giant axon of a squid was first described mathe-
matically by the Hodgkin-Huxley model (Hodgkin and Huxley 1952), which
has been widely applied to many neurons in many species (Pospischil et al.
2008). The state variables are the membrane potential together with gating
variables for the potassium and sodium ion channels. At the resting po-
tential (∼−70mV) both the sodium and potassium channels are closed. As
the membrane potential is increased the sodium channels open causing the
membrane to rapidly depolarise producing an action potential. This causes
the sodium channels to close and opens the potassium channels (∼40mV),
which polarises the neuron. The potassium channels start to close, but are
relatively slow, so the neuron may become hyper-polarised after the spike.
The action potential is a signal that is communicated to other neurons via
synapses. A chemical synapse is formed by two growths (bouton) that leave
a small gap or synaptic cleft (∼10nm) between the axon of the presynap-
tic neuron and the dendrite or cell body of the postsynaptic neuron. The
action potential causes some vesicles in the presynaptic terminal to fuse
with the membrane, releasing neurotransmitter into the synaptic cleft. The
neurotransmitters rapidly diffuse across the synaptic cleft and activate cor-
responding receptors. The effect this has on the membrane potential of the
postsynaptic neuron depends on the neurotransmitter. In general synapses
can be inhibitory e.g. γ−aminobutyric acid (GABA) or excitatory e.g. glu-
tamate. The effect also depends on the current membrane potential and
the reversal potential.The membrane potential, where the neurotransmitter
causes no net flow of ions e.g. in the mature rat brain GABA has a reversal
potential of ∼−70mV so is inhibitory, whereas in the immature brain it is
∼−40mV so is excitatory (Ben-Ari et al. 2012).
Glia can also be involved in synaptic transmission, particularly a star shaped
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class of glia, astrocytes. These can encase synaptic connections and respond
to activity over multiple synapses, elevating intracellular Ca2+ and causing
the release of gliotransmitters, such as ATP, which can directly influence
both the presynaptic and postsynaptic neuron, (Araque et al. 1999) as well
as being metabolised extracellularly to produce adenosine. Astrocytes also
shuttle lactate to neurons as a source of energy (Chih and Roberts 2003).
Astrocytes communicate with one another via gap junctions, which allow
both chemical and electrical signals to pass between them (Nagy et al. 2004).
Direct communication between neurons is also supplemented through broad-
cast communication by neuromodulators. Several neuromodulators have
been identified; dopamine, acetylcholine, adenosine, noradrenaline, and sero-
tonin (Rang et al. 2003). Neuromodulators are distinct from neurotransmit-
ters in that they influence a relatively large volume of brain tissue, although
there are chemicals that serve as both neurotransmitters and neuromodula-
tors, such as acetylcholine. Neurotransmitters are rapidly cleared from the
synaptic cleft, preventing them from influencing other cells, however they
can spill over e.g. by blocking glutamate transporters (Diamond 2001).
Neuromodulators must diffuse through the extracellular space (ECS) to in-
fluence a volume of tissue. To quantify the spatio-temporal dynamics of
adenosine it is essential to account for the effect of the tissue’s geometry.
Brain tissue essentially resembles a foam, with the cells representing the
bubbles and the ECS the water (Kuﬄer and Potter 1964). As neuromodu-
lators like adenosine cannot easily cross the cell membranes their diffusion is
impeded by the tortuosity of the ECS. Tortuosity is a multiplicative factor
of the path length for diffusing particles, due to the geometry of its envi-
ronment. It is empirically defined as the square root of the ratio of the free
to tortuous diffusion coefficients and has been experimentally determined
for many brain regions, with a range of 1.2 − 1.8 (Nicholson 2001). Action
potentials are not modelled in this work, but are considered as a way of
characterising the range of influence of adenosine.
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1.2 Adenosine as a neuromodulator
Adenosine was first implicated in extracellular signalling through investiga-
tions into cardiac function in 1929 by Drury and Szent-Gyorgyi, but it was
not until the 1970s that it was shown to act as a neuromodulator, initially
by the observation of adenosine-mediated changes in cyclic-AMP in guinea
pig cortical slices (Sattin and Rall 1970). Adenosine influences cell sur-
face G-protein coupled receptors (GPCR), also called serpentine receptors
or heptahelical receptors, because they weave through the cell membrane
seven times. They are metabotropic as opposed to ionotropic receptors as
they are indirectly linked with ion channels. Initially two classes of GPCRs
were identified for purines, P1R (for adenosine) and P2R (for ATP/ADP)
(Burnstock 1978), the P1R was later subdivided into four types of adeno-
sine receptor A1R, A2AR, A2BR and A3R (Calker et al. 1979; Van Calker
et al. 1978; Bruns et al. 1986; Ribeiro and Sebastiao 1986). Broadly A1R
mediates a decrease in cyclic AMP levels. It activates several types of K+
channels and inactivates other channels including Ca2+ (Fredholm et al.
2001a). A2AR and A2BR mediate an increase in cyclic AMP levels, they
have high and low binding affinities respectively and A3R mediates a reduc-
tion in calcium currents (Chin 1989). It also seems to play a role in many
conditions, e.g. It has been shown to have both a protective and degenera-
tive role during ischemia, a restriction in blood supply (Gessi et al. 2008).
In the cortex adenosine acts to reduce neuronal activity via A1Rs. Pyramidal
neurons form excitatory glutamatergic synapses. When an action potential
reaches such a synapse it can result in a small voltage change in the post-
synaptic neuron, called an excitatory postsynaptic potential (EPSP). Such
EPSPs can be observed directly via intracellular recording, where a sharp
glass micropipette filled with a conductive ionic solution is inserted into the
cell body or the dendrites, and the voltage is recorded. The characteristic
shape of an EPSP is a rapid rise followed by slow exponential decay (Figure
1.1). Adenosine is able to reduce the amplitude of the EPSP by activating
the A1R which opens several types of potassium channels while closing some
types of calcium channels. (Fredholm et al. 2001b). Extracellular recordings
involve a microelectrode being inserted into the extracellular space to record
the local field potential (LFP). When several neurons spike at the same time
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a population spike can be observed followed by a field EPSP (fEPSP), which
is also used to study the influence of adenosine (Dunwiddie and Diao 1994).
There is usually some adenosine in the extracellular space. This concentra-
tion is called the adenosine tone or endogenous tone and has been observed
in vivo and in vitro either directly via microdialysis (Sharma et al. 2014),
and biosensor recordings (Wall et al. 2007; Sims et al. 2013) or indirectly
by observing the changed EPSPs (Figure 1.1), inhibitory postsynaptic po-
tentials and fEPSPs (Kerr et al. 2013; Zhang et al. 2015; Dunwiddie and
Diao 1994; Clasadonte et al. 2014). The endogenous tone observed varies
with brain region, species and methodology, but is usually between 200nM
and 1µM (Dunwiddie and Masino 2001). It is known to increase during
wakefulness and reduce during sleep (Sims et al. 2013) and has been shown
to increase during development (Kerr et al. 2013).
Figure 1.1: An endogenous tone of adenosine is present in the cortex
and additional adenosine further reduces excitation. Paired intracellu-
lar recordings of two connected rat neocortical layer 5 pyramidal cells, where a
presynaptic neuron is stimulated to produce an action potential, producing an
EPSP recording in the postsynaptic neurons. This shows an endogenous tone of
adenosine in the mature and immature rat cortex, revealed by A1R antagonist
8-cyclopentyltheophylline (8CPT), but the tone is far greater in the mature rat
cortex. Additional bath applied adenosine in still able to reduce the amplitude of
the EPSP. Extracted from figure 1F (Kerr et al. 2013).
Adenosine has been implicated in many psychological disorders, as in the
adenosine hypothesis of schizophrenia (Fuxe et al. 2009; Boison et al.
2011) and in degenerative diseases through the use of A2AR agonists. In
Alzheimer’s disease the agonists have been shown to improve cognitive func-
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tion (Rahman 2009) and in Parkinson’s Disease to reduce the characteristic
motor deficits (Schwarzschild et al. 2006). Adenosine receptors are ex-
pressed ubiquitously throughout the brain, and adenosine has been impli-
cated in a multitude of different functions. In the cortex and hippocampus,
adenosine is thought to be important for working memory (Singer et al.
2012), through the balance of A1R and A2AR activation. Adenosine is able
to shape striatal function though receptor heterodimers, where the adenosine
GPCR is linked with another e.g. A2AR and dopamine D2R. In addition
adenosine can effect glutamate signalling, e.g. alcohol drinking increases
in mice with impaired adenosine clearance (Lee et al. 2012). In the cere-
bellum adenosine has been shown to modulate ethanol and cannabinoid
induced ataxia (Dar and Mustafa 2002). Subsequently adenosine has be-
come a promising target for pharmacological treatments for a wide array of
cognitive, mood and degenerative disorders (Chen et al. 2013). However
the key areas of adenosine study are sleep, epilepsy and hypoxia.
1.2.1 Sleep cycles
Caffeine, the worlds most popular recreational drug, is an adenosine recep-
tor antagonist and promotes wakefulness, whilst adenosine is thought to
promote sleep, the concentration of extracellular adenosine increases during
wakefulness and decreases during sleep. For example microdialysis showed
an increase in adenosine tone ∼30% in the basal forebrain during the dark
cycle (Murillo-Rodriguez et al. 2004), similarly biosensor measurements in
mouse hippocampal slices showed a ∼70% decrease in adenosine tone be-
tween the light and dark cycle (Schmitt et al. 2012).
Conversely, interfering with adenosine concentration influences the dura-
tion of sleep and wakefulness, e.g. direct intracerebroventricular infusion of
adenosine in rats reduced the time spent awake by ∼30% (Virus et al. 1983)
and ethanol leads to increases in extracellular adenosine in the perifornical
hypothalamus, due to the effect of ethanol on adenosine clearance. This in-
crease in extracellular adenosine acts on the A1R of orexin neurons, a class
of neurons which produce orexin, a neuropeptide involved in wakefulness
and appetite. This inhibition reduces stimulation of wake-active neurons
and increases sleep (Sharma et al. 2014). In addition to changes in the
concentration of adenosine during the sleep wake cycles, changes have also
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been observed in the enzymes involved in metabolising adenosine. For ex-
ample, higher enzyme activity was observed in brain homogenates from the
rat cortex taken at night (Kova´cs et al. 2011).
Adenosine fulfils many of the requirements of a sleep regulatory substance
and may be a molecular marker of sleep drive; infusion of adenosine pro-
motes sleep, concentration increases with sleep deprivation and disruption
of receptors or metabolism alters sleep. However, the rapid clearance of
extracellular adenosine makes it unlikely that it is involved in long term
sleep maintenance, instead influencing sleep transitions and intensity (Holst
and Landolt 2015; Krueger et al. 2013). This work quantifies how rapidly
adenosine is cleared from the ECS and the influence sleep-wake changes in
metabolism have on this clearance rate.
1.2.2 Epilepsy and seizures
Epilepsy is a condition where the subject is prone to seizures, characterised
by hypersynchronous discharge of a population of neurons. The excessive
neuronal activity can cause damage to the tissue and cell death. Adenosine is
released during seizures (Figure 1.2) and is involved in seizure termination,
primarily via the A1R. The application of adenosine receptor antagonists
have a proconvulsant effect, whilst agonists reduce the length of seizures
(Dunwiddie and Masino 2001). Endogenous adenosine builds up during
seizures, e.g. measurements made by fast-scan cyclic voltommetry (FCSV)
found a 260% increase in extracellular adenosine prior to seizure termina-
tion (Van Gompel et al. 2014), while biosensor measurements found an
increase of 3.2µM’ of adenosine and its breakdown products (Etherington
et al. 2009).
Adenosine regulation may also cause epilepsy. Adenosine kinase (ADK) is
an enzyme that catalyses the transfer of a phosphate from adenosine triphos-
phate (ATP) to adenosine, resulting in adenosine diphosphate (ADP) and
adenosine monophosphate (AMP). The ADK hypothesis of epileptogenesis
suggests ADK as a diagnostic marker of epilepsy, with overexpression of
ADK in mice reducing adenosine tone and increasing seziure activity, with
increased sensitivity to brain injury from seizure (Boison 2008).
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Figure 1.2: Adenosine biosensor signal rises in response to pathological
network activity. Seizures induced in slices of the rat somatosensory neocortex
with magnesium free solution, produce a large increase in the adenosine (ADO)
biosensor signal but not the null sensor. The ADO biosensor is sensitive to adeno-
sine, inosine and hypoxanthine. So the rise must be due to an increase in extracel-
lular adenosine, or its breakdown products inosine and hypoxanthine. Extracted
from figure 5A (Wall and Richardson 2014).
1.2.3 Hypoxia-ischemia
A lack of oxygen (hypoxia) or an inadequate blood supply (ischemia) to
brain tissue results in a rapid increase in extracellular adenosine (Dale and
Frenguelli 2009). Adenosine released during hypoxia can have a neuropro-
tective effect by reducing electrical activity, conserving energy and causing
vasodilation, attempting to increase the supply of blood and oxygen. Hy-
poxic adenosine release is dependent on prior exposure to hypoxia and can be
displaced e.g. Within 5 minutes of hypoxia adenosine increased by 3.0µM’
in rat hippocampal slices, but this was reduced by ∼45% in a second hypoxic
insult 28 minutes later (Frenguelli et al. 2003).
1.2.4 Adenosine sources
Adenosine can form in the extracellular space by metabolism of ATP, which
is released at synapses as a co-transmitter or from hemichannels in astro-
cytes. Adenosine could also be released directly by transporters or by ex-
ocytosis (Figure 1.3). There is evidence for multiple release pathways de-
pending on brain region and the nature of the stimulus. Adenosine released
spontaneously due to endogenous activity (Nguyen et al. 2014) or exper-
imentally by stimulating cells is termed activity-dependent release (Wall
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and Dale 2007; Wall and Dale 2013; Pajski and Venton 2010; Klyuch et al.
2011; Swamy and Venton 2007). Adenosine may be neuroprotective, and
is released as a result of insults, such as hypoxia, ischemia, oxygen glucose
deprivation, mechanical stimulation (Frenguelli et al. 2003; Frenguelli et al.
2007).
Figure 1.3: Possible mechanisms for adenosine release. 1) ATP can be re-
leased into the extracellular space as a co-transmitter at synapses from hemichan-
nels in astrocytes, which can then be metabolised resulting in adenosine. 2) Indirect
adenosine release can occur when another signalling molecule such as glutamate
provokes adenosine release from a downstream cell. 3) Adenosine can be released
directly either by exocytosis or via transporters. Figure 1 from (Wall and Dale
2008).
Activity-dependent release in the striatum following low frequency stimu-
lus was greatly diminished (∼60%) by chemically inhibiting extracellular
degradation of ATP, but release following a high frequency stimulus was un-
affected. Furthermore neither were affected by inhibiting cellular transport
and the release was dependent on both calcium and glutamate receptors,
suggesting the stimulated neurons signalled other cells which then released
adenosine by exocytosis (Pajski and Venton 2010). With focal stimulation
in the mouse hippocampus ∼60% of the rise in extracellular adenosine is
due to extracellular metabolism of ATP (uncovered using CD73 knockout
mice) with ∼40% of adenosine release due to transporters (Wall and Dale
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2013). In the cerebellum half of activity-dependent adenosine release is due
to metabolism of ATP release by exocytosis from parallel fibers. There are
multiple source of adenosine, this work estimates their duration and range
of influence, which is essential to quantify their impact on network dynamics.
1.3 Volume transmission
Volume transmission (VT) in the brain refers to all the possible mechanisms
that cells could utilise for communication without the need for a connection,
such as a synapse or a gap-junction. These mechanisms have been divided
into physical and chemical signals. The physical signals could comprise of
pressure waves, temperature values and electrical currents (local field poten-
tials). The chemical signals are where a cell releases some substance, (neu-
romodulator, growth factor, etc.) into the ECS, which then diffuses along
concentration, electrical, temperature and pressure gradients to other cells.
The chemical signals can be further classified by whether they are: ‘Safe’,
reach the destination unaltered, (e.g. microvesicles, exosomes) or ‘Unsafe’,
(e.g. neuromodulators, neurotransmitters). ‘Reserved’, only received by
cells with specialised mechanisms for decoding the signal (e.g. adenosine
require GCPR) or ‘Broadcast’ (e.g. carbon dioxide). Lipophilic, able to
pass through the cell membrane (e.g. carbon dioxide) or Hydrophilic (e.g.
neuromodulators). Focusing on neuromodulators in general and specifically
adenosine, it is an unsafe reserved hydrophilic chemical signal. (Agnati et al.
2010).
Reaction-diffusion dynamics in tissue have been studied at different lev-
els of description, particularly focused on the non-linear Michaelis-Menten
kinetics, which characterises many enzyme reactions and active transport
mechanisms (section B.1). Assuming a well-mixed system, the state can be
described by a vector where each element represents the number of molecules
of a chemical species. Representing reactions as transition probabilities be-
tween states gives rise to the chemical master equation, (CME) a Markov
process that provides a full stochastic description of the system. In a well
mixed system at thermal equilibrium (so the probability of a collision be-
tween chemical species is the same throughout the system), in the gas-phase
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(so from collision theory the reaction rate will follow a Maxwell-Boltzmann
distribution) the CME can be derived from a microphysical description of
the system (Gillespie 1992).
The chemical Langevin equations (CLE) is a continuous approximation of
the CME (which is valid when the system is sufficiently large), dealing with
the concentration of each substance (Gillespie 2000). So instead of a vector
representing the number of each chemical species, there is a vector repre-
senting the concentration of each chemical species and the transitions follow
a Gaussian distribution. Reaction rate equations (RRE) are deterministic
approximations of the CLE, i.e. the mean of the CLE and are valid when
the system is large enough that the fluctuations are relatively small. This
can be further reduced using a Quasi-steady-state approximation (QSSA)
to give a one-dimensional ODE (discussed in section B.1).
In order to allow for spatial non-uniformity in the distribution of substances
that occur in tissue, general purpose computational tools have been de-
veloped e.g. MesoRD (Hattne et al. 2005) and Smoldyn (Andrews and
Bray 2004), which have been applied to specific problems in systems bi-
ology, including general problems such as simulating diffusion in various
tortuous topologies (Tao and Nicholson 2004) and specific problems such as
determining the roles of different NMDAR subtypes (Farzan 2010). Here a
macroscopic model of tissue is developed, it could be extended to included
microscopic features of tissue, but little is known about the distribution of
the model components at a subcellular scale.
1.3.1 Volume fraction
Activity of signalling molecules in the ECS interacting with receptors, en-
zymes and transporters depends on their concentration. The concentration
can be defined in two ways; the total concentration, ratio of the amount
of substance with the volume of tissue, or the relative concentration, the
ratio of the amount of substance with the volume of the ECS. The two con-
centrations are related by the free volume fraction, the volume of the ECS
divided by the volume of the tissue α which is around 20% in neural tissue,
but can fall to ∼5% in pathological conditions (Sykova´ et al. 1994). It is
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the relative concentration which is relevant when considering the influence
and clearance of adenosine, however many experimental results are given in
terms of the total concentration.
1.3.2 Cellular transport
Adenosine is a nucleoside, a subunit of nucleic acid adenine, and can be
transported across cell membranes by nucleoside transporters (NT). The
NT are divided into two solute carrier families, SLC28 the concentrative
NT (CNT) and SLC29 the equilibrative NT (ENT), ENTs are further subdi-
vided into four classes ENT1 transport is inhibited by nitrobenzylthioinosine
(NBMPR) whereas ENT2 is insensitive to NBMPR. The other two classes
ENT3 and ENT4 are less well characterised and are thought to be primarily
involved with transport within cells (Baldwin et al. 2004). ENT1 is ubiqui-
tously expressed, they have been ‘ultralocalised’ to subcellular structures in
the rat spinal cord and are found on the soma of neurons, myelinated and
unmyelinated axons, glial and oligodendrocytes. They are expressed both
presynaptically and postsynaptically. However there is some evidence that
they are more densely concentrated in the region around the soma (Governo
et al. 2005). The role of ENTs have also been explored using transgenic mice
which lack ENT1 (Choi et al. 2004). The CNTs are sodium/nucleoside co-
transporters and have been divided into three subtypes, CNT1, CNT2, and
CNT3. CNT1 and CNT2 are found in the rat brain (Anderson et al. 1996),
with CNT2 having a greater affinity for adenosine. However research has
focused on the role of ENTs as there are currently no good inhibitors for
CNTs. Within cells diffusion is far slower, ∼5 − 20 times than free diffu-
sion. This is primarily due to macromolecular crowding (Schnell and Turner
2004), so is less relevant to the range of adenosine signalling that extracel-
lular diffusion. In addition purines are transported between the cytosol and
the nucleus and mitochondria, but this is unlikely to play a substantial role
in adenosine clearance.
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1.4 Purine metabolism
Purines consist of two rings, and form many biologically significant com-
pounds including two of the nucleotide bases adenine and guanine. The
purine metabolism is a group of 27 enzymes catalysing reactions for syn-
thesis, recycling, conversion and disposal of the various purines. Adenosine
triphosphate (ATP) is known as the molecular unit of currency, as it is used
ubiquitously for energy storage and transfer. The evolution of purines for
signalling may be as a result of the ever-present nature of ATP.
Hypoxathine
Xanthine
Inosine
PNPase
XO IMP
HGPRT
Adenylosuccinate
ADSL
ADSS
AMP
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Adenosine
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ATP
AK
ATPase
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XO
PNPase
Adenine
APRTase
AMN
de novo synthesis
sugars and 
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Pruine metabolism excerpt
S-Adenosyl-L-homocysteine 
AdoHcyase
ADA
Figure 1.4: The purine metabolism responsible for synthesis, sal-
vage and removal of adenosine. The enzymes shown are; s-adenosyl-L-
homocysteine hydrolase (AdoHcyase), polynucleotide phosphorylase (PNPase),
adenine phosphoribosyltransferase (APRTase), adenosine monophosphate nucleosi-
dase (AMN), adenosine deaminase (ADA), 5′-nucleotidase (5′N), adenosine deami-
nase (ADA), adenosine kinase (ADK), ATP monophosphatase (ATPase), adenylate
kinase(AK), adenylosuccinate lyase (ADSL), adenylosuccinate synthetase (ADSS),
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), 5′-nucleotidase II (5′N
II), polynucleotide phosphorylase (PNPase) and xanthine oxidase (XO). This is only
a part of the full purine metabolism and many of the enzymes are involved in ad-
ditional reactions not depicted here. E.g. ADK transfers a phosphate from ATP
to adenosine resulting in an ADP and AMP molecule.
There are two sources of AMP, de novo synthesis or building it from the com-
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ponent parts (sugar and amino acids) and the salvage pathway, where the
by-products of consuming ATP are recycled (Berg et al. 2002). The de novo
pathway first involves 10 reactions to create inosine monophosphate (IMP),
the salvage pathway can convert products such as ADP, AMP, adenosine,
inosine, IMP or hypoxanthine to ATP (Figure 1.4). Under resting conditions
there is considerable activity through the futile cycle between adenosine and
AMP (Dunwiddie and Masino 2001).
Immunohistochemistry is used to locate specific enzymes (Nagy et al. 1985)
or transporters (Guille´n-Go´mez et al. 2004) within the brain. This infor-
mation is useful in deciding which processes may be relevant for adenosine
clearance and for comparing brain regions. Quantitative information for the
enzymes of purine metabolism have been determined in either the whole rat
brain or the rat cortex, principally by dissecting the brain and homogenising
it in a centrifuge. Then different concentrations of the substrate are added
to the homogenate to measure the initial rate at which the reaction prod-
ucts are formed, which provides an estimate of the enzyme kinetics. The
transporters require the cells to remain intact, so while they can be located
immunohistochemically, the kinetics can be quantified using radio or flores-
cent labelled purines, and cell cultures rather than brain tissue. However
there is little work on the diffusion and clearance of adenosine in the brain,
with the kinetics of only a few of the enzymes in the purine metabolism and
some of the aspects of transport available. The complex and multifaceted
role of adenosine in both physiological and pathological tissue is further
masked by multiple release and removal mechanisms.
1.5 Measuring extracellular adenosine concentra-
tion
Early methods of measuring adenosine concentrations include direct mea-
surement of the CSF via dialysis or microdialysis, which has good chemical
resolution but poor temporal resolution (typically around 10 minutes) and
due to the large probe size (> 200µm) is likely to cause significant tissue
damage, effecting tissue up to 1mm from the site (Robinson et al. 2008). De-
structive techniques, such as rapid freezing and homogenisation of brain tis-
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sue have also been used (Winn et al. 1979), however it is not clear how much
the methodology will distort these measurements. Indirect measurements
provide a qualitative estimate of the amount of adenosine by measuring its
effect on cells via electrophysiology (Dunwiddie and Diao 1994), however it
is difficult to infer the concentration of adenosine as the effect of additional
adenosine depends on the amount present, described by the dose response
curve of the receptor. More recently positron emission tomography has
been used, which requires the use of labelled receptor agonist/antagonists
that are subsequently displaced by endogenous adenosine (Paul et al. 2011).
Recent developments in microelectrode biosensors (Frenguelli et al. 2003)
and fast-scan cyclic voltammetry (Swamy and Venton 2007) allow adenosine
concentration in tissue to be measured directly at high spatio-temporal res-
olution. However FSCV and biosensors remove the adenosine they detect,
potentially resulting in a significantly lower concentration near the biosensor
surface, this work estimates the extent of this effect has on a biosensor signal.
1.6 Outline
Here two problems are addressed, the first relating to adenosine clearance in
the brain. Information about the various clearance process is taken from an
extensive literature review and used to; construct the first detailed model of
adenosine clearance, estimate both the range of influence and the duration
of an adenosine signal, and identify aspects of adenosine cleanse that have
yet to been quantified. The second is to evaluate the efficacy of biosensors,
which are extensively used to measure the concentration of neuroactive sub-
stances, (including adenosine) in neural tissue. To achieve this a mathemat-
ical model is constructed for a tortuous tissue environment and compared
with a model for the free-flow calibration environment.
In chapter 2 a hierarchy of adenosine transport models are constructed to
evaluate the relative significance of the different clearance mechanisms. Sev-
eral abstractions necessary to create a parsimonious description of adenosine
dynamics are explained, such as not including ATP concentrations and lim-
iting the intracellular space to two cell classes; neurons and glia. Details
of the parameter estimates are given, together with how they are inferred
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from the information obtained from an extensive literature search. Chap-
ter 3 outlines the model prediction and the limits where the model can be
solved analytically and via numerical solutions. These indicate a dominant
role for diffusion and neuronal clearance, as well as the influence of endoge-
nous tone on clearance mechanisms. In chapter 4 the biosensors used to
monitor adenosine activity in brain slices are modelled at microscopic and
macroscopic levels. Particle simulations, analytic and numeric solutions are
obtained in 2D and 3D, showing that a correction is required when biosensors
are calibrated in a free environment, but used in a tortuous one. Finally
the conclusion and discussion of the findings and limitations are given in
chapter 5.
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Chapter 2
Models and parameters
available in the literature
2.1 Introduction
This chapter describes the first detailed model of adenosine transport in
neural tissue, including an approximation of extracellular and intracellular
metabolism. Adenosine is involved in physiological and pathological brain
function, so it would be beneficial to be able to predict the duration and
range of influence of endogenous adenosine. Adenosine is removed from tis-
sue by various clearance mechanisms, which may be be pharmacologically
blocked (Dunwiddie and Diao 1994) or genetically removed (Choi et al.
2004). To quantify the relative importance of the clearance mechanisms a
hierarchy of models is constructed. The structure of the models is general
and can be adapted to different tissue, however as an example, rat corti-
cal tissue is modelled, using parameters obtained by an extensive literature
search. Due to the current ambiguity in adenosine release pathways (Wall
and Dale 2008; Dale and Frenguelli 2009; Nguyen et al. 2014), four abstract
endogenous sources are considered: A constant uniform and a constant point
source, appropriate for modelling the basal tone of adenosine, a brief uni-
form source and a brief point source, corresponding to activity-dependent
and spontaneous release events. The models are applicable to experimental
setups, and bath application of adenosine for tissue slices is considered so
as to inform experimental work.
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The process of release and clearance of extracellular adenosine and the ap-
propriate scale at which to model these processes in tissue is discussed. This
allows the development of a hierarchy of models and consideration of how
reasonable parameters can be inferred from the available literature. The
analytic and numerical solution for the models is described, with discussion
of how it can be applied or compared with experimental work, and the lim-
itations of the approach adopted.
2.2 Model components
A number of physiological processes, and a hierarchy of models is consid-
ered. Removal of adenosine from the extracellular space depends on cellular
uptake and the purine metabolism. Enzymes of the purine metabolism can
either build on the adenosine molecule, creating AMP then ADP and ATP or
breakdown the adenosine molecule giving rise to inosine then hypoxanthine.
A macroscopic model is developed, so appropriate scales are micrometres,
seconds and micro molars, therefore amounts are stated in zeptomols, be-
cause 1zmol in 1µm3 is 1µM.
2.2.1 Adenosine source
A number of spatiotemporal patterns for adenosine sources are considered.
There is uncertainty regarding the mechanisms for endogenous adenosine re-
lease, with evidence for multiple release pathways depending on the brain re-
gion and the nature of the stimulus (Swamy and Venton 2007; Wall and Dale
2008; Cechova et al. 2010; Klyuch et al. 2012a; Nguyen et al. 2014). With
little known about the amount of adenosine released, a range for the source
function S(t, x) has to be inferred. Adenosine could enter the extracellular
space as a result of metabolic break down of ATP, so the metabolic cost of ac-
tivity suggests the relevant order of magnitude. Many activities metabolise
ATP such as; vesicle release 300zmols, mini-EPSP, 1, 000zmols, action po-
tential 640, 000zmol and a neuron 570, 000zmol/s or glia 170, 000zmol/s at
rest (Attwell and Laughlin 2001; Silver et al. 2003). These estimates of
ATP consumption suggest a reverent scale, not a specific source intensity,
as it is not clear how much of the ATP consumption would ultimately be
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converted to adenosine or how much of the adenosine created though energy
consumption would be released into the extracellular space.
The source term S(t, x) in equations (2.17), (2.20), (2.22), (2.28) and (2.34),
for a constant uniform source is S(t, x) = C [µM/s], whereas a brief uniform
source S(t, x) = C0δ(t) [µM]. For a constant point source S(x) = δ(x)F
[zmol/s] and a brief point source S(t, x) = δ(x)δ(t)F0 [zmol]. To inform
experimental work, bath applied adenosine is considered, where the bath-
applied concentration provides the surface boundary condition with a fixed
concentration at the top and bottom of the slice.
2.2.2 Deamination in the extracellular space and within neu-
rons
Adenosine deaminase (ADA), irreversibly deaminates adenosine to inosine.
This is modelled in the QSSA of MM kinetics (Eq. 2.6), although prod-
uct inhibition, where large amounts of inosine inhibits ADA, have been ig-
nored, (which is justified as the effect requires relatively high concentrations,
Ki = 143µM) (Saboury et al. 2002). ADA is part of both the extracellu-
lar metabolism (ecto-ADA) and the neuronal metabolism for a subset of
neurons, including those in restricted areas of the cortex and striatum (Ya-
mamoto et al. 1987). Immunohistochemistry suggests ADA is either absent
in glia or present in such low concentration as to be undetectable (Nagy
et al. 1984; Yamamoto et al. 1990). Cultures show activity for both neu-
rons and glia, which may be due to membrane bound ecto-ADA. In these
models ADA is limited to the extracellular and neuronal metabolism.
2.2.3 Phosphorylation within glia
The purine metabolic pathway contains several cycles, the most important
for controlling basal levels of adenosine is the cycle of AMP to adenosine
via 5′-nucleotidase (5′N) and adenosine back to AMP via adenosine kinase
(ADK) or to ADP via adenylate kinase (AK). AK catalyses the reaction
AMP + ATP ↔ 2ADP and is in part responsible for amplifying small
changes in ATP concentration to large (20 fold) changes in AMP. Currently
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six isoforms of AK have been identified, AK1, AK4 and AK5 have been
localised to brain tissue (Noma et al. 2005), with AK1 limited to neurons
in the rat and mouse brain (Janssen et al. 2004). AK5 is cytosolic and
shows strong staining for neurons and moderate for glia in humans (Kampf
et al. 2009), whereas AK4 is confined to mitochondrial matrix. Unfortu-
nately the kinetics of AK4 and AK5 are currently unavailable for the rat.
The MM constants of AMP Km = 172µM for AK5 humans (Solaroli et al.
2009), compared to Km = 250µM for 5
′N, suggest AMP will preferably bind
to AK5 in glia for low intracellular concentrations of AMP, so most AMP
will be phosphorylated to ADP. Here AMP, together with ADP and ATP
are not explicitly included in the model, but implicitly through the source
term, as they interact with so many other pathways, so would greatly in-
crease the model’s complexity. This may exaggerate the role of ADK, with
all adenosine that is phosphorylated to AMP being removed from the model.
2.2.4 Clearance and salvage within glia
Adenosine deaminated to inosine by ADA can be metabolised by purine nu-
cleoside phosphorylase (PNPase) to produce hypoxanthine. A series of en-
zymes can then recover AMP from hypoxanthine via hypoxanthine-guanine
phosphoribosyltransferase (HGPRT), or further metabolise it via xanthine
oxidase (XO), so it can be removed by erythrocytes through the blood brain
barrier (BBB). The BBB is a highly selective permeable membrane separat-
ing the blood from the cerebrospinal fluid (CSF) that fills the ECS of the
brain. An unsaturating removal rate (µ8) is used to capture the metabolism
of inosine. The removal of inosine is limited to glia, because transport of
nucleosides through the BBB is mediated by astrocytes, and some evidence
suggests PNPase is restricted to glial metabolism (Castellano et al. 1990),
although other work shows activity in both glia and neurons (Zoref-Shani
et al. 1995; Parkinson and Xiong 2004). Removal though the BBB is only
relevent for applying the model in the in vivo case, in vitro loss though the
surface of the slice will have a substantial effect.
20
2.3 Diffusion and tortuosity
Macroscopic models of tissue take an average over; spatial structures, sources
and sinks, with a smaller diffusion coefficient to account for the tortuosity
of the medium. Macroscopic models of brain tissue are considered valid
for length scales of order 10µm (Nicholson 2005). The concentration of
adenosine and its breakdown products are modelled, so it is necessary to ac-
count for the volume fraction of the extracellular and intracellular space, to
deal with transport between them and to translate the source term from an
amount to a concentration of adenosine. The models described below include
diffusion, described by Laplace operator ∇2 which depends on the coordi-
nate system. For a point source spherical coordinates are used, whereas the
bath applied case is solved in one-dimension, the depth into the slice. For a
uniform source and the diffusion term can be removed from the models. Dif-
fusion in the intracellular space is omitted from the models, this is necessary
for any macroscopic model of tissue. A mesoscopic or microscopic model,
with the geometry of cell membranes and distribution of transporters could
include intracellular diffusion. However, it would be difficult to constrain
the parameters of such a model, given the paucity of information available
at this time.
The extracellular space in neural tissue essentially resembles a foam, with
the cells representing the bubbles and the ECS the water. This structure
is typically described by the volume fraction or permeability (α), the ratio
of extracellular volume to the total volume. As well as the tortuosity (θ),
the proportional increase in the average path a particle must take to move
around obstructions. Early estimates of volume fraction and tortuosity were
performed using radio tracers. They would be perfused into the ventricle
cavities of the brain of a living animal. The animal was then killed and the
brain frozen and sectioned. The radioactivity of sections could be measured
together with their distance from the ventricle cavities, allowing the effective
diffusion coefficient to be estimated. The tortuosity squared θ2 is estimated
as the ratio of the free to effective diffusion coefficients;
θ2 =
D∗
D
(2.1)
where D∗ is the free diffusion coefficient and D is the effective diffusion coef-
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ficient in the torturous medium. Additionally the volume fraction and first
order removal kinetics for the blood brain barrier (BBB) can be inferred
(Blasberg et al. 1975). This method allowed the properties of tissue for a
wide variety of chemicals to be measured. However if the analyte is trans-
ported to the intracellular space or lost too rapidly through the BBB it will
not provide an accurate measurement.
Real-time iontophoresis (RTI) is used to deliver a constant point source of
an ion, e.g. Calcium (Ca2+) or Tetramethylammonium+ (TMA+), which
is then measured using an ion-selective microelectrode (ISM) placed at dis-
tance R, usually 30− 60µm away. Then assuming no entry into cells or loss
across the BBB, the solution to the diffusion equation in spherical coordi-
nates provides a function for the concentration M(t) at the ISM, which is
proportional to the signal. When there is uptake into the cells, (assuming
first order kinetics) the concentration is given by (Eq. 2.3), (Nicholson and
Rice 1987).
M(t) =
Qθ2
4piD∗αR
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√
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Where R is the distance between the iontophoresis source and the ISM, D∗
is the free diffusion coefficient of the ion used and Q is the source strength.
A nonlinear fit of (Eq. 2.2) to the signal obtained from the ISM gives
an estimate of α and θ. This method has been extended to include first-
order removal kinetics and anisotropy (Sykova´ and Nicholson 2008). It has
been used to estimate tissue parameters in many brain regions and species
(Sykova´ and Nicholson 2008). Including 1.6 for layers II-III of the rat neo-
cortex (Pe´rez-Pinzo´n et al. 1995) with values ranging from 1.5 for layer II
and 1.7 for layer VI (Lehmenku¨hler et al. 1993), the diffusion curves for
layer I were not stable possibly due to the small layer width or damage
caused by opening the skull.
The obstacles to diffusion may not be spatially uniform and instead prefer-
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Parameter Value Temperature
D∗ 520µm2s−1 Diffusion coefficient of adenosine at 25.5◦C
(Bowen and Martin 1964) in a free environment
D∗ 690µm2s−1 Diffusion coefficient of adenosine at 37◦C
D∗ 610µm2s−1 Diffusion coefficient of adenosine at 32◦C
D 260µm2s−1 Tortuous diffusion coefficient at 37◦C with tor-
tuosity of 1.6 for rat cortex (Pe´rez-Pinzo´n et al.
1995; Nicholson 2001)
D 230µm2s−1 Tortuous diffusion coefficient at 32◦C
Table 2.1: Free and tortuous diffusion coefficients of adenosine. The
free diffusion coefficient of adenosine was estimated at physiological and exper-
imental temperatures using (Eq. 2.11). The effective diffusion coefficient was
estimated from the tortuosity of the rat cortex determined by the diffusion of
Tetramethylammonium+ (TMA+).
entially inhibit diffusion in a specific direction. In this case the tortuosity,
θ and α are tensors not a scalar. For example, in the rat auditory cor-
tex the additional distance required to move within a layer are 1.5 and 1.7
whereas to go perpendicularly within a column is 1.8, determined using
diffusion-weighted magnetic resonance imaging to monitor the apparent dif-
fusion coefficient of water in each of the directions (Vorˇ´ıˇsek et al. 2002).
It has been suggested that bulk flow of metabolites is an important clearance
mechanism, referred to as the glymphatic pathway (Nedergaard 2013; Iliff
et al. 2012). Flow has been observed in vivo through a closed cranial
window in mice, where CSF passes through the para-arterial space where
aquaporin-4 (AQP4) channels on astrocytes facilitated convective flow from
the para-arterial space to the ECS, which drives waste products from arteries
and toward the veins. However this flow is very sensitive to the pressure
gradient, as it is only observed if the cranial window is closed. The flow
occurs in perivascular spaces which have a far wider diameter ∼5 − 10µm
than the space between cells, the ECS ∼40−60nm where there may be little
bulk flow (Wolak and Thorne 2013; Abbott 2004). Hence flow has not been
included in the models.
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2.4 Volume fractions
The extracellular volume fraction (α) is obtained from the same experiments
as tortuosity, by fitting a solution to the diffusion equation (Eq. 2.2) to the
ISM signal obtained. The sum of the extracellular and intracellular (β)
volume fraction together with the solid volume fractions (γ), accounting for
cell membranes, must equal one.
1 = α+ β + γ (2.4)
Here the intracellular volume fraction is divided between neurons (80%) and
glia (20%). Several estimates could be made from the available literature,
all of which give a similar ratio. These include, qualitative analysis of the
volume composition of the human neocortex (84% to 16%) (Bennett 2011),
density and weight ratios from cell isolation (90% to 10%) (Subbalakshmi
and Murthy 1985) and the ratio of neuron soma (18%), glia soma (7%) and
neuropil (75%) in the rat cortex (Miller and Potempa‘ 1990) together with
the division of neuropil between axons, dendrites and glia in the rat hip-
pocamupus (81% to 19%) (Mishchenko et al. 2010). Cell counts combined
with estimates of the cell size suggest a ratio of (84% to 13%) (Subbalak-
shmi and Murthy 1985; Bass et al. 1971; Miller and Potempa‘ 1990). These
estimates appear to contradict a study of antioxidants ascorbate and glu-
tathione (Rice and Russo-Menna 1997), which found a 40% neuronal and
60% glial volume fraction to be consistent with the compartmentalisation of
both antioxidants. However, this may be due to properties of the antioxi-
dants, as it would violate the 3/5 rule, where, for optimal connections, 3/5
of the neuropil is composed of axons and dendrites (Chklovskii et al. 2002).
There are different estimates available for the number and ratio of glia to
neurons in the rat cortex, e.g. a cell isolation study suggests 1.8 times as
many neurons as astrocytes (Subbalakshmi and Murthy 1985) Staining gives
ratios of neurons to glia between 2.1 and 3.5 for different layers of the rat
somatosensory cortex, with an estimated 130, 000 neurons to 53, 000 glia in
1mm3 (Bass et al. 1971). The glia can be further subdivided, cell counts
suggests around 56% of glia in the rat cortex (at 0.75 months) are astro-
cytes, (Ling and Leblond 1973) with a similar proportion of 52% found in
adult rat somatosensory cortex (Ren et al. 1992). The gila have a variety
24
Parameter Value Description
α 0.21 Extracellular volume fraction (Rice and Nichol-
son 1991)
β 0.59 Total intracellular volume fraction based on ex-
tracellular and solid volume fraction (Rice and
Russo-Menna 1997)
βn 0.47 Neuron volume fraction 80% of intracellular vol-
ume
βg 0.12 Glial volume fraction 20% of intracellular vol-
ume
Table 2.2: Volume fractions for extracellular, neuronal and glial space in
the rat cortex.
of intricate shapes related to their function, which makes estimating their
volume quite challenging. Assuming the intracellular volume of each class of
glia is proportional to the volume of its nucleus (estimated from diameter by
assuming it is approximately spherical) provides an estimate for the relative
cell size for the different types (microglia and oligodendrocytes). Together
with the cell counts this suggests that astrocytes account for around 87% of
the glia volume fraction (Ling and Leblond 1973). As astrocytes make up
the majority of the glia volume fraction, it is assumed that the intracellular
metabolism for all glia in the model behave as astrocytes.
2.5 Michaelis-Menten kinetics
The key component of all the models are transporters and enzymes of the
purine metabolism. Here a review of the literature on the purine metabolism
is presented, together the with the methods required to obtain parameters
in a form that can be used in the models. Immunohistochemistry is used to
locate specific enzymes (Nagy et al. 1985) or transporters (Guille´n-Go´mez
et al. 2004) within the brain. This information is useful in deciding which
processes may be relevant for adenosine clearance and for comparing brain
regions. Quantitative information for the enzymes of purine metabolism
have been determined in either the whole rat brain or the rat cortex, prin-
cipally by dissecting the brain and homogenising it in a centrifuge. Then
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different concentrations of the substrate are added to the homogenate to
measure the initial rate at which the reaction products are formed, which
provides an estimate of the enzyme kinetics. The transporters require the
cells to remain intact, so while they can be located immunohistochemically,
the kinetics can be quantified using radio or florescent labelled purines, and
cell cultures rather than brain tissue is used.
The parameters for the enzyme kinetics available in literature are most often
available in the form of Michaelis-Menten (MM) kinetics which describe the
following reaction;
E + S
k1

k−1
ES
k2→ E + P (2.5)
Where E is the enzyme and S is the substrate. The irreversible product
formation ES
k2→ E+P assumes that either there is far more substrate than
product or that the energy released by the reaction is large. By making the
further assumptions that the total enzyme concentration does not change
and that the bound complex [ES] does not change with the same timescale
as the product formation. It is possible to derive the quasi-steady-state
approximation (QSSA);
dP
dt
=
Vmax [S]
Km + [S]
(2.6)
where
Km =
k2 + k−1
k1
(2.7)
Vmax = k2E0 (2.8)
The derivation of the QSSA form (Eq. 2.6) is given in B.1. The enzyme
kinetics are typically determined by removing a region of the brain and
homogenising it with a centrifuge. A detergent may be used to degrade
membranes and the homogenate will be separated into different fractions,
e.g. cytosol, synamtosomes and nuclear fraction. The enzyme reactions are
then determined by adding different concentrations of the substrate (S0)
to the homogenate and terminating the reaction after a fixed time period.
The concentration of the product of the reaction is used to determine the
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velocity V , which is then fitted to the QSSA of the reaction kinetics (Eq.
2.9). Traditionally the kinetics were determined with a double reciprocal (or
Lineweaver-Burk) plot, where the reciprocal of the velocity 1V was plotted
against 1S0 , then a linear fit is used to determine the gradient
Vmax
Km
and
the y-intercept 1Vmax
. Unfortunately this method magnifies small errors in
measurements and depends on extrapolation. An Eadie-Hofstee diagram or
Hanes-Woolf plot could also be used, based on a similar rearrangement of
the MM dynamics and with the same issues. In more recent work typically
software is used to perform non-linear regression (Greco et al. 1982; Perrella
1988).
V =
VmaxS
Km + S
(2.9)
Where V is the reaction velocity, Vmax the maximum reaction velocity, Km
the MM constant and S is the substrate concentration. The kinetics for
ADA in the rat cortex are determined at pH 7.0 30◦C with Vmax = 54± 11
nmol/min/g wet weight andKm = 17±2 with standard deviation from n = 6
(Phillips and Newsholme 1979). ADK kinetics were also determined for the
rat cortex with Vmax = 2.0± 0.5 nmol/min/g wet weight and Km = 25± 6.
Unfortunately, the information available in literature is rarely in an appro-
priate form for use in the models. The enzyme kinetics have been adjusted
using Q10 values to a physiological temperature of 37
◦C, (or 32◦C a tempera-
ture typically used in experiments to avoid damaging the tissue by overheat-
ing it). Similarly the diffusion coefficient was adjusted for the temperature
using the Stokes-Einstein equation. The enzyme kinetics were all obtained
from studies with similar acidity, with a pH between 7 and 7.5. As tissue
was homogenised to measure the enzyme activity, further estimates of the
proportion of enzyme in the neuronal, glial or extracellular space were re-
quired. The volume fraction of extracellular space (α) and space occupied
by membranes are available, the remaining fraction of intracellular space (β)
must be divided between neurons and glia. The models do not distinguish
between different classes of glia or neurons. Although astrocytes and other
types of glia have different roles currently there is insufficient information
regarding purine transport and metabolism. So only astrocytes are included
in the model. Here all the glia volume fraction is assumed to have the as-
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trocytic metabolism (this is likely to be an overestimate of the role of glia),
the other extreme would be to assume that glia which are not astrocytes
contribute to the solid volume fraction of the cell membranes, (this would
be an underestimate of the role of glia).
2.5.1 Temperature correction
The reaction catalysed by an enzyme speeds up as the temperature increases
until it reaches an optimal temperature, beyond which the reaction slows
again as the enzyme is more likely to degrade. Over a relatively small range
of temperatures, it is possible to interpolate to obtain an estimate of the
reaction rate for the desired temperature. The Q10 temperature coefficient
describes the change in a reaction rate as a result of a 10◦C increase in
temperature;
Q10 =
(
R2
R1
) 10
T2−T1
(2.10)
where T1 and T2 are temperatures which result in reactions occurring at
rates R1 and R2 respectively. The Q10 for ADA is 3.7 as the Vmax ∝ k2
(Eq. 2.5) is 199s−1 at pH 7.5 and 20◦C (Kurz et al. 1992) and 385s−1 at pH
7.5 and 25C (Wang et al. 2012). Similarly the Q10 of ADK is 1.9 estimated
based on enzymes obtained from the rat heart (De Jong and Kalkman 1973).
These values are used to provide the parameter estimates for reactions at
the physiological 37◦C given in Table 2.3. Similar estimates were obtained
for the experimental temperature of 32◦C where necessary.
The free diffusion coefficient of adenosine D∗ = 520 ± 1.0µm2/s at 25.5 ±
0.5◦C in water pH 6.0 − 7.0 with and without 1mM MgCl2 buffer (Bowen
and Martin 1964), can provide the diffusion coefficient at the required tem-
perature with the Stokes-Einstein equation;
D =
kBT
6piηr
(2.11)
where kB is Boltzmann’s constant, T is the temperature in kelvin, η is the
dynamic viscosity, for water this is 8.8×10−4Pas (pascal seconds) at 25.5◦C
and 6.9×10−4Pas at 37◦C (Haynes 2012) and r is the radius of the spherical
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particle 0.98nm for (TMA+) and 5.5nm for adenosine. So as the diffusion
coefficient D1 and viscosity is known at temperature T1, then the diffusion
coefficient at temperature T2 is given by;
D2 =
D1η1T2
η2T1
(2.12)
The diffusion coefficient of inosine is similar to that of adenosine, 475 ±
5µm2/s in water and 520 ± 0µm2/s with 1mM MgCl2. Hypoxanthine dif-
fuses faster, with coefficient 720± 1µm2/s in water and 680± 2µm2/s with
MgCl2 (Bowen and Martin 1964), correcting the temperature and account-
ing for tortuosity gives a diffusion coefficient of 320µm2/s.
2.5.2 Volume fraction correction
In a small given volume of brain tissue V is the sum of a volume of cell mem-
branes Vm, intracellular volume Vi and extracellular volume Ve. Consider an
amount of substance in the extracellular space Ne, then the concentration
can be defined in two ways, as the total concentration CT or the relative
concentration CR;
CT =
Ne
V
(2.13)
CR =
Ne
Ve
(2.14)
They are related by the volume fraction CT = αCR, similarly for intracel-
lular concentrations. In these models the relative concentrations are used.
However enzyme kinetics estimated from brain homogenate are given in
terms of activity per wet weight of tissue for amount of protein. In each
case it is necessary to estimate the activity per volume of brain tissue. The
density of brain tissue is similar to water at ∼1.1g/ml and a milligram of
protein is obtained from ∼1g of tissue (Nicholson 1995). Enzyme activity
in the model occurs in sub volumes of the brain tissue (section 2.4) and as
relative concentrations are used, it is necessary to scale the maximum ve-
locity and MM constant by the volume of the compartment. In the ECS by
1
α , in neurons by
1
βn
and glia by 1βg , these apply to the enzymes kinetics but
not to the transporter kinetics (Eqs. 2.26, 2.27, 2.32, 2.33) as the change in
volume fraction is included in the models (section B.2.1).
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2.5.3 Estimation using the steady state
The salvage/removal rate of breakdown products in glia, (µ8) could not be
directly inferred from the literature. It could be calculated from the uni-
form steady-state concentrations, with the concentrations in the CSF (Phillis
et al. 1987) and those obtained from brain homogenates (Winn et al. 1979)
providing the extracellular and total concentration. The intracellular con-
centration is found by subtraction. Then the ratios between neuron and glia
cultures allow the intracellular purines to be divided between neurons and
glia (Matz and Hertz 1989). This approach would suggest a uniform steady-
state concentrations of Ae = 49.3nM, An = 27nM, Ag = 86nM, Pe = 77nM,
Pn = 99nM and Pg = 23nM, where A is adenosine and P breakdown prod-
ucts, with subscripts indicating; e extracellular, n neuronal or g glial. Such
a steady-state could be obtained with µ8 = 4.7 × 10−5/s, a relatively slow
removal rate. However as it is inferred from estimated steady-state concen-
trations, intracellular volume fraction and ENT kinetics, it is unlikely to be
very reliable. Instead a removal rate µ8, of 5×10−4/s is considered relatively
slow and 5/s is relatively fast compared with the rates of other mechanisms
(Table 2.3) and the influence of this parameter is evaluated.
2.6 Transporters
Adenosine is cleared from the extracellular space by nucleoside transporters
(NT). Transport is rapid and significantly alters the extracellular concentra-
tion of adenosine, with the IC50 (the concentration of bath applied adenosine
required to half the amplitude of fEPSPs) ∼30 fold smaller for adenosine
in the presence of uptake inhibitors (Dunwiddie and Diao 1994). However
the enzymes can saturate, and the transporters can reverse their direction
of flow (Brundege and Dunwiddie 1996). Here uptake parameters are esti-
mated from the kinetics of primary cell cultures of rat neurons or astrocytes.
Equilibrative nucleoside transporters (ENTs) transport both adenosine and
its breakdown products between the intracellular and extracellular space ac-
cording to the concentration gradient.
There are two solute carrier (SLC) families relevant to adenosine clearance,
these are the equilibrative nucleoside transporter (ENT or SLC28) and the
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concentrative nucleoside transporter (CNT or SLC29). Concentrative nu-
cleoside transporters use one sodium ion to transport one nucleoside from
the extracellular to the intracellular space and are thought to be the reason
for the higher intracellular concentration of nucleosides (Gray et al. 2004).
Equilibrative nucleoside transporters do not depend on sodium and attempt
to equilibrate nucleoside concentration between the intracellular and extra-
cellular space. ENTs have been subdivided into four classes; ENT1, ENT2,
ENT3 and ENT4. ENT1 is sensitive to the inhibitor nitrobenzylmercap-
topurine riboside (NBMPR), ENT2 which is insensitive to NBMPR but is
inhibited by dipyridamole. ENT3 and ENT4 are less well characterised, but
have lower affinity for nucleoside transport than either ENT1 or ENT2 and
may be primarily involved in transport within cells (Baldwin et al. 2004).
Early work on transporters used four different experimental procedures for
use with erythrocytes (red blood cells) which lack the enzymes to metabolise
adenosine (Wu and Phillis 1984). These include: Zero-trans procedures,
where the substrate concentration is initially zero inside the cell and the
concentration outside the cell is varied. Equilibrium exchange procedure,
where the substrate concentration on the two sides of the membrane are
held equal. Infinite-trans procedure, where the inside of the cell has a sub-
strate concentration in excess of the MM constant. Infinite-cis procedure,
where labelled substrate outside the cell is at concentrations much higher
than the MM constant, and the labelled concentration inside the cell is var-
ied. A variation of the infinite-cis procedure, is ‘accelerated exchange dif-
fusion’, where the labelled concentration inside the cell is varied. This can
distinguish between the dynamics of ‘loaded’ and ‘unloaded’ transporters.
Studies with cultures of neurons or glia have used the infinite-cis procedure
for adenosine transport to infer MM kinetics of the transporter.
The kinetics for the specific class of ENT have been obtained by creating
chimeras expressing the relevant transporter. Using Xenopus oocytes to
produce dose-response curves for inhibitor NBMPR (Yao et al. 1997, figure
5) together with the values for the effect of NBMPR on rat cortical neuron
and astrocyte transport (Nagai et al. 2005, figure 5), can give an estimate
of the relative contribution of ENT1 and ENT2. Equilibrative transport in
neurons is approximately 30% ENT1 and 70% ENT2, while in astrocytes
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it is 15%, and 85% respectively. Such dose-response curves are useful for
altering the parameters of the model to conform to experimental work where
specific transport blockers have been applied (section 3.5.2). RNA extrac-
tion suggests neurons express more CNT2 than astrocytes which gives rise
to the high affinity (ENT2) and low affinity (CNT2) uptake observed in neu-
rons but not astrocytes. Here only the high affinity transport for neuron will
be used, as CNT2 is thought to have only a minor effect on uptake with its
low-affinity transporter only having a significant impact under pathological
conditions. The ENT parameters are inferred from studies of cell cultures
by using an estimate of 1.4ng of protein per neuron and glia transport 1.0ng
of protein per astrocyte (McKinney et al. 1996).
A further difficulty with modelling the transporters is that the kinetics for
the breakdown products inosine and hypoxanthine are currently unknown.
So here the ENTs parameters for breakdown products have been set equal
to those for adenosine transport. Such parameters can be inferred from the
model by comparison with radio labelling studies, but would require the
relevant volume fractions for cell cultures.
Obtaining parameter estimates for the transport of adenosine into neurons
and astrocytes is problematic because of extracellular breakdown. Uptake
kinetics are available for cell cultures (Nagai et al. 2005); however it is dif-
ficult to estimate the equivalent values for tissue. The MM constants are
assumed to be the same between culture and tissue, while the maximum
velocity is based on a cell count estimated from total protein concentration,
this is at best only accurate to the nearest thousand cells (Laughton 1984).
As concentrations are being modelled, the transport between the spaces
must be scaled by the relevant volume fraction, this leads to a system of
four differential equations (2.22-2.25) describing model II where neuronal
transport and metabolism is include with the extracellular diffusion and
metabolism of model I. The transporters like the enzymes are modelled using
the QSSA (Figure 2.1), with parameter values inferred from the literature.
The derivation of the QSSA is based on the assumption of a fixed total
amount of transporters that the concentrations of the bound transporters
changes on a slower timescale and is given in section B.2.
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2.7 Range of influence
The principal effect of adenosine in the cortex is to reduce neuronal activity
via the A1R. A dose-response curve for bath applied adenosine is obtained
by applying different concentrations of adenosine to a tissue slice and mea-
suring the corresponding reduction in excitatory post synaptic potentials
(EPSPs). This curve can be characterised by its IC50 value, the concentra-
tion of adenosine applied to the tissue to halve the amplitude of the EPSPs.
A bath applied IC50 of 15µM was found in layer V pyramidal neurons in
the rat cortex (Kerr et al. 2013), or 2.7µM (Stutzmann et al. 2001). The
lower concentration may be due to using thinner tissue slices. The concen-
tration of adenosine at the synapses is lower than the bath applied concen-
tration due to clearance mechanisms. Using an adenosine agonist, such as
N6-Cyclopentyladenosine (CPA), that is not affected by clearance gives a
second dose-response curve, with IC50 10nM (Stutzmann et al. 2001). Cell
cultures suggest that CPA has approximately 28 times the affinity of adeno-
sine for A1R, based on equilibrium disassociation constants (Kd) of 58nM
for CPA and 1630nM for adenosine (Gerwins et al. 1990). Assuming the
same efficacy allows a local dose-response curve to be estimated by shifting
the CPA curve to match the potency of adenosine, which yields an IC50
value of 280nM, this is the response due to a concentration of adenosine at
the synapse.
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The IC50 is an equilibrium measurement; when considering a brief source it
is necessary to account for the kinetics of the A1R. The proportion of bound
A1R, φ is modelled as single site receptor model, which has the following
form;
∂φ
∂t
= k1Ae(1− φ)− k−1φ (2.15)
where k1 is the binding rate and k−1 is the unbinding rate. Given Kd =
k−1
k1
for this single site model, if Ae = IC50, then by solving for φ50 the steady-
state proportion of bound receptors necessary to halve and EPSP;
φ50 =
IC50
Kd + IC50
(2.16)
With the values given above, φ50 = 0.15, so just 15% of the receptors are
necessary to halve the amplitude of an EPSPs which corresponds with the
observations of spare A1R (Lohse et al. 1987). Assuming this simple single
site receptor model captures the inhibitory process, the range of influence
can then be quantified as the maximum distance from the source where
the proportion of bound receptors exceeds 15%, in the steady state this is
equivalent to the maximum distance where the extracellular concentration
exceeds the IC50.
2.7.1 Adenosine receptors
The A1R has been shown to have a high and low affinity binding state and
there are several endogenous proteins that influence agonist binding. These
include adenosine deaminase (ADA), heat shock cognate protein 73 (HSC-
73), caveolin-1 and protein 4.1G (Ciruela et al. 2010). The A1R is also
involved in several receptor mosaics, including A1R-A1R, A1R-A2AR, A1R-
D1R, A1R-D2, A1R-mGluR1 and A1R-P2Y1R (Fredholm et al. 2011; Franco
et al. 2006; Guidolin et al. 2011). The use of a single state receptor model
here is due to the difficulty in obtaining estimates for the kinetics for the
A1R, while there are several studies involving radioligand binding of A1R in
membrane extracts for more complex receptor dynamics, e.g. 14 parameter
two-state model (Waldhoer et al. 1999). These preparations of membrane
extracts have been shown to be unphysiological (Lohse et al. 2008).
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Recently fluorescence resonance energy transfer (FRET) has been used to
study the binding kinetics of GPCR for intact cells, e.g. k−1 = 0.03s−1,
k1 = 0.4µM
−1s−1 for human A1R and the fluorescent agonist ABA-X-
BY630 with Kd = 80nM (May et al. 2010). However the rat A1R has
a higher affinity than the human receptor and adenosine has a lower affinity
than ABA-X-BY630. A range of plausible kinetics is obtained by scaling
the rate constants independently to obtain the equilibrium dissociation con-
stant Kd =
k−1
k1
, 1630nM for adenosine binding to the rat A1R. Taking the
midpoint of this range gives k−1 = 0.4s−1 and k1 = 0.2µM−1s−1, which
corresponds to a half-life (t1/2) of 2s, faster than other values for GPCR ob-
tained from intact cells, as FRET studies tend to use high-affinity agonists.
E.g. neurokinin A receptor t1/2 3s with agonist Kd of 9.4nM (Palanche et al.
2001) and A3R t1/2 53s with agonist Kd of 7.2nM (May et al. 2010).
2.8 Models
A hierarchy of models is developed using the literature to define the current
best estimates of their parameters. A simple mathematical approximation
is deduced and compared to computational results. An endogenous source
of adenosine is modelled in two ways; a constant source is used to model the
basal tone of adenosine, whereas a brief source is used for activity-dependent
or spontaneous release. A uniform source is considered, this is appropriate
when adenosine acts as a global modulator of activity, such as sleep or ad-
diction (Dunwiddie and Masino 2001; Nam et al. 2013), or for comparison
with measurements made with low spatial resolution, e.g. high performance
liquid chromatography of the outflow from a tissue slice (Pedata et al. 1993).
Due to evidence of heterogeneities in the adenosine signal, (Wall et al. 2007),
an isolated point source is also modelled. This allows the range of influence
of an adenosine source to be estimated. Finally an experimental setup is
considered where adenosine is applied to the surface of a tissue slice, this
provides insight into standard experimental setups and could be used to
validate the model.
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The simplest model in the hierarchy is the diffusion model, where adeno-
sine just diffuses through the extracellular space with no uptake or break-
down and is described by the following parabolic partial differential equation
(PDE);
∂Ae
∂t
= D∇2Ae + 1
α
S(t, x) (2.17)
where D is the effective diffusion coefficient that takes into account the tor-
tuosity of the extracellular space, α is the extracellular volume fraction or
porosity and S(t, x) [µM/s] is a generic source in terms of a total concentra-
tion so it is scaled to give the relative concentration (section 2.5.2). Initially
the concentration is zero. Endogenous non-uniform sources are solved in
spherical coordinates assuming radial symmetry, with the boundary condi-
tions;
lim
r→∞Ae(t, r) = 0 (2.18)
∂Ae
∂r
∣∣∣∣
r=0
= 0 (2.19)
In models with more state variables, similar initial and boundary condi-
tions are applied. In the bath applied case, the boundary conditions are
Ae(t,±h2 ) = A0, where A0 is the applied concentration of adenosine and h
is the depth of the slice.
2.8.1 Model I
Extracellular breakdown by ADA is added to the diffusion model (Figure
2.2a). It is described by the coupled PDEs;
∂Ae
∂t
= D∇2Ae − V1Ae
K1 +Ae
+
1
α
S(t, x) (2.20)
∂Pe
∂t
= D∇2Pe + V1Ae
K1 +Ae
(2.21)
where Ae is the extracellular concentration of adenosine and Pe is the con-
centration of breakdown products, V1 is the maximum velocity and K1 the
MM constant for ecto-ADA.
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2.8.2 Model II
Model II additionally takes into account removal by neurons, (Figure 2.2b).
∂Ae
∂t
= D∇2Ae − V1Ae
K1 +Ae
+
1
α
JAn +
1
α
S(t, x) (2.22)
∂Pe
∂t
= D∇2Pe + V1Ae
K1 +Ae
+
1
α
JPn (2.23)
∂An
∂t
= − 1
βn
JAn −
V4An
K4 +An
(2.24)
∂Pn
∂t
= − 1
βn
JPn +
V4An
K4 +An
(2.25)
Where βn the neuronal volume fraction and V4 and K4 are the MM param-
eters for ADA, Ae and Pe are the extracellular concentration of adenosine
and its breakdown products, An and Pn are the corresponding neuronal con-
centration. This model includes ENTs, the QSSA (Figure 2.1), which gives
the following formula for the transport depending on the intracellular and
extracellular concentration of adenosine and its breakdown product;
JAn =
V2
K2
(
1 + Pe+PnK3
)
+Ae +An
(An −Ae) (2.26)
JPn =
V3
K3
(
1 + Ae+AnK2
)
+ Pe + Pn
(Pn − Pe) (2.27)
2.8.3 Model III
Model III includes the extracellular and the glial metabolism but not neu-
ronal uptake, (Figure 2.2c). Transport into the intracellular space has the
same form as model II but with different parameters, (Figure 2.1). AMP is
not modelled, this simplification avoids the inclusion of ATP which is used
ubiquitously in the cell. The clearance/salvage pathway for the breakdown
product inosine is modelled as a single unsaturating rate µ8. The resulting
system is as follows;
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∂Ae
∂t
= D∇2Ae − V1Ae
K1 +Ae
+
1
α
JAg +
1
α
S(t, x) (2.28)
∂Pe
∂t
= D∇2Pe + V1Ae
K1 +Ae
+
1
α
JPg (2.29)
∂Ag
∂t
= − 1
βg
JAg −
V7Ag
K7 +Ag
(2.30)
∂Pg
∂t
= − 1
βg
JPg − µ8Pg (2.31)
where βg is the volume fraction of glia, V7 and K7 are the MM parameters
for ADK and µ8 is a first order approximation of the clearance and salvage
pathways. The ENTs are modelled using the QSSA (Figure 2.1), which gives
the following equations for transport;
JAg =
V5
K5
(
1 +
Pe+Pg
K6
)
+Ae +Ag
(Ag −Ae) (2.32)
JPg =
V6
K6
(
1 +
Ae+Ag
K5
)
+ Pe + Pg
(Pg − Pe) (2.33)
Where Ae and Pe are the extracellular concentration of adenosine and its
breakdown products, with Ag and Pg the corresponding glial concentrations.
2.8.4 Model IV
The full tissue model combines the extracellular space (ECS), neurons and
glia, (Figure 2.2d). Transport between the intracellular and extracellular
space, (Figure 2.1c) and the intracellular compartments are modelled as be-
fore, (Eq. 2.24, 2.25) and (Eq. 2.30, 2.31). The extracellular concentrations
are determined by;
∂Ae
∂t
= D∇2Ae − V1Ae
K1 +Ae
+
1
α
JAn +
1
α
JAg +
1
α
S(t, x) (2.34)
∂Pe
∂t
= D∇2Pe + V1Ae
K1 +Ae
+
1
α
JPn +
1
α
JPg (2.35)
2.9 Hippocampus
The models described here can be applied to different species or brain regions
by altering the parameter values. In addition to the rat cortex estimates, pa-
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rameter estimates for rat hippocampus were obtained (Table 2.4 and Table
2.3), to demonstrate the wider applicability of the models and allow compar-
ison of the effects of ENT inhibitors in different brain regions (section 3.5.2).
Although ENT1 and ENT2 have not been measured in either neurons or glia
of the rat hippocampus, the relative amount of isolated mRNA for ENT1
is 1.5, which is 8% higher than the cortex. Similarly for ENT2 is 0.7 which
is 52% higher than the cortex. Assuming the same ratio of expression of
ENT1 and ENT2 transporters in hippocampal cells as cortical cells, this
suggests an increase ∼40% in maximum velocity for neurons and ∼50% for
glia (Anderson et al. 1999).
Adenosine deaminase (ADA) measured in homogenised hippocampus at
37◦C, pH 7, has Michaelis-Menten constant Km = 40µM and Vmax =
36nmol/mg protein/30min (Geiger and Nagy 1986). The homogenate was
also shown to have activity 4nmol/mg tissue/30min and was further subdi-
vided into P1 containing the dense nuclear fraction, P2 composed of the mi-
tochondria, myelin, microsomes and synaptosomes, which provides a crude
estimate for the ecto-ADA activity of 22% and P3S the soluble fraction cor-
responding to the cytosolic-ADA 68%. As with the rat cortex, adenosine
kinase (ADK) has not been characterised in the rat hippocampus, so the
kinetics derived from the whole brain are used.
The hippocampus is formed of the dentate gyrus, an outer layer around
the hippocampus proper or four Cornu Ammonis regions (CA1-CA4), the
largest of these are CA1 and CA3. The volume fraction for the regio inferior
(CA3) is α = 0.13 and regio superior (CA1) is α = 0.20. The tortuosity for
CA1 is 1.5 and CA3 is 1.6 (Pe´rez-Pinzo´n et al. 1995). To obtain an estimate
for the whole hippocampus (Table 2.4), these values can be averaged over
the relative volume of the regions, regio superior 17mm3 and regio inferior
13mm3 (West et al. 1978).
The solid volume fraction is γ ≈ 0.2, based on the ratio of the density
of neural tissue to water, which implies an intracellular volume fraction
β = 1 − γ − α = 0.63, similar to both the cortex β = 0.59 (Rice and
Nicholson 1991) and the striatum β ≈ 0.65 (Nicholson 1995). The neuronal
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Parameter Value Description
α 0.17 Extracellular volume fraction
(Pe´rez-Pinzo´n et al. 1995)
β 0.63 Total intracellular volume
fraction
βn 0.50 Neuron volume fraction 80%
of intracellular volume
βg 0.13 Glial volume fraction 20% of
intracellular volume
D∗ 690µm2s−1 Diffusion coefficient of adeno-
sine at 37◦C in a free en-
vironment(Bowen and Martin
1964)
D 300µm2s−1 Diffusion coefficient given
tortuosity of 1.58 for rat
hippocampus (Pe´rez-Pinzo´n
et al. 1995)b
Table 2.4: Volume fractions and diffusion coefficients for the rat hip-
pocampus. Temperature changed using the Stokes-Einstein equation (Eq. 2.11).
Estimates of tortuosity based on the diffusion of Tetramethylammonium+ (TMA+)
volume fractions have been estimated in the rat hippocampal neuropil using
electron microscopy reconstruction as ∼90% and glial as ∼8% (Mishchenko
et al. 2010). However there is no estimate for the volume fraction which
includes the cell bodies, so a similar volume ratio of neuronal (80%) to glial
(20%) intracellular space as the cortex is assumed.
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Chapter 3
Adenosine sources and range
of influence
3.1 Introduction
Extracellular adenosine can increase as a result of normal neuronal activity,
(Wall and Dale 2007; Brundege and Dunwiddie 1996; Klyuch et al. 2011;
Klyuch et al. 2012a; Klyuch et al. 2012b; Sims and Dale 2014; Cechova
et al. 2010; Pajski and Venton 2010; Nguyen et al. 2014), pathological
neuronal activity (seizures) (Etherington et al. 2009), hypoxia (Frenguelli
et al. 2003; Fujita et al. 2011; Gourine et al. 2005), ischemia (Dale and
Frenguelli 2009; Frenguelli et al. 2007) and damage (Ross et al. 2014; La-
tini and Pedata 2001). Extracellular adenosine also increases during waking
and falls during sleep (Clasadonte et al. 2014; Sharma et al. 2014) and is
affected by alcohol (Sharma et al. 2014; Clasadonte et al. 2014). There is
uncertainty regarding the mechanisms for endogenous increase in extracel-
lular adenosine concentration, with evidence for multiple release pathways
depending on brain region and the nature of the stimulus.
For the models a number of idealised endogenous sources are considered:
a constant uniform and constant point source, appropriate for modelling
the basal tone of adenosine; and a brief uniform and brief point source,
corresponding to activity-dependent and spontaneous release events. Here
the models are used to estimate the duration of an adenosine signal and
its range of influence, as a function of the source intensity. In general the
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adenosine signal appears to be relatively short and highly localised e.g. the
range (∼20µm) and duration (∼7s) for relatively brief point source (Fig-
ure 3.9n,o), or the characteristic length scale of a constant point source
(∼ 40µm). The hierarchy of models allows a comparison of the different
clearance mechanisms and suggests that neuronal uptake has the greatest
effect on extracellular adenosine concentrations. The uniform source is used
to determine the endogenous tone that would result from different source
intensities. The model of a uniform source suggests changes in adenosine
concentration with the sleep/wake cycle are unlikely to be the result of a
simple change in source intensity, with more adenosine being produced when
awake.
Numerical solutions are obtained using finite differences, forward time center
space for a brief point source are obtained using a fourth order Runge-Kutta
method for spherical coordinates. Isotropy allows it to be solved in terms
of the radius alone (Figure 3.1a). A time-step of 1ms and a uniform grid
of 100,000 points between 1µm and 5cm is used. The large upper limit is
to ensure boundary has little influence on the solution. The time-step and
space-step satisfy the Von Neumann stable condition for the diffusion equa-
tion Dδ
2
x
δt
< 12 and are validated by reducing the values and demonstrating
no substantial effect on the solution. The source is initially distributed in a
sphere with volume 1µm3 of extracellular space. The steady state is found
by iterating until the total changes in the state of the system falls below a
threshold of 0.1nM/s. Similarly the time dependant solution for the bath
applied problem is found via a fourth order Runge-Kutta method, using a
uniform grid of one thousand points between a depth of 0 and either 300µm
or 400µm (Figure 3.1b).
3.2 Low concentration limit
These nonlinear models cannot be solved analytically, however the models
become linear in both the high and low concentration limit. In the high
extracellular concentration limit, ecto-ADA kinetics and ingress to the in-
tracellular space are described by zero-order kinetics. The low concentration
limit is also linear, with a first-order reaction, where the velocity is given
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Ae(
h/2)=A0
Ae(-
h/2)=A0
zr
Ae(0)=
F/α Ae(∞)=0
a) b)
Figure 3.1: Schematic of the domain and boundary conditions. a) A
constant point source is solved radially, for the steady-state solution the boundary
at r = 0 is given by Fα , whereas for brief source the condition is
F0
α δ(t). In both
cases the concentrations are otherwise initially zero and limr→∞Ae(r) = 0. b) For
bath applied adenosine the tissue slice is relatively thin, so it is reasonable to solve
it for depth alone. The boundary conditions at the surface of the slice ±h2 (where h
is the thickness of the slice) are equal to the applied concentration A0 [µM] which
may be zero (section 3.3.1.1).
by a constant rate multiplied by the adenosine concentration. The steady
state for the low extracellular concentration limit can be written in terms of
a characteristic length scale λ (Table 3.1), determined by the ratio of diffu-
sion to clearance. The steady-state extracellular adenosine concentration in
the low concentration limit is described by;
0 = ∇2Ae − Ae
λ2
+
S(x)
Dα
(3.1)
The length scale for model IV (derived in section B.3) is;
λ =
√
D
(
µ1 +
1
α
(
βnµ2µ4
βnµ4 + µ2
+
βgµ5µ7
βgµ7 + µ5
))−1
(3.2)
where µi =
Vi
Ki
is the removal rate of a given mechanism in the low concen-
tration limit, i.e. µ1 ecto-ADA, µ2 neuronal transport, µ4 neuronal ADA,
µ5 glial transport and µ7 ADK. The length scale for other models can be
obtained by removing the relevant clearance terms. The extracellular con-
centration of breakdown production in the low concentration limit is also
determined with an additional linear differential equation;
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Model
λ Vmax τ
(µm) (µM/s) (s)
I) Extracellular only 122.2 1.4 56.8
II) Extracellular & neuronal 41.0 2.8 6.4
III) Extracellular & glial 85.8 2.1 28.1
IV) Extracellular, neuronal & glial 38.7 3.5 5.7
Table 3.1: Neurons have a substantial impact on the range of influence
for a constant point source compared with the effect of glia. The steady-
state solution in the low concentration limit (section 3.2), provides a characteristic
spatial scale (λ) and temporal scale (τ = λ2/D). The maximum removal velocity
Vmax is the sum of the relevant maximum velocities for transporters and enzymes
in the high concentration limit, these characteristic scales are listed for models I-IV.
They show that the clearance mechanisms localise the effect of adenosine.
0 = ∇2Pe + Ae
κ21
− Pe
κ22
(3.3)
Where for model IV;
κ1 =
√
D
(
µ1 +
1
α
βnµ3µ4
βnµ4 + µ2
)−1
(3.4)
κ2 =
√
Dα
βgµ8 + µ6
βgµ6µ8
(3.5)
This low concentration limit provides a good approximation of the non-
linear solution (Figure B.1c), because diffusion substantially diminishes the
concentration with distance from the source (Figure 3.6).
3.3 Constant sources and the adenosine tone
The adenosine tone varies with the sleep/wake cycle (Sims et al. 2013) and
with age (Kerr et al. 2013). This tone must result from a balance between
a source of adenosine and the clearance mechanism. Here this is described
in the models with a constant source. The constant source may give rise to
a steady-state concentration, which can be found analytically for models I
and II (Eq. 3.6), or numerically for models III and IV.
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3.3.1 Uniform sources
The extent to which glia clear adenosine from the extracellular space is in-
fluenced by the removal rate of breakdown products µ8, (representing the
action of enzymes PNPase, XO and HGPRT as well as transport through the
BBB via erythrocytes). It is clear comparing the fast and slow removal rates
that in model III glia can have a substantial impact on the basal tone by
clearing adenosine from the ECS, (Figure 3.2), as without sufficiently rapid
removal of breakdown products they accumulate and competitively inhibit
uptake of adenosine by both neurons and glia. In the presence of neurons,
(model IV) removal of breakdown products is the dominant role played by
glia. So in model IV neurons act as a source of breakdown products, be-
cause ADA is faster then ecto-ADA, while glia act as a sink, salvaging the
breakdown products.
Glia are essential for the removal of breakdown products, by both salvage
and transport through the BBB via erythrocytes. Subsequently for a uni-
form source, models I and II do not have a steady state for the breakdown
products, they accumulate indefinitely (Figure B.3). However, the steady
state can be obtained for extracellular adenosine, by considering a high con-
centration limit of the breakdown products, in which case model II is the
same as model I, which has an analytic solution;
A∗ =
K1C
αV1 − C (3.6)
Where C is the source in terms of the total concentration (section 2.5.2), i.e.
S(t, r) = C [µM/s] in (Eqs. 2.20, 2.22, 2.28, and 2.34). In figures 3.2 and
3.5 the source is given in terms of a relative concentration, i.e. S(t, r) = αC
[µM/s] in (Eqs. 2.20, 2.22, 2.28, and 2.34). This solution shows that there
is a maximum velocity at which adenosine can be removed. This is the
case for all the models (Vmax in Table 3.1), this maximum velocity assumes
that the extracellular adenosine concentration is far greater than that of
the breakdown products (section B.4), if this is not the case, saturation of
transporters will reduce this maximum velocity towards the value given for
model I. If the source of adenosine exceeds this maximum velocity, then the
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Figure 3.2: The endogenous tone of adenosine diverges as the source rate
approaches the maximum removal rate. The uniform steady-state concentra-
tion of a) extracellular adenosine with fast removal of breakdown products in glia
µ8 = 5/s (solid) and slow removal µ8 = 5× 10−4/s (dashed). With a slow removal
rate µ8, transporters become saturated by breakdown products which rapidly in-
crease in b) extracellular space, d) neuronal space, and f) glia. Hence the addition
of glia and neurons in model IV has little effect on the resulting endogenous tone
and a) the extracellular solutions of models III and IV meet with models I and II.
For rapid removal of breakdown products, neurons and glia do have a substantial
impact, however for larger sources the transporters ultimately become saturated
and the endogenous tone diverges for all models.
concentration will grow indefinitely. This also means that a small change
in the source rate could substantially increase the endogenous tone (Figure
3.2).
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3.3.1.1 Eﬄux from a tissue slice
The eﬄux from a tissue slice may be measured via high performance liquid
chromatography (Fowler 1993) or with biosensors (Wall et al. 2007), to infer
either the endogenous tone or a release event. Modelling adenosine in vitro
means the boundary conditions at the edge of the slice may influence the
observed signal. Here the low concentration limit (section 3.2) is used to de-
termine the relative effect of clearance mechanisms and boundary conditions
on a constant uniform source. This simplified model can be used to deter-
mine the eﬄux from a tissue slice, taking the steady-state low concentration
limit and a constant source S(x, t) = C [µM/s], (Eq. 2.17, 2.20, 2.22, 2.28
and 2.34) given the following ODE; ;
0 = ∇2A− A
λ2
+
C
Dα
(3.7)
Where C [µM] is the source intensity, λ is the length scale (Eq. 3.2) (Ta-
ble 3.1). The steady-state solution for a slice of tissue, thickness h with
boundary conditions A
(
h
2
)
= A
(
−h
2
)
= 0 is;
A(z) =
Cλ2
Dα
(
1− cosh
(
z
λ
)
cosh
(
h
2λ
)) (3.8)
Then the loss rate due to clearance mechanisms is;
Lc =
1
h
∫ h
2
−h
2
dz
D
λ2
A(z) (3.9)
=
C
αh
(
h− 2λ tanh
(
h
2λ
))
(3.10)
The loss rate due to flux at the boundaries of the slice is;
Lb =
1
h
(
D
dA
dz
∣∣∣z=−h
2
−DdA
dz
∣∣∣z=h
2
)
(3.11)
= 2
Cλ tanh
(
h
2λ
)
αh
(3.12)
Together with the length scales (Table 3.1) this suggests that clearance
mechanisms surpass loss through the slice surface for slices thicker than
∼100µm.
51
Figure 3.3: Clearance mechanisms have a greater influence on adenosine
concentration than the boundary conditions for slices thicker than 100µm
The percentage of a constant uniform source lost in the steady-state due to clear-
ance mechanisms and diffusion out of the slice. a) For a 300µm slice with range
clearance length scales λ (Table 3.1) (the average distance adenosine diffuses before
being removed by endogenous clearance mechanisms), dashed line at λ = 40µm for
comparison with b) the effect of influence of slice thickness on loss of adenosine,
with λ = 40µm, dashed line at thickness 300µm for comparison with a).
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3.3.1.2 Sleep cycles
Extracellular adenosine increases during waking periods and decreases dur-
ing sleep. Here the simplest way to incorporate aspects of the sleep/wake
cycle into a model of adenosine clearance is considered. This is with two
constant uniform sources representing extracellular adenosine produced in
a waking and a sleeping state. The different rates could result from higher
waking brain activity or as a result of circadian clocks regulating astro-
cytic ATP release (Marpegan et al. 2011). Cw [nM/s] is a source intensity
for waking states with a smaller source Cs [nM/s] for sleeping states. The
model suggests an initial rapid change in extracellular concentration, fol-
lowed by a slower change dependent on glial dynamics. With fast removal
of breakdown products (µ8 = 5/s) 95% of the rise from sleeping to waking
adenosine concentration occurs within 40s, similarly 95% of the fall from
waking to sleeping concentration takes place within 75s. Whereas with slow
removal (µ8 = 5 × 10−4/s) the same rise takes 80s, and the fall takes 6.7
hours. (Figure 3.4a,b).
Modelling the larger changes in concentration seen in old rats, 97nM to
waking concentration 128nM (Murillo-Rodriguez et al. 2004) shows similar
dynamics (Figure 3.4c,d), taking 40s to rise and 100s to fall with fast adeno-
sine removal compared to 2.3 hours and 7.7 hours with slow breakdown
product removal rate. Monitoring the changes in adenosine concentrations
in the rat hippocampus suggests a slow increase during the dark period
which returns to baseline within an hour (the next data point) at the onset
of the light period (Huston et al. 1996). Whilst the rapid removal of break-
down products is consistent with the model, the temporal resolution is too
low to validate the model’s predictions. The model suggests the change in
extracellular adenosine concentration with sleep/wake cycle is unlikely to be
due to a simple increase in adenosine production during waking states. As
with such rapid accumulation of adenosine it is unlikely it could serve as a
marker for sleep drive (Holst and Landolt 2015).
Evidence suggests that the activity of some enzymes of the purine metabolism
are reduced during waking periods. The enzymes relevant for the clearance
models are ADA, which is reduced by 43% and ADK which is reduced by
54% of the day time (sleeping) levels (de Sa et al. 1993). Reducing purine
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metabolism in the waking state has little effect on the dynamics in either
young or old rats (Figure 3.4), but substantially reduces the source intensity
required for a given endogenous tone (Figure 3.5)
The model can also be applied to sleep deprivation, It suggests there would
be no change in adenosine tone as a result of sleep deprivation because
the steady state would be reached in the normal waking hours and persist
throughout the sleep deprived state, consistent with some observations in
vitro (Sims et al. 2013). Extracellular adenosine appears to increase with
sleep deprivation in the basal forebrain (BFB) (Kalinchuk et al. 2006),
but not the cortex. The adenosine clearance models do not explain the
discrepancy, but it may be due to differences in the source. In the BFB
the peak adenosine release resulting from α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPAR) stimulation increased with sleep
deprivation, while in the cortex it remained the same (Sims et al. 2013).
This suggests that the amount of adenosine as a result of neuronal activity
during sleep deprivation would increase in the BFB, while remaining un-
changed in the cortex.
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Figure 3.4: Changing the source intensity corresponding to sleep/wake
states of rats rapidly alters the extracellular adenosine concentration
but the time required to reach a steady state is dependant on the glia
metabolism. Both plots show the change from the observed sleeping extracellular
adenosine concentration [Ae]s (62nM in young 97nM in old rats) to waking con-
centration [Ae]w (72nM in young and 129nM in old rats). a) and c) Fast removal
of breakdown products in glia µ8 = 5/s. With corresponding source intensities re-
quired for the steady-state extracellular adenosine; a) waking Cw = 2.5nM/s with
constant metabolism (blue) or Cw = 1.5nM/s with reduced metabolism (red) and
sleeping Cs = 2.1nM/s. c) waking Cw = 4.2nM/s with constant metabolism (blue)
or Cw = 2.7nM/s with reduced metabolism (red) and sleeping Cs = 3.2nM/s. b)
and d) Slow removal of breakdown products in glia µ8 = 5 × 10−4/s. With cor-
responding source intensities required for the steady-state extracellular adenosine;
b) waking Cw = 0.9nM/s with constant metabolism (blue) or Cw = 0.8nM/s with
reduced metabolism (red) and sleeping Cs = 0.8nM/s. d) waking Cw = 1.5nM/s
with constant metabolism (blue) or Cw = 1.1nM/s with reduced metabolism (red)
and sleeping Cs = 1.3nM/s. Arrows indicate the time when the source intensity
changes i.e. the first arrow is at waking while the second is at sleep onset
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Figure 3.5: Reduced enzyme activity in awake rats allows a smaller source
intensity to produce a substantially greater endogenous tone of extra-
cellular adenosine. Solid lines show the daytime (sleeping) tone resulting from a
constant uniform source, dashed lines show the endogenous tone where the maxi-
mum velocity of ADA (V1 and V4) are reduced by 43% and ADK V7 is reduced by
54% of the day time (sleeping) level (de Sa et al. 1993). We assume fast removal
of breakdown products in glia µ8 = 5/s.
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3.3.2 Isolated point source
There is evidence of heterogeneities in the basal tone of adenosine from direct
measurements using biosensors and indirectly from the difference in EPSPs
when an A1R agonist or antagonist is applied, (Wall et al. 2007; Kerr et al.
2013), which could arise from spatial variation in the sources. The simplest
way to capture such variation in the models is with an isolated point source.
Here the low concentration limit (section 3.2) is solved analytically and two
numerical solutions are compared. One considers a relatively large source
F = 10, 000zmol/s, ∼1.5% of the total ATP required to generate one ac-
tion potential per second, and the other considers a relatively small source
F = 1, 000zmol/s, corresponding to the ATP required for a single mEPSP
or for ∼5 vesicles releases per second. The two examples are almost iden-
tical, scaled for concentration (Figure 3.6), because rapid diffusion in the
ECS ensures that, apart from a small region around the source, the concen-
tration is below the MM constants of both transporters and ecto-ADA, e.g.
for the large source term, the concentration is 15µM within 1µm but is less
than 1µM around 12µm from the source. This means that the clearance
mechanisms are well described by the linear low concentration limit.
The range of influence is an important factor to consider when modelling
heterogeneities in the basal tone of adenosine. For relatively small sources
the range for all models is determined by diffusion with clearance mecha-
nisms having only a minor effect. The range due to diffusion scales linearly
with the size of the source (Eq. 3.14) and logarithmically with clearance
length scale (Eq. 3.16), as the concentration profiles for the models differ
more from diffusion as r increases. So for larger sources the clearance mech-
anisms are able to reduce the range of influence, having a localising effect
(Figure 3.6c). As the range of influence is primarily determined by diffusion,
it means that increases in the basal tone or reductions in the volume fraction
(which would both reduce the amount of additional adenosine required to
reach the IC50) would greatly increase the range of influence for a constant
point source. Conversely, inhibiting transporters e.g. with alcohol, or re-
duction in purine metabolism would have a relatively minor effect on the
range of influence.
The steady-state for the diffusion model (Eq. 2.17) can be solved analytically
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Figure 3.6: The concentration of extracellular adenosine for an isolated
point source is primarily determined by diffusion. Two numerical solutions
of the steady-state concentration profiles resulting from a constant point source.
The extracellular adenosine concentration is primarily determined by diffusion, with
the clearance mechanisms having a relatively minor effect. As the model assumes
spherical symmetry the concentration profiles are given for the radial distance from
the source. a) shows the extracellular adenosine concentration resulting from a
large source F = 10, 000zmol/s and b) small source F = 1, 000zmol/s. Inserts
show an enlargement of the concentration close (blue box) and far (red box) from
the source, with contour plots showing the inhibitory concentration of 20%, 40%,
60% and 80% of A1R, with scale arrow of 50µm. While the concentrations in
a) are far greater than b) the shape of the profile is very similar, as diffusion
dilutes the concentration in tissue so the concentration profile is well approximated
by the linear low concentration limit (Eq. 3.15). The furthest distance from the
source where the concentration exceeds the IC50 of A1R r50 (i.e. the distance a
synapses could be from the source where the EPSPs amplitude would be halved
due to the extracellular adenosine concentration), is indicated in a) and b) and in
c) it is shown as a function of source intensity. The behaviour is dominated by
diffusion with the clearance mechanisms having a more prominent role for larger
source intensities. Fast removal of breakdown products µ8 = 5/s (solid) and slow
µ8 = 5× 10−4/s (dashed).
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(section B.5). For a constant point source the steady-state concentration Ae,
scales as ∼1r (Eq. 3.13), where r is the distance from the source. This result
also provides an estimate for the range of influence, r50, the furthest distance
where the concentration exceeds the IC50, this distance grows linearly with
the source intensity F (Eq. 3.14).
Ae =
F
4αpiDr
(3.13)
r50 =
F
4αpiDIC50
(3.14)
When the concentrations are lower than the MM constants, the nonlinear
clearance kinetics are well approximated by linear rates (Figure B.1c), (given
by the ratio of the maximum velocity and MM constant), this low concentra-
tion limit (section 3.2) can be solved analytically (section B.3). The constant
point source Ae (Eq. 3.15), provides a good steady-state approximation over
the source range considered. As with the solution for the diffusion model it
also provides an estimate of the range of influence, which grows logarithmi-
cally rather than linearly with source intensity F (Eq. 3.16), where W is
the product-log function.
Ae =
F
4αpiDr
exp
(
− r
λ
)
(3.15)
r50 = λW
(
F
4αpiDλIC50
)
(3.16)
The limit (Eq. 3.15) and range (Eq. 3.16) are given in terms of character-
istic distance, λ, the square root of the ratio of the removal rate and the
diffusion coefficient (Eq. 3.2), the average distance an extracellular adeno-
sine molecule diffuses before it is cleared for the ECS. Comparison with the
diffusion result (Eq. 3.13) shows the relatively rapid removal of adenosine,
(Table 3.1), e.g. the distance λ is as low as ∼40µm for model IV, which
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suggests endogenous adenosine has a local effect and also shows the domi-
nant role neurons play in the clearance of adenosine. However this assumes
that intracellular concentrations are the result of transport from the extra-
cellular space. If for example, neuronal release via ENTs were the source of
extracellular adenosine, the length scale would be similar to model III.
3.4 Brief endogenous and activity-dependent re-
lease
Extracellular adenosine concentration can change rapidly due to insult or
neuronal activity. These are described in the model with a brief source.
A uniform source is considered, which is comparable to multiple releases
distributed throughout this tissue corresponding to a short insult, such as
oxygen-glucose deprivation or a seizure. The model hierarchy (section 2.8)
is used to determine the relative importance of the different clearance mech-
anisms. An isolated point source, comparable to activity-dependent release,
is also considered. In this case both the range of influence and the effi-
cacy of the different clearance mechanisms are evaluated and as before the
adenosine signal is found to be highly localised and the dominant clearance
mechanism is neuronal uptake and metabolism.
3.4.1 Uniform sources
Activity-dependent and spontaneous release events have been observed in
several brain regions, including the cerebellum (Klyuch et al. 2012b) and
striatum (Cechova et al. 2010; Nguyen et al. 2014). The release mechanisms
vary with brain region and stimulus, often involving multiple pathways e.g.
half of the increase in extracellular adenosine concentration in the cerebellum
is due to extracellular metabolism of ATP whereas the other half is due to
direct exocytosis (Klyuch et al. 2012a). The release events are characterised
by a rapid increase in the extracellular adenosine concentration followed by a
much slower decay due to diffusion and clearance (Klyuch et al. 2011). Here
an instantaneous rise in extracellular adenosine concentration is considered
and the model is used to study the role of the various clearance mechanisms.
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Unlike the constant source, the duration of the extracellular adenosine con-
centration also has to be taken into account. If the concentration rapidly
diminishes it will not have time to bind to A1Rs. To account for this a single
state model of the A1R, is used (Eq. 2.15), to estimate the percentage of
inhibition resulting for the proportion of bound A1R (section 2.7).
Examples are given of a relatively large source C0 = 100µM, where the initial
clearance velocity is near its maximum value, (Table 3.2), and a small source
of C0 = 1µM. Note the sources here are given as a relative concentration
i.e. multiplied by the free volume fraction, so that S(x,t)α = C0 [µM] in (Eqs.
2.20, 2.22, 2.28, and 2.34).
Neuronal transport is clearly the dominant clearance mechanism for a brief
uniform source. This is apparent by the rapid clearance of extracellular
adenosine in models (II and IV) with neuronal uptake, compared to models
(I and III) lacking neuronal uptake Figure 3.7a,e. E.g. The concentration
arising from a small source (Figure 3.7a) falling below IC50 in ∼7s in model II
compared with ∼35s for model III. Neuronal adenosine (Figure 3.7b,f) peaks
as neurons become a source of breakdown products, competitively inhibiting
further adenosine uptake. While the neuronal adenosine concentration re-
mains less than the extracellular adenosine concentration, the combination
of adenosine and breakdown products within neurons can rapidly exceed the
extracellular combination, saturating ENTs (Figure 3.7e,f), this occurs be-
tween 11s C0α = 1nM and 80s C0α = 100µM. Neurons then act as a source
of breakdown products, as neuronal ADA is faster than ecto-ADA. Similarly
glial transport peaks where influx is balanced by ADK (Figure 3.7c,g), the
rapid removal of breakdown products prevents them accumulating within
glia.
With larger initial concentrations, all models show an initial exponential
decline in extracellular adenosine (Figure 3.7a), with the additional mecha-
nisms simply increasing the clearance velocity, and neuronal clearance hav-
ing the greatest effect. The duration of the adenosine signal can be charac-
terised by the time required for the estimated activation of the single site
model of the A1R to fall below 50% (Figure 3.8a), similar to the low con-
centration clearance rate τ (Table 3.1) for small sources. Alternatively the
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duration of the signal could be quantified by the average survival time of
a molecule of adenosine released as part of an initial concentration (Figure
3.8b). For small sources this is equal to the steady-state characteristic scale
given in (3.1). This relatively long time scale suggests that the adenosine
could mix throughout the whole uniform volume, (as the mean displacement
of a molecule scales as
√
6Dt and the uniform volume will be comparatively
small).
The separation between models with (II and IV) and without (I and III)
neuronal uptake is also apparent from the initial clearance velocity (Figure
3.8c), where even for small concentration neuronal uptake has a substantial
effect on the clearance velocity. The effective Vmax and Km (Table 3.2)
are determined by a nonlinear fit of the saturating MM kinetics (Eq. 2.9)
to these initial velocities. There is a dramatic increase in the velocity in
model II, combined with a reduction of Km, (Table 3.2), again highlighting
the dominant role of neuronal clearance. The removal rate of breakdown
products in glia (µ8) has almost no effect on this single MM reaction ap-
proximation, because of the relatively slow transport into glia. These single
MM reactions are a poor approximation of the clearance dynamics for model
II-IV, particularly for a small source because of the relatively rapid satura-
tion of ENTs.
Model
Km Vmax Ratio
(µM) (µM/s) (s−1)
I 80.72 (±0.18) 1.42 (±6.28×10−7) 0.018
II 13.58 (±0.36) 2.63 (±1.34×10−2) 0.194
III 56.57 (±0.30) 2.05 (±1.97×10−3) 0.036
IV 15.86 (±0.37) 3.28 (±1.45×10−2) 0.207
Table 3.2: Neuronal uptake dramatically increases the maximum removal
velocity. The MM parameters obtained via a nonlinear fit to initial clearance
velocity (Figure 3.8c) with a 95% confidence interval of the fit given in brackets.
Notice that the µ8 parameter has little effect on the parameter estimates because
of the relatively slow transport into glia.
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Figure 3.7: Neuronal uptake is the dominant clearance mechanism for a
brief uniform source. Examples of the concentration dynamics for a large a)-d)
100µM and small e)-h) 1µM source. Relative concentrations are shown on the
left, while total concentrations are shown on the right to allow direct comparison
between extracellular, neuronal and glial adenosine. Adenosine (solid) and break-
down products (dashed) in a)-c), e)-g), while d) and h) show the removal in glia
of adenosine by ADK (solid lines) or by the unsaturating clearance of breakdown
products (dashed lines). Examples shown have the rapid removal of breakdown
products in glia (µ8 = 5/s).
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Figure 3.8: Neuronal uptake is the dominant clearance mechanism for
a large range of brief uniform source intensities. a) the duration of the
adenosine signal, characterised as the time required for the estimated activation of
A1R to fall below 50%. b) the average survival time of a molecule of adenosine.
c) the initial clearance velocity, the removal rate in glia has very little impact on
the initial clearance velocity. With rapid removal of breakdown products in glia
(µ8 = 5/s) shown by solid lines and slow removal (µ8 = 5 × 10−4/s) is shown by
dashed lines.
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3.4.2 Isolated point source
There are multiple pathways implicated in activity-dependent release, with
evidence for direct neuronal adenosine release, e.g. postsynaptically in
the hippocampus (Lovatt et al. 2012), glia release, or extracellular ATP
metabolising enzymes (Wall and Dale 2008). Here these mechanisms are
modelled with a brief point source of adenosine and its range of influ-
ence is considered using a simple model of the A1R (section 2.7). It is
found to be highly localised reaching ∼25µm with a relatively large source
F0 = 50, 000zmol and primarily determined by diffusion. By integrating
over the concentration profiles, the total amount of adenosine in the intra-
cellular and extracellular spaces can be compared with the clearance of a
brief uniform source, because of rapid diffusion in the extracellular space
the removal clearance of both the large and small source are very similar.
While any brief point source will increase the concentration above the IC50
of A1R sufficiently close to the source, 200zmol is required to achieve half
activation within 1µm (Figure 3.9n). The range of influence of adenosine
scales with volume, as F
1
3
0 and is primarily determined by diffusion, (regard-
less of whether the range is based on the IC50 concentration or proportion
of bound receptors), with clearance mechanisms having a minor effect. Dif-
fusion rapidly dilutes the adenosine source, so for a small source clearance
mechanisms have very little influence on range, (Figure 3.9i,k) or duration
(Figure 3.9j,l). However, a larger source takes longer to be diluted by diffu-
sion, so clearance mechanisms can have a more substantial effect, especially
neuronal transport, (Figure 3.9b-f). There is a clear separation between
models with (II and IV) and without (I and III) neuronal uptake.
The receptor model results in both a slower rise and decay compared to the
concentration profiles (Figure 3.9a,b,g,h). The duration of the adenosine
signal, characterised as the time required for the extracellular concentration
to fall below IC50 throughout the tissue, scales as ∼F 2/30 (for the diffusive
case, section B.5). Whereas the time required for inhibition due to A1R to
fall below 50%, rapidly increases to ∼5s (Figure 3.10o).
The dominant role of neuronal uptake on adenosine clearance can be seen
by the clear separation between the profiles for models with (II and IV) and
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without (I and III) neuronal clearance (Figure 3.9a,g). This is also apparent
from the percentage inhibition i.e. the reduction in amplitude of an EPSP
for a synapse located at the source of adenosine (Figure 3.9b,h), this is also
apparent in the duration of the adenosine signal (charterised either by the
time above the IC50 or the time taken for percentage inhibition to fall bellow
50%) and peak inhibition. However the primary factor in determining the
adenosine profile is diffusion, particularly apparent from the peak adenosine
concentration which is almost identical for all models (Figure 3.9c,i).
A comparison of the clearance mechanisms is given by integrating over the
concentration profiles to obtain the amount of purines in tissue at a given
time (Figure 3.10). This has a very similar form to the small brief uniform
source (Figure 3.7e), because diffusion is able to rapidly dilute the concen-
trations. As before models II and IV deviate from this form because of the
rapid neuronal uptake, which suggests the neuronal ENTs saturate after the
initial burst, as in the uniform case.
The rate of removal of breakdown products within glia (µ8) has only a minor
effect on the extracellular amounts. Initially removal of breakdown prod-
ucts in glia dominates for rapid removal (µ8=5/s), (Figure 3.10d,h), but
as breakdown products build up the salvage pathway surpasses it, with the
crossover time in both model III and IV of 40s. This suggests the model is
able to adequately quantify extracellular concentration, but can only give a
qualitative description of the glial dynamics, without a better estimate of
the dynamics of the purine metabolism in glia.
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Figure 3.9: For a brief point source, the range of influence of adenosine
is primarily determined by diffusion with clearance mechanisms only
having a substantial impact for relatively large sources. A relatively large
source F0 = 50, 000zmol a)-f) is compared with a small source F0 = 1, 000zmol
g)-l) in both cases there is rapid removal of breakdown products in glia (µ8 = 5/s).
a) and g) are concentration profiles of extracellular adenosine at 5µm, 15µm and
25µm with inset of a log-linear plot. b) and h) the percentage inhibition based
on the proportion of bound A1R with inset of a log-linear plot. c) and i) the
peak adenosine concentration is determined by diffusion. d) and j) the duration
of the adenosine signal. e) and k) the peak inhibition. f) and l) the duration of
the adenosine signal. m) example contour plots for the large source showing 10%,
30%, 50% 70% and 90% inhibition. n) the range of influence of adenosine. o) the
duration of the adenosine signal.
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Figure 3.10: Neuronal uptake is the dominant clearance mechanism for
a brief point source. a) and e) extracellular adenosine (solid) and breakdown
products (dashed) indicate a substantial difference between models with (II and IV)
and without (I and III) neuronal transport. b) and f) neuronal adenosine (solid)
rapidly peaks at ∼5s and becomes a source of breakdown products (dashed). c)
and g) glial adenosine (solid) also reaches a peak at ∼ 3s for model III, or ∼ 7
for model IV. Break-down products (dashed) do not accumulate due to the rapid
removal mechanism. d) and h) initially glia are primarily removing adenosine
by creating AMP (solid) due to the large amount of extracellular adenosine, but
removal of breakdown products (dashed) becomes dominant as they accumulate
extracellularly. With rapid removal of breakdown products in glia µ8 = 5/s.
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3.5 Bath applied adenosine
The models developed here are applicable to experimental conditions. For
example bath application of adenosine to a tissue slice has been used ex-
tensively to study the effect of adenosine on synaptic transmission and has
produced estimates of the efficacy of adenosine clearance, suggesting ∼20
fold less adenosine at the synapse than the bath (Dunwiddie and Diao 1994;
Kerr et al. 2013; Zhang et al. 2015).
Here the models are used to obtain a steady-state concentration profile when
100µM or 10µM are applied at both the top and bottom of a 400µm slice.
When 100µM is applied the inhibitory effect of A1R exceeds 99% in the
steady state (Figure 3.11b) and reaches 50% throughout the slice within
∼15s. Whereas with 10µM applied in model IV the concentration is re-
duced to 0.3µM in the middle of the slice, but due to the high affinity of
the A1R, this still achieves at least 50% inhibition (Figure 3.11d). The
breakdown products penetrate the slice more easily due to relatively slow
uptake by glia, so the total amount gradually exceeds the adenosine in the
slice even with relatively fast removal in glia (µ8 = 5/s). The high applied
concentration may have unwanted side effects, for example activating low
density A2BR and A3R which require ∼70 and ∼90 fold higher concentration
of adenosine than A1R (Fredholm et al. 2011). The use of high applied con-
centration have been avoided in several studies, by using a net so that the
applied adenosine reaches both the top and bottom of the slice (Dunwiddie
and Diao 1994; Stutzmann et al. 2001; Kerr et al. 2013) or more commonly
using A1R antagonists that are not susceptible to the purine metabolism.
The time for the whole slice to exceed 50% activation with 100µM applied
is around 25s for model I and III and 85s for models II and 310s for model
IV. Bath applied adenosine studies typically allow several minutes for the
synaptic adenosine concentration to become stable (Dunwiddie and Diao
1994), these models confirm that this is clearly adequate. The breakdown
products rapidly accumulate in the slice in models II and IV due to relatively
rapid metabolism of neuronal ADA, with 100µM applied, the total amount
of breakdown products exceeds the extracellular adenosine concentration in
models II (by 140s) and IV (by 155s). Similarly the extracellular concen-
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tration breakdown products in the steady state is greater than adenosine
through the middle of the slice in models IV (between 177− 223µm) and II
(between 155− 245µm).
The steady-state extracellular concentrations in model IV are similar for
both slow (µ8 = 5 × 10−4/s) and fast (µ8 = 5/s) breakdown product re-
moval. The glia concentration of adenosine are also slightly higher with
fast removal, with 100µM applied, model III has a minimum steady-state
concentration of 0.3µM for fast removal compared with 0.15µM for slow re-
moval, similarly 0.2µM and 0.1µM for model IV. So while the model can
quantify the extracellular concentration of adenosine in tissue, it does not
adequately describe the glial adenosine dynamics.
3.5.1 Effective dose response curve
Here the model is indirectly compared with an experimental operative. The
local dose-response to extracellular adenosine of A1 receptors can be de-
termined from the response to agonists and their binding affinity e.g. N6-
Cyclopentyladenosine (CPA). The model gives a concentration profile of
adenosine resulting for a bath applied concentration, by assuming a uniform
distribution of synapses and receptors, the dose-response to bath applied
adenosine to be calculated and compared with experimental observations
(Stutzmann et al. 2001). The bath applied IC50 is 2.7µM for adenosine and
10nM for CPA which is shifted for the higher potency of CPA to give an
estimated 100nM IC50 for adenosine in the absence of any clearance mech-
anisms. The model of clearance then shifts this response curve further to
an IC50 of 1.1µM (Figure 3.12). The discrepancy between this estimate and
the observed value could be due to underestimating the impact of clearance
mechanisms. However, it could also be due to heterogeneities in the distribu-
tion of synapses and adenosine receptors. Synapses near the surfaces of the
slice, where the model predicts the highest concentration of adenosine, are
less likely to survive and contribute to the observed inhibition. It could also
result from heterogeneities in the clearance mechanisms themselves, ecto-
ADA has been shown to colocalize and even form a dimer with A1R (Gracia
et al. 2008) and ENTs may be preferentially located near synapses.
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Figure 3.11: The extracellular adenosine concentration remains compara-
tively high throughout the slice despite up to a ∼20 fold decrease from the
applied concentration. The steady-state concentration of extracellular adeno-
sine for a large source (100µM) falls to 50%, 35% 35% and 22% of the applied
concentration for models I-IV respectively, a small source (10µM) can fall as low as
3%. a) Extracellular adenosine concentration and b) % inhibition due to A1R fol-
lowing application of 100µM. Similarly c) and d) for 10µM application. Removal of
breakdown products in glia with rate µ8 = 5/s (solid) or µ8 = 5×10−4/s (dashed).
3.5.2 ENT Blockers
The model predicts that reducing the maximum velocity of ENTs by block-
ing some of them, will drastically increase the extracellular adenosine con-
centration (Figure 3.13). Dose response curves suggest 5µM of NBMPR
would reduce neuronal uptake by ∼11% and uptake by astrocytes by ∼19%
by blocking ENT1s. Similarly 1µM of dipyridamole produces a ∼20% reduc-
tion in ENT2 uptake, causing an estimated 17% reduction in neurons and
a 14% reduction in glia transport, by interpolation of the data presented in
(Yao et al. 1997; Nagai et al. 2005).
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Figure 3.12: Modelling adenosine clearance shifts the dose response curve
closer to the observed inhibition. a) Bath applied adenosine in (Stutzmann
et al. 2001) gives an estimated IC50 for adenosine of 2.7µM (blue line) and A1R
agonist CPA of 10nM. The CPA curve is shifted by the relative potency of CPA to
adenosine, giving an estimated IC50 of adenosine in the absence of clearance (dashed
black line). The model (evaluated at points indicted by red crosses) provides a
further shift in the CPA dose response curve to account for adenosine clearance (red
line). b) The average adenosine concentration in the tissue slice and a percentage of
the bath applied concentration clearly shows the saturation of clearance mechanisms
as the concentration is moved far beyond physiological levels. c) The extracellular
adenosine concentration with 100µM applied, scale bar shows 10µm vertical and 5s
horizontal.
This is not apparent in bath application experiments in the rat cortex or
hippocampus, where application of both 5µM of NBMPR and 1µM of dipyri-
damole had no statistically significant effect on the extracellular concentra-
tion of bath applied adenosine. This was measured by subtracting the re-
sponse of an inosine biosensor (sensitive to inosine and hypoxanthine) from
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Figure 3.13: The extracellular concentration of adenosine in the rat cor-
tex is substantially greater as ENTs are blocked, however the combina-
tion of adenosine and its breakdown products shows a smaller increase.
Concentration profiles for 30µM bath applied adenosine for a 400µm slice of the rat
cortex at 32◦C for 3 minutes. a) extracellular adenosine c) extracellular breakdown
products or d) the combination of both extracellular adenosine and its breakdown
products. The ENT velocities (V2, V3, V5 and V6) are reduced to represent the
proportion that have been inhibited. d) The relative change in the average con-
centration of adenosine, breakdown products and the combination of the two, for
reduced transport velocity shows the higher extracellular adenosine concentration
offset by a lower concentration of breakdown products, with fast removal of glia
breakdown products (µ8 = 5/s)
adenosine biosensor (sensitive to adenosine as well as inosine and hypox-
anthine). (Data provided by Marianne Cobham, M. J. Wall lab, School
of Life Sciences, University of Warwick). This could be due to a greater
role for CNTs or other, uninhibited classes of ENTs. However other studies,
particularly in the hippocampus have seen a significant decrease in the post-
synaptic EPSPs with bath application of transporter inhibitors (Clasadonte
et al. 2014), which suggests the failure to observe a change with biosensors
could be due to spatial heterogeneities of the clearance mechanisms, or the
accumulation of cytosolic ADA around the biosensors. When the biosensors
are inserted into tissue, their large diameter ∼100µm disrupts cells, this
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Figure 3.14: The extracellular concentration of adenosine and inosine are
both substantially greater as ENTs are blocked in the rat hippocampus.
Concentration profiles for 30µM bath applied adenosine for a 400µm slice of the
rat hippocampus at 32◦C. a) extracellular adenosine c) extracellular breakdown
products and d) adenosine and its breakdown products combined. The percentage
of ENT inhibited is modelled by reducing the transport velocities; V2, V3, V5 and
V6. b) The relative change in average concentration of adenosine and breakdown
products for reduced transport velocity shows a substantial rise in both adenosine
and its breakdown products, with fast glia removal of breakdown products µ8 = 5/s
is apparent from the large increase in extracellular adenosine. If cytosolic
ADA remains in or around the polymer matrix of the biosensor, then both
the inosine and the adenosine biosensor would measure adenosine and the
subtraction used to estimate the adenosine concentration would be an un-
derestimate and so unlikely to capture the change due to ENT blockers.
Therefore it may be better to consider the change in purine concentration
instead, in which case the change resulting from ENT blockers would be
far less in the cortex (Figure 3.13) and so more likely to be obscured by
experimental variability.
In the rat hippocampus changes in extracellular purine concentrations (adeno-
sine, inosine, hypoxanthine) tone was successfully observed using biosensors,
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with 5µM of NBMPR and 10µM of dipyridamole there was an increase in ex-
tracellular purines of 0.6±0.2µM’ in 7 of 9 hippocampal slices (Etherington
et al. 2009). The combined concentration of adenosine and its breakdown
products, show a similar increase to adenosine in response to ENT blockers
in the hippocampus (Figure 3.14).
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Chapter 4
Modelling biosensors in
tortuous environments
4.1 Introduction
Biosensors have become invaluable for both in vitro and in vivo experiments.
Biosensors have been used to measure neurotransmitters and neuromodula-
tors, such as: glutamate (Oldenziel et al. 2006; Hu et al. 1994), acetylcholine
(Bruno et al. 2006; Zhang et al. 2010), ATP (Wells et al. 2015; Lopata´rˇ
et al. 2015; Lalo et al. 2014; Llaudet et al. 2005), adenosine, inosine and
hypoxanthine (Wall and Richardson 2014; Van Gompel et al. 2014; Klyuch
et al. 2012a; Llaudet et al. 2003). Biosensors consist of three components;
a selective biological element, a detector element and a device to record and
display the result. Here biosensors which use enzymes to select for the ana-
lyte and electrochemically detect the product of the reactions are considered.
Such biosensors are typically formed of a microelectrode surrounded by a
permeable medium where enzymes are immobilised and will metabolise an
analyte to create an electroactive product.
Many biosensors developed for brain tissue use oxidative enzymes, followed
by detection via fixed potential amperometry (FPA). There are many con-
siderations in the construction and use of biosensors to ensure that the signal
observed provides an accurate measure of the desired substrate. These in-
clude; interference from other substrates of the enzyme cascade, interference
from O2, a non-linear enzyme response due to substrate or product inhibi-
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tion and a reduction in signal proportional to the sensors size (Dale et al.
2005). However, these difficulties have been overcome for many different
substrates, including glutamate, acetylcholine, ATP, glucose, lactate, H2O2
and adenosine.
Biosensors are typically formed of a platinum or carbon fibre core, on which
a conducting polymer matrix such as pyrrole or paraphenylene are deposited.
The electrochemical polymerization is achieved by either holding the core at
a constant potential or by cycling the potential. This allows the thickness of
the matrix to be controlled and reproduced. A thin layer biosensor is created
when the enzyme is attached (immobilised by absorption) to the surface of
the polymer matrix (Kobayashi et al. 2001), or by cross-linking the enzyme
to create a matrix principally of covalently bonded enzyme (Mikeladze et al.
2002). A thick layer biosensor is made when the enzyme is immobilised by
entrapment within the free volume of the polymer matrix, (Llaudet et al.
2003) or covalently bonded to the polymer matrix (Kotanen et al. 2014).
An in vivo study of glutamate in the striatum of anaesthetized rats mea-
sured the basal tone as ∼18µM (Oldenziel et al. 2006), by subtracting the
signal from a null sensor and using a flow-injection analysis system (Olden-
ziel and Westerink 2005) for calibration. Then inserting a micropipette
in the vicinity (within 100µm) of the biosensors and applying either; potas-
sium chloride, excitatory amino acid kainate or glutamate reuptake inhibitor
DL-threo-beta-Benzyloxyaspartate. All induced dose dependent increases in
extracellular glutamate. Finally the sodium channel blocker tetrodotoxine
(TTX) was injected, reducing extracellular glutamate by 90%, suggesting
most of the basal tone is derived from vesicle release.
Acetylcholine has also been studied with anaesthetized rats (Zhang et al.
2010), using biosensors to show that hippocampal theta oscillations are cou-
pled to acetylcholine (ACh) release. They used amperometric choline sen-
sors in the dorsal CA1 area and separated a low frequency signal containing
chemical information with a high frequency signal representing the local
field potential (LFP). They induced theta oscillation with a tail pinch and
showed an increase in choline concentration to around 100nM, and that the
maximal phasic release of ACh in CA1 occurs around the pyramidal layer,
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and the releases lag 20− 50s behind the onset of theta oscillations.
Biosensors were surgically implanted in the rat cerebral cortex to monitor
glucose concentrations during the sleep/wake cycle (Dash et al. 2013). As in
the other studies mentioned, the sensor was calibrated in vitro, but then in
vivo injections of the substrate and saline were used as confirmation. The
study focused on how brain glucose levels change during periods of high
energy need. They compared the normal sleep/wake cycle with 3 hours of
sleep deprivation. The glutamate concentration showed a rise during non
rapid eye movement (NREM) sleep (∼12mM) and a fall during REM sleep
(∼4mM), the onset of the fall is delayed by sleep deprivation.
In many studies biosensors are calibrated in a free environment before and/or
after being used in tissue. The calibration is used to estimate the concentra-
tion of analyte from the biosensor’s response. However, these studies fail to
take into account differences in the diffusion characteristics of tissue, where
analyte is limited to the ECS and the diffusion coefficient is reduced by
tortuosity. Here mathematical and computational models are developed to
compare the response of biosensors in both free and tortuous environments.
A single enzyme reaction is considered as well as an enzyme cascade, where
the product of one reaction is the substrate of another, with multiple reac-
tions required before an electroactive product is detected. Damage caused
by biosensor insertion is modelled with additional free space around the
biosensor. An estimate is made of a ratio by which the experimental re-
sponse of the biosensor should be scaled to account for differences between
the free-flow calibration and diffusive experimental environments. Finally,
the influence that the model parameters have on such a correction is con-
sidered.
4.2 Mathematical modelling
In order to characterise the response of biosensors and assist in their de-
sign, extensive mathematical and computational modelling has been used,
quantifying the influence of substrate and product inhibition (Sˇimelevicˇius
and Baronas 2010; Sˇimelevicˇius and Baronas 2011), geometry (Sˇtikoniene˙
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et al. 2010) and enzyme kinetics (Ivanauskas et al. 2008; Simelevicius et al.
2012). However, the effect that tissue structure can have on the biosen-
sor’s response has yet to be considered. Chemicals in tissue must diffuse
through the tortuous ECS, which is characterised by a reduced volume frac-
tion or porosity α, (typically ∼ 0.2 in brain tissue) and the tortuosity θ
(typically ∼1.6). The tortuosity is the proportional increase in the average
path length a particle must take because of obstructions. This influences
the macroscopic description by reducing the diffusion coefficient. Measure-
ments of these macroscopic characteristics of tissue have been made in many
brain regions and species under both physiological and pathological condi-
tions (Sykova´ and Nicholson 2008).
4.2.1 Single enzyme model
A biosensor with a single enzyme in tissue is described by a model in cylin-
drical coordinates, with radial symmetry, and three regions. The biosen-
sor is centred at the origin, and the radius of the edge of the core is rb,
this is followed by the enzyme which is immobilised in a polymer matrix
with thickness w and porosity αb and diffusion coefficient Db. Inserting the
biosensor may distort the extracellular space around it. This is incorporated
into the model with a free volume thickness d with diffusion coefficient Df .
The tissue is modelled with diffusion coefficient Dt and porosity αt (Figure
4.1). The tissue is modelled as maintaining a constant concentration of the
analyte, as a balance between a constant uniform source and endogenous
clearance mechanisms. The concentration of the analyte A is described by
the partial differential equations;
∂A
∂t
=

Db∇2Ab − VmaxAb
Km +Ab
rb ≤ r < rf
Df∇2Af rf ≤ r ≤ rt
Dt∇2At + S − f(At) rt ≤ r
(4.1)
Where Vmax and Km are the Michaelis-Menten parameters of the biosensor
enzyme, S is a uniform source of the analyte in tissue and f(At) describes
the clearance mechanisms. The concentrations of analyte are defined as the
amount of analyte in a given volume, ignoring the obstructions such as cells
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Figure 4.1: A schematic of the model for a cylindrical biosensor. The
biosensor is comprised of a conducting core, typically platinum or carbon fibre
(thickness rb) surrounded by a polymer matrix with the immobilised enzyme (thick-
ness w) forming the enzyme layer. In the calibration model a boundary condition
would be applied to the edge of the polymer matrix. Whereas the tissue model
may include a free region (thickness d) representing tissue that has been damaged
or distorted by the biosensor, followed by normal tissue. a) An idealised model
where the biosensor is sufficiently long that boundaries at the top and bottom can
be ignored and the concentration is only a function of the radius. b) An idealised
model for the biosensor in calibration. c) An in vitro model where the tissue has
the same depth as the biosensor (lb +w), this is similar to the idealised model, but
with the addition of boundary conditions on the top and bottom of the slice. d)
An in vivo model where the insulating plastic sheath is also inserted a distance lp
into the tissue, the biosensor has length lb + w.
or the polymer matrix i.e. total concentration (section 2.5.2). The simplest
case is an infinitely long biosensor so that the depth in tissue is not included
in the model. Additional radial symmetry means the Laplace operator is;
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∇2 = d
dr2
+
1
r
d
dr
(4.2)
Simulations are used (section 4.3) to confirm that there must be continuity of
relative concentrations between regions (Eq. 4.3, 4.5) but the flux between
regions depends on the total concentrations (Eq. 4.4, 4.6).
Ab (t, rf )
αb
= Af (t, rf ) (4.3)
−Db∂Ab
∂r
∣∣∣∣
r=rf
= − Df ∂Af
∂r
∣∣∣∣
r=rf
(4.4)
Af (t, rt) =
At (t, rt)
αt
(4.5)
−Df ∂Af
∂r
∣∣∣∣
r=rt
= − Dt∂At
∂r
∣∣∣∣
r=rt
(4.6)
Where the radii are; the biosensors core rb, the start of the free volume
rf = rb + w and the start of the tissue rt = rf + d.
For a range of substrate concentrations the MM kinetics can be approxi-
mated by a linear rate vb =
Vmax
Km
. This is a reasonable approximation as
biosensors are designed to operate within their linear regime. In tissue and
in the absence of the biosensor there is a steady-state concentration of the
analyte A∗, where S = f(A∗). Consider the series expansion of S − f(At)
about A∗;
S − f(At) = −vt (At −A∗t ) +O
(
(At −A∗)2
)
(4.7)
vt =
df(At)
dAt
∣∣∣∣
A=A∗
(4.8)
Then a linear model for a single enzyme biosensor is given by;
∂A
∂t
=

Db∇2Ab − vbAb rb ≤ r < rf
Df∇2Af rf ≤ r ≤ rt
Dt∇2At − vt (At −A∗) rt ≤ r
(4.9)
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For example if clearance in tissue is due to an enzyme described by MM
kinetics;
f(At) =
VmaxAt
KmAt
(4.10)
Then both S and vt can be determined;
S = VmaxA
∗
A∗ +Km
(4.11)
vt =
(S − Vmax)2
KmVmax
(4.12)
Or the clearance rate can be obtained directly;
vt =
VmaxKm
(Km +A∗)2
(4.13)
Where Vmax and Km are the Michaelis-Menten parameters of the enzyme
in tissue. The boundary conditions are;
lim
r→∞A(t, r) = A
∗ (4.14)
dA(t, r)
dr
∣∣∣∣
r=rb
= 0 (4.15)
The electroactive product, typically hydrogen peroxide (H) formed in the
polymer matrix of the biosensor is described by the following PDE;
∂H
∂t
= Dh∇2H + vbAb (4.16)
Where Dh is the diffusion coefficient of the electroactive product in the
polymer matrix. The rate of the electrochemical reaction is governed by the
Butler-Volmer model which is dependent on the holding potential, typically
the electrochemical reaction is far faster than the enzymatic reaction. This
suggests the concentration of the product at the core of the biosensor will
be zero. Hydrogen peroxide is toxic, so is rapidly removed in tissue e.g. by
catalase which does not saturate for physiological concentrations and has
activity of ∼19, 000U per ml of brain tissue, where U is the enzyme unit,
the amount of enzyme required to catalyse 1µmol of per minute. These
assumptions give the following boundary conditions;
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H(t, rf ) = 0 (4.17)
H(t, rb) = 0 (4.18)
4.2.1.1 Flow injection calibration
In flow injection calibration, where the biosensor is placed in a bath with
applied concentration S0 flowing through it (Figure 4.1b), if there is a suf-
ficiently rapid flow, the system has the following boundary conditions;
1
αb
Ab(rf ) = S0 (4.19)
dA(r)
dr
∣∣∣∣
r=rb
= 0 (4.20)
H(rf ) = 0 (4.21)
H(rb) = 0 (4.22)
The analyte at the edge of the polymer matrix will be replaced far faster
than it is metabolised (Eq. 4.19) and as before there is no flux of the ana-
lyte at the core (Eq. 4.20). The flow in the bath will remove electroactive
product produced in the polymer matrix (Eq. 4.21) and a relativly rapid
electrochemical reaction will remove the product at the core (Eq. 4.22).
4.2.2 Two-enzyme and three-enzyme cascade model
The inosine biosensor is composed of two layers of enzymes and the adeno-
sine biosensor of three (Llaudet et al. 2003). In both cases the outer most
layer holds xanthine oxidase (XO), and the next layer contains purine nu-
cleoside phosphorylase (PNP). The adenosine biosensor has an additional
innermost layer of adenosine deaminase (ADA), so adenosine or inosine has
to diffuse through the outer layers before being metabolised. As before, a
linear approximation of the reactions with rates vb for XO, vb2 for PNP and
vb3 for ADA in the biosensor are used. Together with vt, vt2 and vt3 in the
tissue and the corresponding steady-state concentration of hypoxanthine
A∗, inosine A∗2 and adenosine A∗3. This model can be solved analytically
for the idealised biosensor to give steady-state concentration profiles for
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adenosine, inosine, hypoxanthine and the electroactive product for both the
two-enzyme inosine biosensor (Figure 4.9) and the three-enzyme adenosine
biosensor (Figure 4.9). The solution is used to estimate a correction for the
calibration.
4.2.3 Quantifying biosensor responses
There are many characteristics used to quantify and compare biosensors
(Baronas et al. 2009), here several are considered in order to compare the
operation of biosensors in free and tortuous environments. The biosensor
signal or current density I(t) [nA/mm2];
I(t, S0) = neFDh
∂H(t, r)
∂r
∣∣∣∣
r=rb
(4.23)
Where ne is the charge (in number of electrons) of the electroactive product
H [µM], ne is 2 for hydrogen peroxide, with diffusion coefficient (in the
polymer matrix) Dh [m
2/s], F = 96, 485C/mol is Faraday’s constant and
S0 [µM] is the bulk substrate concentration. Let H
∗(r) be the steady-state
concentration of the product, then the steady-state current density is;
I∗(S0) = neFDh
dH∗(r)
dr
∣∣∣∣
r=rb
(4.24)
The response time can be defined as the rise time; the time required for the
signal to reach some proportion ξ of the steady-state response.
T = arg min
t
{
I(t, S0)
I∗ (S0)
≥ ξ
}
(4.25)
Biosensors are used to estimate analyte concentrations by calibrating with
a known concentration;
C =
I∗ (S0)
S0
(4.26)
Where I∗ is the steady-state signal (Eq. 4.24) with applied concentration
S0 and C [nA/µM] is the calibration which does not depend on the applied
concentration (S0) provided it is within the linear regime, e.g. S0 up to
20µM adenosine (Llaudet et al. 2003).
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The diffusion modulus;
σ2 =
w2Vmax
KMDb
(4.27)
Where w is the thickness of the enzyme layer, can determine if the biosen-
sor’s response is primarily controlled by the enzyme kinetics σ2  1, i.e.
relatively little enzyme is immobilised around the biosensors, so factors that
influence the enzyme kinetics will have a substantial effect on the current
response. Whereas if σ2  1 then the enzyme’s response is diffusion con-
trolled and is subsequently better for determining the substrate concentra-
tion (Baronas et al. 2009).
Models of biosensors are typically applied to the case where the biosensor
is placed in a well-stirred medium (Schulmeister 1990). The biosensor may
operate under an external diffusion limitation, when transport from the bulk
to the biosensors is much slower than the diffusion within the enzyme layer.
Conversely, the biosensor may operate under an internal diffusion limita-
tion, where transport through the enzyme layer is far slower. In a well
stirred medium there will persist a layer around the biosensor where trans-
port is primarily due to diffusion and not convection. The concentration of
substrate will asymptotically increase towards the bulk concentration with
distance from the biosensor. The Nernst diffusion layer approximation sug-
gests there is a layer of width δ, where transport is solely due to diffusion,
so the flux within the layer is constant, for r ∈ [rf , rf + δ) The width of the
diffusion layer will depend on the flow and viscosity of the medium, provided
the flow in the bath is sufficiently rapid, the diffusion layer will be relatively
small and so will not substantially alter the biosensor signal. The sensor may
also be coated in a permeable membrane, providing an additional diffusion
layer (Baronas et al. 2014) in order to reduce interference from other sub-
stance that could react electrochemically at the core e.g. ascorbate. Such
permeable membranes could readily be incorporated into the model, but as
interference is not considered, their only influence would be to reduce the sig-
nal in both the calibration and tissue models as a function of their thickness.
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4.3 Simulations
Particle simulations are used to confirm the choice of continuity conditions
(Eq. 4.3-4.6). Let the amount (number of particles) divided by the free vol-
ume be the relative concentration CR while the number of particles divided
by the total volume is the total concentration CT (section 2.5.2). These are
related by the free volume fraction or porosity α, with CT = αCR. Two
particle simulations are implemented, the first uses an explicitly discretized
grid with square or cubic obstructions, so that a particle takes an integer
position. At each time step it tries to move in a direction chosen uniformly
at random and remains stationary if obstructed. The second represents the
particles position with a vector of floating point numbers. In each there is
a region with and without square obstacles. Particles move through regions
until they reach an inner boundary, at which point they are replaced by
another particle at an outer boundary. This continues until a steady state
is reached, the concentration of particles is then used to compare possible
continuity conditions. It does not represent a real system, but is used to
confirm the intuition about the continuity conditions. The simulation does
not give a good representation of tissue, as the tortuosity for a given free
volume fraction is far lower than tissue. More biologically plausible obsta-
cles such as Voronoi tessellation, does not greatly increase the tortuosity.
However the required tortuosity could be obtained by including lakes (Jin
et al. 2008) or dead-space (Hrabe et al. 2004) in the ECS.
4.3.1 Spatially discrete simulations
The discrete simulation can be efficiently implemented by repeating a grid
of obstacles, the dimensions are determined by the desired length L of the
simulation, the spatial step size ∆X and the diffusion coefficient as follows;
∆X =
2MN
L
(4.28)
∆T = 2dD∆
2
X (4.29)
Where M is the number of times the N × N grid is repeated and d is the
number of spatial dimensions and D is the diffusion coefficient.
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D = lim
t→∞
1
2dt
〈
(x(0)− x(t))2
)
(4.30)
Where x(t) is the position of the particle at time step t. The mean squared
displacement scales with the number of time steps, so setting the time step
(Eq. 4.29), gives the required diffusion coefficient. Alternatively, the mean
squared displacement can be used to estimate the tortuosity θ that results
from the obstacles.
Here a 2D simulation of three concentric circles is used to confirm the con-
tinuity conditions. The largest of radius R is where particles are added to
the simulation and cannot move beyond it. Within it are two smaller circles
radius rt and rb, between rt and R there are square obstacles creating a
tortuous environment. Alternative shaped obstacles or Voronoi tessellation
does not greatly alter the relationship between porosity and tortuosity (Tao
and Nicholson 2004) and would not effect the continuity conditions. In the
simulation between rb and rt there is free space (Figure 4.2a). If a particle
reaches the inner circle rb it is removed and a new particle is added at a
random point on the outer edge (radius R). In the steady-state the flux at
rb will equal the flux at rt (Eq. 4.31). The simulation can be used to confirm
that the concentration of particles (A), must be the relative concentration
in the continuity conditions (Figure 4.2b) and the total concentration for
the continuity of the flux (Figure 4.2c), where the steady-state gradient of
the total concentration at rb is approximately equal to the gradient at rf
scaled by the tortuosity.
D
dA
dr
∣∣∣∣
r=rb
=
D
θ2
dA
dr
∣∣∣∣
r=rt
(4.31)
4.3.2 Spatially continuous simulations
With the spatially continuous simulations time step ∆T must be sufficiently
small so as to approximate the underlying continuous process. It is shown
that ∆T =
1
1024 provides a good approximation (Figure 4.3).
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Figure 4.2: The discrete particle simulation confirms choice of continuity
conditions between regions. a) The 2D grid consists of a circle with square
4 × 4 obstacles (green) with free space between them (blue) and a region without
objects (radius 160). An ensemble of 50 particles are simulated, when a particle
reaches the centre radius 80, (dark blue) it is removed and a new particle is added
on the edge. b) The relative and total concentration as a function of the radius
in the steady-state (after 1 million time steps), dashed lines show the start of the
outer/tortuous region and the inner edge of the simulation. The pulses in the
total concentration results from a greater number of particles at the radii that
include more space between objects, this is why they are eliminated in the relative
concentration. They could also be removed with a coarser averaging. c) Using
the total concentration (averaged over a radius of 20), the gradient at both the
inner boundary (rb) and the outer boundary (rt) are shown. The steady-state
gradient at the rf in the final 1,000 time steps, divided by the estimated tortuosity
θ = 1.35 (calculated from the MSD), is approximately equal to the steady-state of
the gradient at rb, confirming the use of total concentration for the flux.
As with the spatially discrete simulation, the continuous simulation can be
used to confirm the choice of total concentrations for the continuity of fluxes
and relative concentration for the continuity of concentrations (Eq. 4.3)-(Eq.
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Figure 4.3: A time step of ∆T = 11024 is sufficient to approximate the
underlying continous process. a) Smaller time steps increase the MSD because
the distance lost due to collisions is reduced. Each time step shows the average
over an ensemble to 3,000 particles moving in a 2D grid with square obstacles. b)
An example path with ∆T =
1
1024 (scale bar 5 units) c) The gradient of the mean
square displacement provides an estimate for the effective diffusion coefficient 0.55,
extrapolation suggests this will tend to 0.56 as ∆T → 0, both give an estimated
tortuosity of θ = 1.34
4.6). The simulation uses square objects in a square grid, with free space of
length L at the leftmost edge. The concentration is defined by the number
of particles at a given distance along the x-axis, divided by either the total
space (total concentration) or the free space (relative concentration). As
before, in the steady-state the flux into the free region should equal the flux
out of it;
D
dA
dx
∣∣∣∣
x=0
=
D
θ2
∇dA
dx
∣∣∣∣
x=L
(4.32)
A particle simulation with a 50 × 50 grid (the length and time scale are
arbitrary, such that the free diffusion coefficient D = 1), with a free region
extending to L = 10, followed by a tortuous region with volume fraction
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α = 925 and tortuosityθ = 1.34 (calculated from the MSD). Particles are
allowed to diffuse through the tortuous region, replacing them when they
reach x = 0 with a new particle at x = 50, until a steady-state is reached.
It becomes clear that the condition on the flux (Eq. 4.32) is satisfied by the
total and not the relative concentration (Figure 4.4). With the two fluxes
in (Eq. 4.32) differing by only ∼1% after 50,000 time steps.
Figure 4.4: Continuity conditions should be applied to the flux of the
total concentration. An ensemble of 1, 700 particles diffuse in a 2D (50 × 50)
field with a free region extending from x = 0 to 10, followed by a region with
square (4 × 4) obstacles (Inset; a schematic of the domain). A particle starts at
x = 50 and when it passes x = 0 it is removed and a new particles is added at
x = 50. The concentration as a function of the distance along the x-axis (number
of particles within a 110 region at a given time step), is shown as a heat map
with the initial distribution of particles at the top and the final distribution at the
bottom. Below this map are the number of particles as a function of distance along
the x-axis, averaged over the final 5,000 time steps, which is proportional to the
total concentration. The peaks in the number of particles correspond to vertical
gaps between the square obstacles. In this steady-state the gradient of the total
concentration at x = 0 (-8.2× 10−4) and at the start of the tortuous region x = 10
(-8.3 × 10−4) (scaled by the tortuosity θ = 1.34 from MSD) differ by ∼1%. This
confirms that continuity conditions of the flux between regions (Eq. 4.32) must be
given in terms of total concentrations.
4.4 Parameter estimation
The parameters that describe the biosensor are the radius of the core rb,
the thickness of the enzyme layer w, the tortuosity of the polymer matrix
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µ, (used to determine the diffusion coefficients) and the free volume fraction
of the enzyme layer αb. However, an extensive literature review found these
values are seldom specified in publications (Table A.1). The free volume frac-
tion in the polypyrrole matrix is difficult to determine, as it is known to de-
pend on deposition conditions, doping agents, inert additives and thickness,
with the initial (< 100nm) thickness governed by nuclei growth, whereas
later layers follow a 1D transversal growth (Garcia-Belmonte 2003). A com-
parison of the free volume of polypyrrole with different dopant-ions measured
with nitrogen gas (Hallik et al. 2007) has volume fractions between 0.26 and
0.56, but nitrogen is much smaller (14g/mol) than either hydrogen peroxide
(34g/mol) or hypoxanthine (136g/mol) so this may overestimate the rele-
vant free volume. Given the diffusion coefficient in the polymer matrix is
equal to the free diffusion (Sarissa Biomedical Ltd.). The free volume frac-
tion was estimated as 0.15 from the steady-state calibration response of the
hypoxanthine biosensor 2.60±0.28nA (± standard error, n = 4) with 10µM
hypoxanthine applied (Table 4.1).
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In constructing the hypoxanthine biosensor 10µl containing the pyrrole monomer
and 5U xanthine oxidase (XO) (Llaudet et al. 2003), the percentage of im-
mobilized enzyme is not estimated although it is suggested that it may be far
greater than the 8% (Coche-Guerente et al. 1995) obtained using a similar
technique. Then assuming the enzyme is uniformly distributed the activity
5U in 10µl suggests a velocity of 8.34mM/s in the 10µl volume. If only
8% is entrapped the rate for the volume of the enzyme matrix is 0.67mM/s
at 25◦C. At 32◦C the maximum velocity is 71% higher (Mondal and Mitra
1994), suggesting a velocity of 1.14mM/s, together with Km of 6.41 (Mondal
and Mitra 1994), this provides an estimated removal rate of vb = 178/s. Two
reactions occur in the hypoxanthine biosensor; hypoxanthine → xanthine +
H2O2 and xanthine → urate +H2O2. Both reactions are catalysed by XO,
for simplicity they are modelled as a single reaction, where the analyte (hy-
poxanthine) produces twice as much of the electroactive product (hydrogen
peroxide).
In homogenate of the rat cerebrum and cerebellum, xanthine oxidase ac-
tivity was found to be 19.5mU/g of tissue at 30◦C (Hashimoto 1974). As-
suming hypoxanthine clearance is due to xanthine oxidase and this activity
is uniformly distributed in the brain, gives an average clearance velocity of
0.31µM/s. Using this value for the maximum clearance together with the
Km of 6.41 (Coche-Guerente et al. 1995), suggests a source rate S of 24nM/s
(Eq. 4.11) and a clearance rate vt of 43× 10−3/s (Eq. 4.12).
In whole rat brain homogenate XO activity was 2.26 nmol/mg protein/hour
at 37◦C (Betz 1985). Assuming 10mg of tissue produces 1mg of protein sug-
gests an average velocity 0.60µM/s. PNP activity has been found in the CSF
but the kinetics have not been determined for inosine but for a 2-amino-6-
mercapto-7-methylpurine ribonucleoside (MESG), (Silva et al. 2004). The
kinetics are Vmax = 10.2 ± 0.6U/g which is approximately 0.17µM/s and
Km = 142.5 ± 29.5µM which gives a clearance rate of vt2 of 1.1 × 10−3/s
(Eq. 4.13).
The adenosine biosensor used 1U of ADA in 10µl entrapped in polypyrrole,
which suggests a velocity of 1.67mM/s in the 10µl volume. Assuming only
8% is entrapped, gives a velocity of 133µM/s at 25◦C. Using the Q10 of
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ADA 3.74, gives a velocity of 649.8µM/s. ADA from the bovine spleen, has
a Km = 93 ± 2.1µM (Sharoyan et al. 2006), which gives a removal rate of
vb3 = 6.99/s.
4.4.1 Reliability of response
The estimation of parameters from the biosensor calibration responses, and
in particular the rise times, were considered. However the peak response of
the sensors varies considerably, (Figure 4.5) and the same sensor can show
both a decline (e.g. calibrations 4-5) or increase (e.g. calibration 1-3) in re-
sponsiveness after successive experiments. This may be due to a reduction
in the thickness of the enzyme layer with use. The rise times (Eq. 4.25) and
fall times vary considerably between calibrations (Figure 4.6), which is more
likely to reflect nonlinear flow in the bath than characteristics of the sensors,
and means that rise time data is unlikely to be useful in determining the
sensor parameters. (Data provided by Marianne Cobham, M. J. Wall lab,
School of Life Sciences, University of Warwick).
94
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
0
0.5
1
1.5
2
2.5
3
3.5
4
calibration
pe
ak
 re
sp
on
se
 (n
A)
 
 
ADO adenosine
ADO inosine
INO inosine
Figure 4.5: Peak adenosine biosensor response during calibration. The
peak response is the average over a 1s window, with error bars showing the maxi-
mum and minimum response within the window. Lines join successive calibrations
performed with the same biosensors before and after it is used in tissue. The peak
calibration responses are quite variable, even for the same biosensor, which limits
the extent calibration data could be used to infer the parameters. Data provided by
Marianne Cobham, M. J. Wall lab, School of Life Sciences, University of Warwick
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Figure 4.6: Time required for adenosine biosensors to reach peak re-
sponse and to return to baseline during calibration. The rise time is the
duration between 10% and 90% of the peak response, conversely the fall time is the
duration of 90% to 10%. The three layer adenosine biosensor (ADO) is calibrated
with either adenosine or inosine, while the two-layer inosine biosensor (INO) is cal-
ibrated with inosine. The variability in a) the rise time and b) fall time may be the
result of nonlinear flow in the bath and it suggests that calibration data can not
be used to reliably infer the biosensor parameters. The difference (rise time - fall
time) shows the rise time tends to be greater than the fall time. Data provided by
Marianne Cobham, M. J. Wall lab, School of Life Sciences, University of Warwick
96
4.5 Model response and calibration multiplier
The dynamics of the tissue and calibration models are determined by the
PDE (Eq. B.165), this is solved numerically (code C.2). There is a rapid
rise time in calibration reaching 95% of the steady-state response within
0.1s. The tissue models overshoot the steady-state response, as the biosen-
sor metabolises all the nearby analyte, after which there is a slow decay
to the steady-state response, reaching 105% within 20s (Figure 4.7). The
addition of a free region diminishes the initial peak and increases the time
required to reach the steady-state response, this is because the analyte gen-
erated in the tissue has to diffuse further to be detected.
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Figure 4.7: The response of the tissue model is both quantitatively and
qualitatively different from calibration. The dotted lines show the steady-
state response and the inset shows the calibration model. The signal for the cali-
bration model rapidly reaches the steady-state response. Whereas the tissue models
with (d = 5µm) and without (d = 0µm) a free region have an initial peak as the
biosensor reacts with all the available analyte. The tissue response then slowly
decays towards the steady-state, as the analyte has to diffuse further to reach the
biosensor.
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Biosensors connect currents to concentration by calibrating with a known
concentration (Eq. 4.26). Biosensors are typically calibrated in a free-flow
environment, however the models show this will produce a substantially
larger signal than would be observed in tissue for the same analyte concen-
tration (Figure 4.8b). Let the calibration multiplier be;
m =
I∗t (A∗)
I∗c
(
A∗
αt
) (4.33)
Where I∗t is the steady-state signal (Eq. 4.24) of the tissue model (Figure
4.1a) and I∗c the steady-state signal of the calibration model (Figure 4.1b),
for the same relative concentration i.e. A∗ in tissue and A
∗
αt
in the free-
flow environment. The relative concentration is used as it is more relevant
than the total concentration for quantifying chemical signals and ensures
m ∈ [0, 1]. As the models are both linear A∗ factors out, so a similar multi-
plier matched for the total concentrations
I∗t (A∗)
I∗c (A∗)
is obtained by multiplying
m by αt ≈ 15 .
The calibration multiplier is the amount by which the free-flow steady-state
current should be multiplied to provide an estimate of the calibration signal
for the tissue environment;
Cˆ =
mI∗ (S0)
S0
(4.34)
Where Cˆ [nA/µM] is the calibration corrected for differences in the free-flow
and tissue environment. The inverse of the calibration multiplier ( 1m) is the
proportion of tissue concentration that would be underestimated using con-
ventional calibration (Eq. 4.26).
Idealised biosensors with two or three-enzyme layers are considered and an-
alytic solutions were obtained for the steady-state concentration profiles and
responses. The calibration multiplier for the two-enzyme biosensor depends
on both the second analyte and the analyte concentration (Eq. 4.35). Sim-
ilarly the calibration multiplier for the three-enzyme biosensor depends on
all three analyte concentrations (Eq. 4.36). The calibration multiplier is
0.05 for the two-enzyme biosensor and 0.03 for three-enzyme sensor, (pa-
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rameter values from Table 4.1). Typically biosensors that are sensitive to
multiple analytes are calibrated to each separately, in which case different
calibration multipliers are estimated for each analyte. However the amal-
gamated multiplier estimated here is sufficient to demonstrate the need for
such a correction and for comparison between one, two and three-enzyme
biosensors.
mb =
I∗t (A∗, A∗2)
I∗c
(
A∗
αt
,
A∗2
αt
) (4.35)
mc =
I∗t (A∗, A∗2, A∗3)
I∗c
(
A∗
αt
,
A∗2
αt
,
A∗3
αt
) (4.36)
Where mb is the calibration multiplier of the two-enzyme biosensor with
steady-state tissue concentration of the first analyte A∗ e.g. hypoxanthine
and the second analyte A∗2 e.g. inosine. Similarly the calibration multiplier
for the three-enzyme biosensor mc also depends on the concentration of the
third analyte A∗3 e.g. adenosine.
Calibration multipliers can be obtained for each analyte separately. Let
C be the calibration of the single-enzyme biosensor as before and C1 and
C2 are the calibration for the first and second analyte of the two-enzyme
biosensor;
C
(2)
1 =
I∗ (S0, 0)
S0
(4.37)
C
(2)
2 =
I∗
(
0, Sb0
)
Sb0
(4.38)
These are obtained experimentally by placing the biosensor in a free-flow
environment and applying S0 of the first analyte (Eq. 4.37) or S
b
0 of the
second analyte (Eq. 4.38). Then in an experiment the concentration of the
second analyte would be estimated as;
A2 =
1
C
(2)
2
(
I∗2 − I∗1
C
(2)
1
C
)
(4.39)
Where I∗2 the steady-state current of the two-enzyme biosensor and I∗ the
response of the corresponding single-enzyme biosensor. Subtraction is nec-
99
essary as the two-enzyme biosensor is sensitive to both analytes. To account
for the difference between the free-flow calibration environment and the tor-
tuous tissue environment two calibration multipliers are required;
mb1 =
I∗t (A∗, 0)
I∗c
(
A∗
αt
, 0
) (4.40)
mb2 =
I∗t (0, A∗2)
I∗c
(
0,
A∗2
αt
) (4.41)
Whereas (Eq. 4.40-4.41) are obtained from the models of the biosensor
in tissue and the calibration environments. Then a better estimate of the
concentration of the second analyte can be obtained by subtraction;
A2 =
1
mb2C
(2)
2
(
I∗2 − I∗1
mb1C
(2)
1
mC
)
(4.42)
Similarly for the three-enzyme adenosine biosensor;
C
(3)
1 =
I∗ (S0, 0, 0)
S0
(4.43)
C
(3)
2 =
I∗
(
0, Sb0, 0
)
Sb0
(4.44)
C
(3)
2 =
I∗ (0, 0, Sc0)
Sc0
(4.45)
Where S0 is the applied concentration of the first analyte (Eq. 4.37) , S
b
0
of the second analyte (Eq. 4.38) and Sc0 of the third analyte. Then in an
experiment the concentration of the third analyte would be estimated as;
A3 =
1
C
(3)
3
(
I∗3 −
C
(3)
2
C
(2)
2
(
I∗2 − I∗1
C
(2)
1
C
)
− C
(3)
3
C
I∗1
)
(4.46)
Where I∗3 the steady-state current of the three-enzyme biosensor, I∗2 the
response of the corresponding two-enzyme biosensor and I∗ the response of
the single-enzyme biosensor. Their calibration multipliers are required to
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account for the difference between the free-flow and tissue environments;
mc1 =
I∗t (A∗, 0, 0)
I∗c
(
A∗
αt
, 0, 0
) (4.47)
mc2 =
I∗t (0, A∗2, 0)
I∗c
(
0,
A∗2
αt
, 0
) (4.48)
mc3 =
I∗t (0, 0, A∗3)
I∗c
(
0, 0,
A∗3
αt
) (4.49)
The multipliers are obtained from the models of the three-enzyme biosensor
in tissue (I∗t ) and the calibration (I∗c ) environments. An improved estimated
of the concentration of the third analyte is;
A3 =
1
mc3C
(3)
3
(
I∗3 −
mc2C
(3)
2
mb2C
(2)
2
(
I∗2 − I∗1
mb1C
(2)
1
mC
)
− m
c
1C
(3)
1
mC
I∗1
)
(4.50)
Where I∗3 is the steady-state response of the three-enzyme biosensor, I∗2 the
two-enzyme biosensor and I∗1 the single-enzyme biosensor. The multipliers
for a model of a three-enzyme adenosine biosensor (with the parameters in
Table 4.1) are given in Table 4.2.
The calibration multipliers determined for models of a single, two and three
layer biosensor are very small, suggesting the tissue concentration obtained
using conventional calibration would underestimate the analyte concentra-
tion by up to ∼40 fold. The multiplier is determined by the model pa-
rameters (Table 4.1), so this may be exaggerated, but does emphasise the
necessity of accounting for the tortuous environment in which biosensors are
used.
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Biosensor hypoxanthine inosine adenosine combined
single-enzyme 0.024 - - 0.024
two-enzyme 0.021 0.148 - 0.046
three-enzyme 0.019 0.056 0.120 0.028
Table 4.2: Calibration multipliers for each biosensor model. Either
the combined calibration multiplier (Eqs, 4.33, 4.35 and 4.36), or the cali-
bration multiplier when the biosensor is exposed to the first analyte (hypox-
anthine), second analyte (inosine) or third analyte (adenosine) separately.
4.5.1 Steady-state solutions
The steady-state solutions in cylindrical coordinates (section B.9) are given
in terms of modified Bessel functions;
M0(r) = I0 (κr) + γK0 (κr) (4.51)
M1(r) = I1 (κr)− γK1 (κr) (4.52)
γ =
I1 (κrb)
K1 (κrb)
(4.53)
κ =
√
vb
Db
(4.54)
Where σ = κw is the root of the diffusion module (Eq. 4.27), a dimen-
sionless characteristic of the biosensor. The parameters suggest σ = 9.4,
as σ2  1 the response of the biosensor is controlled by diffusion not the
enzyme kinetics, allowing the biosensor to accurately measure the analyte
concentration. For calibration the steady-state solution is;
Ab(r) = BbM0(r) (4.55)
Bb =
αb
M0 (rf )
(4.56)
In the case where there is no tissue damage, i.e. rf = rt, the steady-state
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solution is;
A(r) =
{
BbM0 (r) rb ≤ r < rt
A∗ +BtK0 (cr) rt ≤ r
(4.57)
c =
√
vt
Dt
(4.58)
Bb =
A∗
αt
[
M1 (rt)
αb
+
Db
Dt
κM1 (rt)K0 (crt)
αtcK1 (crt)
]−1
(4.59)
Bt = −BbDb
Dt
κM1 (rt)
cK1 (crt)
(4.60)
Finally the addition of a free diffusion layer around the biosensor has the
following steady-state solution;
A(r) =

BbM0 (r) rb ≤ r < rf
A∗
αt
+
Bt
αt
(
K0 (crt)− a log
(
r
rt
))
rf ≤ r < rt
A∗ +BtK0 (cr) rt ≤ r
(4.61)
Bt = −BbDb
Dt
rfκM1 (rf )
rtcK1 (crt)
(4.62)
Bb =
A∗
αt
[
M0 (rf )
αb
− Df
Db
(rfκM1 (rf ))
×
(
log
(
rf
rt
)
− Df
Dt
K0 (crt)
αtrtcK1 (crt)
)]−1 (4.63)
a =
Dt
Df
rtcK1 (crt) (4.64)
In each case;
H(r) = 2Bb
Db
Dh
(M0 (rf )−M0 (rb)) log
(
r
rb
)
log
(
rf
rb
)
+M0 (rb)−M0(r)]
(4.65)
Where Bb is given be (Eq. 4.56) for calibration and (Eq. 4.59) for the tissue
model without damage and (Eq. 4.63) for the tissue model with, and free
region around the biosensor.
Analytic solutions to the two and three-enzyme sensor have been obtained
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and have a similar form to (Eq. 4.65). The steady-state concentration
(Figure 4.8) shows the limited influence an additional free region has for
the single enzyme model. The influence of the biosensor is also relatively
limited, reaching 95% of the unperturbed tissue concentration (A∗) within
250µm. The calibration multiplier for the single enzyme biosensor is 0.02,
which implies that the concentration found in tissue through using conven-
tional calibration should be ∼40 fold greater.
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Figure 4.8: The relative concentrations of both the analyte and product
within the enzyme layer (25 − 45µm) are far greater in the free-flow
environment than in tissue, where the applied concentration in the free-
flow environment is the relative steady-state tissue concentration A
∗
αt
.
The rapid metabolism in the enzyme later (rate vb) substantially diminishes the
concentration in the surrounding tissue. a) The analyte in the polymer matrix
(25−45µm) is vastly greater for the calibration model (Eq. 4.55) than either tissue
model with (Eq. 4.61) or without (Eq. 4.57) a free region around the biosensor
caused by tissue damage. The inset shows that the additional free region has little
effect and both tissue models result in a very low concentration in the enzyme
layer. The concentration in tissue approaches the steady-state concentration in the
absence of the biosensor (A
∗
αt
) within a relatively short distance determined by the
rate of activity in tissue vt. b) The electroactive product is also substantially greater
during calibration, the inset shows the concentration for the two tissue models is
∼25 fold lower than calibration. This plot show the relative concentrations, so they
are continuous between regions. Parameter values from Table 4.1.
The concentration profile of analyte for an idealised two-enzyme biosensor is
similar to (Figure 4.8a), but with contribution from both tissue on the right
and the reaction of the second analyte on the left. The second reaction rate
in the biosensor (vb2) is far slower than the first (vb), subsequently the second
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Figure 4.9: The steady-state tissue concentrations around the biosensor
is greatly reduced, resulting in far less electroactive product than the
free-flow environment, where the applied concentration is the relative
steady-state tissue concentration A
∗
αt
. The two-layer biosensor has a region of
the enzyme layer (25− 45µm layer 1) that reacts with the second analyte (inosine)
and a region (45− 65µm layer 2) that reacts with the analyte (hypoxanthine). a)
the analyte concentration. b) The second analyte (inosine) c) The electroactive
product is the result of the reaction in layer 3, it either diffuses though layer 1
to be detected at the biosensor or diffuses into tissue and is destroyed. d) The
concentration of electroactive product for a model of the free-flow environment.
This plot show the relative concentrations, so they are continuous between regions.
Parameter values from Table 4.1.
analyte penetrates the enzyme layer and the concentration in tissue is not as
dramatically reduced. However the biosensor effects a larger region due to
the slower reaction rate in tissue vt2 (Figure 4.9b). As with the single-enzyme
biosensor a free-flow environment with the same relative concentrations as
tissue (far from the biosensor) results in far more electroactive product in
the steady-state.
The concentration profile of the analyte in the three-layer biosensor (Figure
4.10), in layer 1 is almost half that of the two-layer biosensor (Figure 4.9a),
because it has a larger region to fill (layers 1 and 2). The second analyte and
has a much greater concentration (∼3 fold) than in the two-layer biosensor
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Figure 4.10: The greater volume of enzyme layers for the three-enzyme
biosensor reduces the concentration of the electroactive product close
to the biosensor. a) The analyte (hypoxanthine) reacts within layer 3 forming
the electroactive product. b) The second analyte (inosine) reacts within layer 2.
c) The third analyte (adenosine) within layer 1, producing the second analyte.
d) The steady-state concentration electroactive product in the tissue environment
with (d=5µm) and without (d=0µm) a free region is substantially lower than a
free-flow environment d) with the same relative concentration. These plots show
the relative concentrations, so they are continuous between regions. Parameter
values from Table 4.1.
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(Figure 4.9b), as it is produced in tissue and by reaction of the third ana-
lyte. The concentration of electroactive product is less than for the two-layer
biosensor, because the analyte has to travel further to reach the core, more
is lost to tissue or the free-flow environment, so the product concentration
in layer 1 is almost 3/4 that of the two-layer biosensor (Figure 4.9c,d).
4.6 Sensitivity analysis
The calibration multiplier (Eq. 4.33) depends on the parameters of the
model. Here the multiplier is determined for a range of values for each
parameter in turn, while the others remain fixed at the values given in
Table 4.1.
4.6.1 Single enzyme biosensor
The signal in both the calibration and tissue models is lower for wider cores,
but the core width has a similar effect on both models, so core radius has
almost no effect on the calibration multiplier (Figure 4.11a). The thickness
of the enzyme layer influences both the calibration and tissue models. There
is a peak in the steady-state signal for a layer of thickness ∼2µm in calibra-
tion and ∼0.5µm in the tissue model. The signal diminishes with a thicker
layer, as more of the product is lost as it diffuses into tissue, or the bath
and is removed. Conversely a thinner layer also reduces the signal as fewer
reactions can take place to produce the electroactive product. As the signal
for both the calibration and the tissue model is reduced for thinner layers,
the calibration multiplier increases, e.g. m = 0.95 for a layer thickness of
1nm.
The steady-state gradient of the electroactive product at the core of the
biosensor is almost unaffected by tortuosity. Whereas the same gradient in
the tissue model is greater the more tortuous the enzyme layer, as the influ-
ence of the biosensor on the concentration of analyte around the biosensor
is diminished. This is apparent in the calibration multiplier, (Figure 4.11f)
e.g. m ≈ 0.5 for a matrix tortuosity of 25.
The reaction rate in tissue vt obviously does not influence the calibration
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model, but the faster vt the greater the signal for the tissue model, as the
biosensor will have less of an influence on the analyte concentration in tissue,
which is being removed and replaced more rapidly. However, vt only appears
in the model as a ratio of the relatively large diffusion coefficient in tissue
(Eq. 4.58), so small changes in vt have little effect on the calibration multi-
plier (Figure 4.11d). E.g. vt ∼100 for m ∼0.5. While the tortuosity of the
tissue (Figure 4.11g) has a substantial influence, it has been estimated for
many species, brain regions and experimental conditions (Nicholson 2005),
so it may be known prior to the experiment.
The steady-state response of the calibration model is larger when the enzyme
reaction in the biosensor is faster, reaching 95% of the maximum response
at vb ≈ 30/s. The signal from the tissue model has a maximum at vb ≈ 5/s,
the signal in the tissue model is diminished if the reaction rate is faster than
this, as the concentration of analyte in tissue is reduced. When vb is slow,
both models have a similar response and the calibration multiplier is larger
(Figure 4.11e) e.g. For vb = 1/s then m ∼0.5. However, in constructing a
biosensor it is not desirable to have a slow reaction rate and subsequently
a small diffusion module (Eq. 4.27), as the response is controlled by the
enzyme kinetics in the biosensor rather than the substrate concentrations
around it.
The steady-state response of the calibration model is linearly dependent
on the volume fraction of the enzyme layer αb, whereas the steady-state
response of the tissue model is substantially greater with a larger volume
fraction when αb < 0.1, but almost unaffected by changes in volume frac-
tion when αb > 0.2. So for a small volume fraction, both the calibration
and tissue response are diminished as the calibration multiplier is increased
(Figure 4.11h), e.g. m ∼0.5 for αb ∼0.003.
The tortuosity and porosity of tissue gives rise to substantially lower steady-
state concentrations in the matrix around the biosensor. This difference is
exacerbated by rapid metabolism in the biosensor (vb). However, a rapid
reaction in the biosensor is desirable in biosensor design. Consider the diffu-
sion module (Eq. 4.27), for a slow reaction σ2  1 and the response becomes
dependent on the enzyme kinetics of the sensor rather than the analyte con-
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Figure 4.11: The calibration multiplier is dependent on the parame-
ters, however it remains relatively small for a wide range of values.
The estimated calibration multiplier of 0.02 for the parameters given in Ta-
ble 4.1 is shown in red, while a single parameter is varied to see the impact
it has on the calibration multiplier. a) The radius biosensor core (rb) can
vary from ∼7µm using carbon fibre to over ∼50µm with platinum, but this
has a similar effect on both the calibration and tissue model, so has little
influence on the calibration multiplier. b) For a very thin matrix width
both the calibration model and tissue model have a very low response. c)
The free region has little effect on the tissue model response (Figure 4.8c).
d) The velocity of removal in tissue vt has a limited effect on the response,
its unlikely to reach very large values as this would mean the tissue was
producing and destroying the analyte very rapidly. e) A slow reaction rate
in the biosensor vb means the response in both models is determined more
by the enzyme than the analyte, so the response is similar and the cali-
brate multiple closer to 1. f) The matrix tortuosity has a greater impact on
the tissue model than the calibration model as it determines the effect the
biosensor has on analyte concentration in tissue, for larger values this effect
is diminished and the biosensor response in tissue is closer to the response in
calibration. g) While the tissue volume fraction influences the response, it
is unlikely to vary greatly during an experiment and estimates are available
in the literature for many brain regions (Nicholson 2005). h) It is difficult
to estimate the matrix volume fraction and it can have a substantial impact
on the required calibration multiplier.
centration. The diffusion module for the single-enzyme biosensor is σ = 9.4,
as σ2  1 the response of the biosensor is controlled by diffusion not the
enzyme kinetics, allowing the biosensor to accurately measure the analyte
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concentration in calibration, but also gives rise to a calibration multiplier
of 0.02. The parameters for biosensors are rarely published and may vary
between biosensors and with use e.g. the polymer matrix is known to decay
with repeated use.
4.6.2 Two-enzyme biosensor
The two-enzyme biosensor has an estimated calibration multiplier of 0.05 for
the parameters (Table 4.1). The solution can be used as before to determine
the influence each parameter has on the calibration multiplier. Unlike the
single enzyme case, here the calibration multiplier is based on calibration
with a combination of the two analytes (Eq. 4.35). As with the single en-
zyme layer, the matrix properties have the greatest effect on the calibration
multiplier. With a greater matrix tortuosity the signal in the tissue model
is closer to the signal in the calibration model (Figure 4.12i), similarly for a
smaller matrix volume fraction (Figure 4.12j).
4.6.3 Three-enzyme biosensor
An adenosine biosensor with three-enzyme layers is considered. As before
analytic solutions are obtained for the concentration of each substrate and
used to determine the signal during calibration, tissue, and the correspond-
ing calibration multiplier, mc = 0.02. As before there are several parameters
determining the enzyme layer thickness, biosensor reaction rate and matrix
porosity (Figure 4.13) which when reduced slow the reaction in both cali-
bration and tissue to such an extent that the calibration multiplier is close
to 1.
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Figure 4.12: The matrix thickness, tortuosity and volume fraction
have the greatest impact on the calibration multiplier. a) The
radius biosensor core (rb) has a similar effect on both calibration and tissue
models. b) The thickness of layer 1, (where the reaction of the second
analyte occurs) has little effect, unlike c) the thickness of the second layer
(where the reaction of the analyte occurs), as it is this reaction that produces
the electroactive product. If this is slow, both calibration and tissue model
will produce a similar response. d) The thickness of free region has little
effect on the concentration of product in the sensor, so does not substantially
influence the response (Figure 4.9). e) The reaction rate of the analyte in
tissue (vt) has a greater impact on the multiplier than f) the second analyte
vt2 , due to the comparatively slow reaction in the biosensor of the second
analyte compared with the first. g) Similarly changing the reaction rate of
the analyte vb in the biosensor has a greater impact than changing the rate
of the second analyte h) vb2 , as the second analyte has to go though both
reactions to result in electroactive product. i) The matrix tortuosity, j) the
matrix volume fraction, k) tissue tortuosity and l) tissue volume fraction
have the same effect on the multiplier as the single layer biosensor (Figure
4.11). The combined calibration multiplier of 0.05 for parameters in Table
4.1 is shown with a dashed line.
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Figure 4.13: The three-enzyme biosensor has more parameters so
their individual influence on the calibration multiplier is dimin-
ished. As before, the parameters of the enzyme layer have the greatest
impact on the calibration multiplier. a) The radius of the biosensor core
(rb) has a similar effect on both calibration and tissue models, so has little
impact on the calibration multiplier. b) The thickness of layer one (the
inner most layer where the reaction of the third analyte occurs) and c) layer
two (the middle layer where the reaction of the second analyte occurs) have
little influence on the calibration multiplier compared with d) the third
layer thickness (where the reaction of the first analyte occurs producing the
electroactive product), as this layer is a bottleneck, where all three analytes
must react to be detected. e) The free region has little effect on the con-
centration of product in the enzyme layer (Figure 4.8b). The reaction rate
in tissue of the f) analyte vt, g) second analyte vt2 and h) third analyte vt3
determine the range of influence the biosensor has on the analyte concen-
trations and so influence on the calibration multiplier. As with layer width,
the reaction rate in the biosensor of i) the analyte vb is a bottleneck for the
formation of the electroactive product, so has a far greater impact on the
combined calibration multiplier than either the j) second analyte vb2 or k)
third analyte vb3 . l) The matrix tortuosity m) the biosensor volume frac-
tion, n) the tissue tortuosity and o) volume fraction have the same effect on
the combined multiplier as for the single layer biosensor (Figure 4.11). The
estimated combined calibration multiplier of 0.02 for parameters in Table
4.1 is shown by the dashed line.
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4.7 Tissue depth
The idealised model (Figure 4.1a) can be expanded to account for the finite
length of a biosensor inserted into tissue. Here a single-enzyme biosensor is
considered. As before the analyte A is described by the PDE (Eq. 4.1) and
by making linear approximations (Eq. B.165). However, in this case the
Laplace operator is;
∇2 = 1
r
∂
∂r
(
r2
∂
∂r
)
+
∂
∂z2
(4.66)
Additional boundary conditions are needed for the slice surfaces. A simple in
vitro case is consider where the whole biosensor length (lb) is inserted into a
slice of tissue with the same depth (lb). The tissue is in a bath with artificial
cerebrospinal fluid (aCSF) flowing over both the top ( lb2 ) and bottom (-
lb
2 ).
The insulation on the biosensor is assumed to cover the enzyme layer at the
top and there is no polymer matrix at the base of the sensor (Figure 4.1b).
Typically a tissue slice will have a far greater length than depth as thick
slices can become hypoxic, so a boundary condition is applied in the limit
r →∞. These assumptions give the boundary conditions;
A
(
t, r,
lb
2
)
= 0 rf < r (4.67)
dA(t, r, z)
dz
∣∣∣∣
z=
lb
2
= 0 rb < r ≤ rf (4.68)
A
(
t, r,− lb
2
)
= 0 (4.69)
lim
r→∞A(t, r, z) = A0(z) (4.70)
dA(t, r, z)
dr
∣∣∣∣
r=rb
= 0 (4.71)
dH(t, r, z)
dz
∣∣∣∣
z=
lb
2
= 0 rb < r ≤ rf (4.72)
H
(
t, r,− lb
2
)
= 0 (4.73)
H (t, rb, z) = 0 (4.74)
H (t, rf , z) = 0 (4.75)
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Where A0(z) is the steady-state concentration of analyte in the tissue slice
without the biosensor, it is given by;
A0(z) = A
∗
1− cosh (cz)
cosh
(
c lb2
)
 (4.76)
c =
√
vt
Dt
(4.77)
Where the boundaries are at ± lb2 , this is also the initial condition of the
tissue. In the initial condition for the free region, and enzyme layer, both
the analyte and the product are zero. The continuity conditions are the
same as (Eq. 4.3-4.6) for all z.
An in vivo case is also considered where a biosensor of length lb is inserted
at depth lp into tissue and plastic insulation covers the top of the polymer
matrix, which extends around the whole sensor (Figure 4.1c). The boundary
conditions require zero flux of the analyte at the core, at r = 0 and at the
surface. The analyte concentration is fixed at A∗ as the depth or radius
tends to infinity. The boundary conditions on the product require it to be
zero at both the core and at the edge between the enzyme layer and the
free region, with zero flux at r = 0 and at the top of the enzyme layer,
where it meets the plastic sheath. The analyte concentration is initially A∗
in the tissue and zero in the free region and enzyme layer. The product
concentration is initially zero. The continuity conditions are similar to (Eq.
4.3-4.6) with continuity of the relative concentrations between regions and
continuity of the flux of the total concentrations.
4.7.1 Model response
More realistic in vitro and in vivo models are considered (Figure 4.1c,d).
The concentration in each model are determined numerically, (code C.3)
and used to infer the biosensor’s response. As with the time-dependent re-
sponse for the idealised model, there is a sharp initial rise, (Figure 4.14)
followed by a slow decay as the sensor removes the nearby analyte, until
it reaches the steady-state response. The heat maps show that the analyte
does not penetrate far into the enzyme layer, as it is rapidly converted to
the electroactive product.
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Steady-state responses for the in vivo model give a calibration multiplier of
0.041 similar to the idealised model, which does not include depth. Sim-
ilarly the in vitro model has a calibration multiplier of 0.034. While the
model response differs from the idealised biosensor, it still demonstrates the
need to account for differences between the calibration and the experimental
environments, quantified by the calibration multiplier (Eq. 4.33).
115
Figure 4.14: The signal obtained from the in vitro and in vivo model
has a similar form to the idealised model, but it is quantitatively
different. a) the time-dependent response for the in vitro model is far
smaller than both the idealised and in vivo model, in part due to a lower
concentration of analyte in tissue. There are three time points (indicated
by red crosses) where the concentration profiles of the analyte (top) and
product (bottom) are shown, b) at 0.5s, c) at 2.5s and d) at 5s. These
show the decline in the concentration of analyte and product towards e) the
steady-state concentrations. The electroactive product is only shown in the
enzyme layer, as it is not in tissue, so the length scale is much smaller. Notice
that the initial distribution in tissue has a depth dependent concentration
profile (Eq. 4.76). f) the time-dependent response for the in vivo case also
with three time points (indicated by red crosses) where the concentration
profiles of the analyte (top) and product (bottom) are shown, g) at 0.5s, h)
at 2.5s and i) at 5s. Which tend towards j) the steady-state concentrations.
Here the biosensor core and plastic sheath are included in the model (Figure
4.1d), indicated by the white area in the top right. The concentration of
electroactive product is shown in the enzyme layer, hence the smaller length
scale. Time step 1µs and ∆R = ∆Z = 1µm. The grid size 500× 500µm for
the in vitro model and 1000× 1000µm for the in vivo model with insertion
depth 20µm and sensor length 500µm.
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Chapter 5
Conclusion
The interactions between transport and metabolism of the neuromodulator
adenosine have not previously been well quantified. This study provides
the first detailed model of the spatiotemporal dynamics of adenosine in
tissue. The mechanisms included in the model are; diffusion and break-
down by adenosine deaminase (ADA) in the extracellular space; competi-
tive transport between the extracellular and intracellular space by equili-
brative nucleoside transporters (ENT); neuronal breakdown by ADA and
glial metabolism via adenosine kinase. A hierarchy of models was consid-
ered, starting with extracellular metabolism only, then including neurons,
or glia, or both. Analysis of these models determines that the concentra-
tion following local adenosine release is primarily determined by diffusion
through the tortuous extracellular space (chapter 3). The literature search
provided estimates of the model parameters as well as identifying aspects
of the purine transport and metabolism that have yet to be experimentally
quantified (chapter 2). The model predicts the range of influence of an iso-
lated adenosine source, characterised as the maximum distance where the
amplitude of an EPSP would be halved due to the activation of A1Rs, the
most abundant class of adenosine receptors in the neocortex. The great-
est influences on this effective range are the tortuous diffusion coefficient,
extracellular volume fraction, and the endogenous adenosine tone (chapter
3). Purine biosensors measure both adenosine and its breakdown products
inosine and hypoxanthine by an enzymatic cascade that produces hydrogen
peroxide which is electrochemically detected. The response of the sensor is
typically compared with flow-injection calibration to estimate the concentra-
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tion in tissue. In chapter 4 mathematical models of the biosensors allowed
the response to be correctly scaled to account for the tortuosity and volume
fraction of the tissue.
5.1 Adenosine clearance
It is shown that the range of influence of a point source of adenosine is pri-
marily determined by diffusion. The model indicates that neuronal metabolism
is the dominant clearance mechanism due to its rapid uptake and breakdown
of adenosine, e.g. for a small constant point source in the steady state,
neuronal clearance reduces the total amount of extracellular adenosine to
around 12% of model I, compared to around 50% by glia. This suggests
that the role played by glia in maintaining the endogenous tone of adeno-
sine is predominately as a release mechanism. In the bath applied case the
clearance mechanisms frustrate penetration through the tissue slice, how-
ever, experimental work is able to mitigate this effect by applying far higher
concentrations of adenosine than occur endogenously, by using adenosine
receptor agonists that are not affected by uptake and metabolism and by
using a perfusion system to increase the flow of adenosine through the slice.
5.1.1 Diffusion
The model predicts that for quantities of adenosine expected during normal
brain function, the primary factor determining the range of influence is dif-
fusion. Subsequently factors that influence diffusion will have a substantial
effect on the adenosine signal. The diffusion coefficient is influenced both
by temperature and by the tortuosity of the ECS. Adenosine has a neuro-
protective role, with studies that focus on pathological conditions such as
epilepsy and ischemia, which reduce the extracellular volume fraction and
increase tortuosity of the ECS (Sykova´ et al. 1994), decreasing the rate
of diffusion through the tissue, and localising the influence of adenosine re-
lease. Additionally the tortuosity of the ECS varies with species and brain
region (Sykova´ and Nicholson 2008). Lastly several slice preparation and
experimental procedures can also alter tortuosity and extracellular volume
fraction (Wetherington et al. 2008; Aitken et al. 1995).
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Extracellular adenosine concentrations are correlated with the need for sleep
(Sims et al. 2013; Clasadonte et al. 2014) with the ECS having been shown
to increase substantially from ∼15% in awake to ∼25% in anaesthetised
mice, while the tortuosity is unchanged (Xie et al. 2013). The extracellular
concentrations and cellular transport will be reduced in the anaesthetised
state, decreasing both the gradient of the curve and the influence of clear-
ance mechanisms, thus increasing the range of influence (Figure 3.6c, Figure
3.9n).
5.1.2 Clearance mechanisms
The clearance mechanisms have a significant effect for uniform sources and
bath applied adenosine. They only have a substantial impact on point
sources that are sufficiently large to compensate for rapid dilution due to dif-
fusion. Previous work has suggested that the dominant removal mechanism
for adenosine is via ADK: based on it higher binding affinity (Boison 2006).
The substantial increase in the endogenous tone of adenosine when it is in-
hibited with iodotubercidin (Etherington et al. 2009) and overexpression of
ADK in transgenic mice causes both spontaneous seizure activity (Fedele
et al. 2005) and more damage during ischemia (Pignataro et al. 2006).
Whereas ADA has a lower binding affinity and inhibition with erythro-9-(2-
hydroxy-3-nonyl)adenine (EHNA), it does not have a significant impact on
adenosine signalling in physiological conditions, depending on brain region
(Latini and Pedata 2001), consistent with variations in expression of ADA
between regions (Yamamoto et al. 1987). The models presented here only
consider clearance of adenosine, and as glia play only a minor role in clear-
ance, they predict that blocking ADK will have little effect. However this
does not contradict previous findings. Breaking the cycle between AMP and
adenosine mediated by ADK and 5′N, would turn glia into a source of adeno-
sine. This has been demonstrated in the rat cerebellum, where the increase
in endogenous tone following application of iodotubercidin, was prevented
when ENT blockers, NBTI and dipyrimole were applied (Wall et al. 2007).
Transport of adenosine is known to be a vital clearance mechanism (Dun-
widdie and Diao 1994), consistent with the model results. Clearance of the
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endogenous adenosine during physiological conditions could be accomplished
by cellular transport and the relatively slow glia clearance, even with dimin-
ished ADA activity. While ADA remains important for clearance of larger
more pathological concentrations (Dunwiddie and Masino 2001). For bath
applied adenosine the salvage of breakdown products by glia is clearly signif-
icant, experimentally glia may be ablated (Bush et al. 1998) or the salvage
pathway may be blocked with an XO inhibitor, such as febuxostat (Honorat
et al. 2013). In either case the extracellular concentration of breakdown
products may be sufficient to cause unwanted side effects, such as increases
in brain-derived neurotrophic factor (Muto et al. 2014) or activation of a sig-
nal transduction pathway that regulates axonal growth (Dachir et al. 2014).
5.1.3 Parameters
The simplified salvage pathway used in these models attempts to account for
removal of inosine and xanthine through the blood brain barrier (BBB), how-
ever it ignores both direct removal of adenosine in glia through the BBB and
the creation of AMP via hypoxanthine and inosine monophosphate (IMP).
It is difficult to test the validity of this simplification. There is a cycle be-
tween inosine and IMP, and in pathological conditions conversion of IMP
to inosine is believed to be the main source of astrocytic inosine rather
than uptake from the ECS (Schultz and Lowenstein 1978). However, given
the difficulties of obtaining parameter estimates for the speed and affinity
of inosine transport, a more detailed model of the salvage pathway would
not improve the accuracy of these models. Experiments of the kind used
to establish the parameters of adenosine transport e.g. using radiolabeled
adenosine molecules in cell cultures, could be conducted for inosine allowing
the effect of competitive inhibition to be accurately modelled. Given this
data it may be constructive to separate the breakdown products into inosine
and hypoxanthine, as hypoxanthine is known to have a very low transport
affinity, Km ∼1mM. The models here primarily focus on adenosine, but ino-
sine can also bind to A1R, A2AR or A3R (Hasko´ et al. 2004) and may have
significant cognitive effect (Kaster et al. 2013).
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5.1.4 Model hierarchy
The spatial resolution of macroscopic models are limited, requiring around
∼10µm for the averages over spatial structures to be valid. This makes it
inappropriate for studying heterogeneities in adenosine concentration that
may occur about a synapse. Similarly, diffusion is not modelled in the in-
tracellular space.
Without knowing the source of extracellular adenosine it is difficult to esti-
mate the minimum release required to affect multiple synapses. Given the
synaptic density in the rat parietal cortex gives an average distance between
synapses of 1.6µm (Calverley et al. 1988). An alternative is to use the
spine density to estimate an average upper bound on the distance between
synapses, 1.7 ± 0.3 µm of dendrite per spine for thick tufted layer 5 pyra-
midal neurons of the rat visual cortex (Larkman 2004). In both cases the
method here is inappropriate at this scale, as it fails to account for the local
microstructures around the synapse.
It would be desirable to be able to further subdivide the tissue by type of
glia, i.e. oligodendrocytes, microglia and astrocytes, as well as the classes
of neurons, e.g. inhibitory interneurons and excitatory primary neurons.
This could be achieved using cell cultures to perform transport and uptake
studies of adenosine. Transport focuses on the short time scale so as not
to include intracellular metabolism, whereas uptake looks over longer time
scales. Experimental validation of such a model will be challenging, given
the small spatial scales involved.
5.1.5 Brain regions and sources
This model could easily be adapted for other species and brain regions by
changing the parameters, although there are substantial difference in the
purine metabolism e.g. neuronal ADA is restricted to a subset of neurons
and is most prominent in the tuberomamillary nucleus and is more abun-
dant in glia than neurons in mice. Adenosine influence on neuronal activity
is primarily mediated by the A1R; however in the striatum the A2AR also
has a prominent effect. It is not clear that the simple receptor model used
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here would adequately capture the effect of adenosine. Adenosine receptors
are also influenced by several endogenous proteins and other GPCRs. A fas-
cinating extension is to incorporate the growing body of work on activity-
dependent adenosine release, with the goal of coupling the slow diffusive
dynamics and fast network dynamics.
As the first detailed model of adenosine dynamics in neural tissue, several
assumptions have been made to produce a parsimonious model. Several pa-
rameters could not be inferred from the literature, in particular estimates
of kinetics AK in glia and ENTs velocity and affinity for inosine, while oth-
ers are highly uncertain, such as the removal rate of breakdown products
in glia. The models predict concentration profiles are primarily determined
by diffusion, while clearance mechanism have a substantial impact for large
point sources that are able to persist despite rapid diffusion, and for uniform
sources. Neuronal uptake is the dominant clearance mechanism due the rel-
atively rapid neuronal ADA compared with ecto-ADA. They also occupy a
greater volume and have faster transporters than glia.
5.2 Biosensor modelling
The modelling performed in chapter 4 for hypoxanthine, inosine and adeno-
sine biosensors (Llaudet et al. 2003), could readily be applied to any of the
biosensors used in tissue (Table A.1) or other tortuous media. The main
barrier for such analysis is the paucity of published information regarding
the properties of the biosensors. The advantage of modelling biosensors in
tissue is the ability to more accurately estimate the concentration of an-
alytes in tissue, which is essential for any quantitative understanding of
chemical signalling. The modelling suggests tissue concentration could be
up to ∼40 fold greater than the estimates obtained by conventional cali-
bration. Although this is on the parameters of the biosensor, for a wide
range of parameters this underestimation is still substantial. It may be that
biosensors are less well suited to detecting the analyte where the calibra-
tion and tissue signal are similar, e.g. the model suggests a slower reaction
rate for the enzyme in the biosensor will reduce the underestimation of tis-
sue concentration, however this will also mean the biosensor response will
122
be more dependent on the enzyme than the analyte concentration around it.
Additionally layers could be added to the model, for example an additional
Nafion layer is often used to reduce interference from negatively charged
molecules like ascorbate, or the Nernst diffusion layer could be included
in calibration. These inactive layers would have a solution following the
logarithm of the radius, and as they are relatively thin would have little
influence on the calibration multiplier. In particular the thickness of the
Nernst diffusion layer, (used to account for the depletion of analyte about
the electrode), is obtained by extrapolating the concentration gradient at
the electrode surface to a radius where the bulk concentration is reached.
While it is relevant during calibration, its thickness will diminish with the
flow rate and so will not have an influence on the signal for sufficiently rapid
flow.
This study only considered cylindrical biosensors, however many other shapes
are often used, for example disk shapes are quite common (Table A.1) and
the analysis could readily be repeated for such shapes. However more com-
plex geometries are also used, for example the plate-gap model describes
a biosensor created by depositing the enzyme into a porous electrode e.g.
carbon paste electrode (Gavalas et al. 1998), where there is an outer mem-
brane over multiple enzymes deposits which are surrounded by the electrode.
While both mathematical and numerical modelling has been performed for
the plate-gap biosensor (Baronas et al. 2006; Ivanauskas and Baronas 2008),
the diffusion characteristics of tissue have not been taken into account.
In conclusion, this work includes both the first detailed model of adenosine
clearance in tissue and a mathematical model of the biosensors that are
frequently used to measure adenosine. While there are limitations in both
the models developed, principally in estimating parameter values, together
they provide a foundation for the quantitative study of adenosine signalling
in the brain.
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Appendix A
Biosensors review
An extensive literature review of many of the biosensors available for various
neurochemical species, shows that the key parameters necessary for mod-
elling the response of the biosensor are rarely published. These paramters
are liklely to vary greatly given the wide range of techniques that are used
to form the enzyme layer and the variety of enzymes used to select a specific
analyte.
Sensor Layers Enzymes Parameters
ATP (Llaudet
et al. 2005)
silicate layer glycerol kinase
(GK)
rb 3.5µm (carbon fibre)
glycerol-3-
phosphate ox-
idase (G3POx)
12.5µm or 25µm (platinum)
ascorbate oxidase
(20U/10µl)
w unknown
Cosubstrate:
glycerol
µ unknown
Electroactive
product: 1 H2O2
αb unknown
GK Vmax = 420fmol/s Km = 165µM
G3POx Vmax = 590fmol/s Km = 133µM
ATP (Patel et al.
2011)
poly-phenol
film
glucose oxidase
(GOx)
rb 25µm platinum disc
hexokinase
(HEX)
w unknown
Compete for glu-
cose
µ unknown
Electroactive
product: 1 H2O2
αb unknown
GOx Vmax unknown Km = 10.69µM
HEX Vmax unknown Km unknown
Glucose (Endo et al.
2010)
Nafion layer glucose oxidase
(GOx)
rb 88µm
2 layers cross
linked GOx
and BSA
Electroactive
product: 1 H2O2
w unknown
µ unknown
αb unknown
GOx Vmax unknown Km unknown
Glucose (Chen et al.
2002)
polyphenol
layer
glucose oxidase
(GOx)
rb 42.5µm
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with cross-
linked
Electroactive
product: 1 H2O2
w 0.5µm
GOx, BSA
and 3-ATS
µ unknown
outer
polyurethane
layer
αb unknown
GOx Vmax unknown Km unknown
Hypoxanthine (Li et al.
2008)
FeTPPNPs
layer
xanthine oxidase
(XO)
rb 1.5mm glassy carbon core
cross-linked Electroactive
product: 2 H2O2
w unknown
XO, BSA and
GA
µ unknown
layer αb unknown
X0 Vmax unknown Km unknown
Hypoxanthine (Coche-
Guerente
et al. 1995)
amphiphilic
pyrrole
xanthine oxidase
(XO)
rb 2.5mm disk
Electroactive
product: 2 H2O2
w unknown
µ unknown
αb unknown
X0 Vmax unknown Km unknown
Hypoxanthine (Llaudet
et al. 2003)
lactobionamide
pyrrole
xanthine oxidase
(XO)
rb 3.5µm (carbon fibre)
amphiphillic
pyrrole
Electroactive
product: 2 H2O2
12.5µm or 25µm (platinum)
anti-fouling
layer
w ∼20µm
µ unknown
αb unknown
X0 Vmax unknown Km unknown
Inosine As above additional
layer
Purine nucleoside
phosphorylase
(PNP)
wi unknown
amphiphillic
pyrrole
‘ PNP Vmax unknown Km unknown
Adenosine As above additional
layer
adenosine deami-
nase (ADA)
wa unknown
amphiphillic
pyrrole
‘ ADA Vmax unknown Km unknown
Glutamate (Hu et al.
1994)
Nafion layer glutamate oxi-
dase (GO)
rb 88µm
cellulose ac-
etate layer
ascorbic acid oxi-
dase (AAO)
w unknown
cross-linked Electroactive
product: 1 H2O2
µ unknown
BSA, GA
and enzyme
layer
αb unknown
GO Vmax unknown Km unknown
Glutamate (Tian et al.
2009)
poly(phenylene
diamine)
glutamate oxi-
dase (GO)
rb 3.5µm (carbon fibre)
sol-gel later Electroactive
product: 2 H2O2
12.5µm or 25µm (platinum)
w unknown
µ unknown
αb unknown
GO Vmax unknown Km = 776µmol/L
Glutamate (Mikeladze
et al. 2002)
redox poly-
mer (PVI19-
dmeOs)
glutamate oxi-
dase (GlOx)
rb 1.5mm graphite core (13% porosity)
cross-linked
poly(ethylene
glycol)
horseradish per-
oxidase (HRP)
w unknown
enzyme layer Electroactive
product: 1 H2O2
µ unknown
αb unknown
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GO Vmax unknown Km = 3 or 7mM
Glucose (Kotanen
et al. 2014)
polypyrrole
(PPy) with
SBA co-
valently
bonded to
GOx
glucose oxidase
(GOx)
rb 50µm
and Lactate PPy(SBA-
con-GOx)
or P(Py-co-
PyBA-con-
GOx)
lactate oxidase
(LOx)
w unknown
Second layer
Py PyBA
with en-
trapped
LOx
Electroactive
product: 1 H2O2
each
µ unknown
αb unknown
GOx Vmax unknown Km = 7.2 or 19.7mM
LOx Vmax unknown Km unknown
Lactate (Kobayashi
et al. 2001)
2 thin films
of con-
canavalin
A with at-
tached LOx
lactate oxidase
(LOx)
rb 1.5mm disk
Electroactive
product: 1 H2O2
w ∼0
µ unknown
αb unknown
LOx Vmax unknown Km unknown
Acetylcholine (Chen et al.
1998)
20 monolay-
ers alternat-
ing between
avidin an at-
tached ChOx
choline esterase
(ChE)
rb 1.5mm disk
additional
layer of
avidin and
attached
ChE
choline oxidase
(ChOx)
w ∼210nma
Electroactive
product: 3 H2O2
µ unknown
αb unknown
ChE Vmax unknown Km unknown
ChOx Vmax unknown Km unknown
D-serine (Zain et al.
2010)
poly-ortho-
phenylenediamine
(PPD) layer
d-amino acid oxi-
dase (DAAO)
rb 1.5mm graphite core (13% porosity)
Nafion layer Electroactive
product: 1 H2O2
w unknown
GA and
DAAO later
µ unknown
αb unknown
DAAO Vmax unknown Km = 3 or 7mM
Choline (Razola et al.
2003)
BSA
crosslinked
to HRP with
GA, paraffin
and PHZ
horseradish per-
oxidase (HRP)
rb 1.5mm disk
CHOx with
dialysismem-
brane
choline oxidase
(CHOx)
w unknown
Electroactive
product: 2 H2O2
µ unknown
αb unknown
HRP Vmax unknown Km unknown
CHOx Vmax unknown Km unknown
D-Serine (Shigetomi
et al. 2013)
D-amino acid oxi-
dase (DAAO)
rb 25µm
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Electroactive
product: 1 H2O2
w unknown
µ unknown
αb unknown
DAAO Vmax unknown Km unknown
Table A.1: Review of published information for a variety of biosensors.
Where Km is given it is based on K
app
m of the biosensors response. a] estimated form
(Gokel 1997). The following acronyms are used; (3- aminopropyl)trimethoxysilane
(3-ATS), bovine serum albumin (BSA), iron (III) mesotetraphenylporphyrin
nanoparticles (FeTPPNPs), glutaraldehyde (GA),4-sulfobenzoic acid (SBA), pyrrol
(Py), 4-(3-pyrrolyl)butyric acid (PyBA), Phenothiazine base (PHZ)
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Appendix B
Mathematics appendix
B.1 Enzyme kinetics
E + S
k1

k−1
ES
k2→ E + P (B.1)
Where E is the enzyme and S is the substrate. By assuming the total
enzyme concentration does not change (E0) and that the concentration of
the complex ES does not change on the same timescale as the product
formation;
E0 = [E] + [ES] (B.2)
d [ES]
dt
= 0 (B.3)
Then the ODE for the complex can be written as;
d [ES]
dt
= k1 [E] [S]− k1 [ES]− k2 [ES] (B.4)
= 0 (B.5)
[ES] = k1 (E0 − [ES]) [S]− k−1 [ES]− k2 [ES] (B.6)
=
k1E0 [S]
k2 + k−1 + k1 [S]
(B.7)
=
E0 [S]
Km + [S]
(B.8)
Km =
k2 + k−1
k1
(B.9)
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Then the rate of product formation is given by;
d [P ]
dt
= k2 [ES] (B.10)
=
Vmax [S]
Km + [S]
(B.11)
Vmax = k2E0 (B.12)
B.2 Transporter kinetics
Suppose the transporters have the following kinetics;
E +Ae
k1

k2
EA
k2

k1
E +Ai (B.13)
E + Pe
k3

k4
EP
k4

k3
E + Pi (B.14)
Assume the total concentration of transporters does not change and that
the concentrations of the complex changes on a slower timescale than the
equilibration of the intracellular and extracellular concentration of adenosine
and it’s breakdown products.
E0 = [E] + [EA] + [EP ] (B.15)
d [EA]
dt
= 0 (B.16)
d [EP ]
dt
= 0 (B.17)
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Suppose the intracellular and extracellular space occupy the same volume
fraction, then let A = [Ae] + [Ai] be the total adenosine concentration.
d [EA]
dt
= k1 [Ae] [E] + k1 [Ai] [E]− 2k2 [EA] (B.18)
= 0 (B.19)
[EA] =
k1
2k2
[E] ([Ae] + [Ai]) (B.20)
=
k1
2k2
(E0 − [EA]− [EP ])A (B.21)
=
E0 − [EP ]
2k2
k1
+A
A (B.22)
=
E0 − [EP ]
KA +A
A (B.23)
Similarly
[EP ] =
E0 − [EA]
2k4
k3
+ P
P (B.24)
=
E0 − [EA]
KP + P
P (B.25)
Substituting (Eq. B.25) into (Eq. B.23) gives
[EA] =
E0 (KP + P )A− E0AP
(KA +A) (KP + P )−AP (B.26)
=
E0KPA
KAKP +KAP +KPA
(B.27)
Similarly
[EP ] =
E0KAP
KAKP +KPA+KAP
(B.28)
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Where KA =
2k2
k1 and KP =
2k4
k3
. The concentration transported is then
given by;
d [Ai]
dt
= k2 [EA]− k1 [E] [Ai] (B.29)
= k2 [EA]− k1 (E0 − [EA]− [EP ]) [Ai] (B.30)
=
(k2 + k1 [Ai])E0KPA− k1E0 [Ai] (KAKP +KPA+KAP ) + k1E0KAP
KAKP +KPA+KAP
(B.31)
=
k2E0KPA− k1E0 [Ai]KAKP
KAKP +KPA+KAP
(B.32)
=
k2E0KPA− 2k2E0 [Ai]KP
KAKP +KPA+KAP
(B.33)
=
k2E0KP ([Ae]− [Ai])
KAKP +KPA+KAP
(B.34)
=
VA ([Ae]− [Ai])
KA
(
1 +
P
KP
)
+A
(B.35)
Where VA = k2E0, similarly with VP = k4E0;
d [Pi]
dt
=
VP ([Pe]− [Pi])
KP
(
1 +
A
KA
)
+ P
(B.36)
B.2.1 Volume fractions
The above derivation is valid if the extracellular volume fraction (α) is equal
to the intracellular volume fraction (β). The concentrations are given by
their relative volumes (2.5.2) and the second order reaction rates (with units
µM−1s−1) may be scaled by the relevant volume fraction. Let the trans-
porter [E] and bound transporter [EA] and [EP ] be represented by their
total concentration, while adenosine and its breakdown products are rep-
resented by the relative concentration. Again using the quasi-steady-state
assumptions (Eqs. B.15-B.17) gives;
d [EA]
dt
=
k1
α
α [Ae] [E] +
k1
β
β [Ai] [E]− 2k2 [EA] (B.37)
= 0 (B.38)
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Where [Ae] is scaled by α to give the total concentration, similarly [Ai] is
scaled by β, as the reactions are then given in terms of total concentrations,
the reactions rate k1 is also scaled by the corresponding volume fraction.
This is identical to (Eq. B.18), so [EA] is given by (Eq. B.27) and [EP ] by
(Eq. B.28). Then;
d [Ai]
dt
= k2
1
β
[EA]− k1 1
β
[E] [Ai] (B.39)
=
1
β
VA ([Ae]− [Ai])
KA
(
1 +
P
KP
)
+A
(B.40)
Where [EA] and [E] are scaled by 1β to give the relative concentration, as
the reaction is in terms of the relative concentration, k1 is not scaled by the
volume fraction. Similarly;
d [Ai]
dt
=
1
α
k2 [EA]− k1
α
[E] [Ae] (B.41)
=
1
α
VA ([Ai]− [Ae])
KA
(
1 +
P
KP
)
+A
(B.42)
Notice that as E0 represents a total concentration, so unlike the enzyme
kinetics VA and VP do not need to be scaled by the volume fraction (section
2.5.2). While k1 and k3 represent the relative rates
B.3 Low concentration limit
In low concentration limit the Michaelis-Manton kinetics are equal to first
order removal rates µi =
Vi
Ki
and the description of the transporters (Eq.
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B.43-B.46) are given by (Eq. B.47-B.50).
JAn =
V2K3 (An −Ae)
K2K3 +K2 (Pe + Pn) +K3 (Ae +An)
(B.43)
JPn =
V3K2 (Pn − Pe)
K2K3 +K2 (Pe + Pn) +K3 (Ae +An)
(B.44)
JAg =
V5K6 (Ag −Ae)
K5K6 +K5 (Pe + Pg) +K6 (Ae +Ag)
(B.45)
JPg =
V6K5 (Pg − Pe)
K5K6 +K5 (Pe + Pg) +K6 (Ae +Ag)
(B.46)
jAn = µ2 (An −Ae) (B.47)
jPn = µ3 (Pn − Pe) (B.48)
jAg = µ5 (Ag −Ae) (B.49)
jPg = µ6 (Pg − Pe) (B.50)
The low concentration limit for model IV is;
∂Ae
∂t
= D∇2Ae − µ1Ae + 1
α
(
jAn + j
A
g
)
+
S
α
δ (r) (B.51)
∂Pe
∂t
= D∇2Ae + µ1Ae + 1
α
(
jPn + j
P
g
)
(B.52)
dAn
dt
= − 1
βn
jAn − µ4An (B.53)
dPn
dt
= − 1
βn
jPn + µ4An (B.54)
dAg
dt
= − 1
βg
jAg − µ7Ag (B.55)
dPg
dt
= − 1
βg
jPg − µ8Pg (B.56)
In the steady-state the intracellular concentrations are proportional to the
extracellular concentrations;
A∗n =
µ2
βnµ4 + µ2
A∗e (B.57)
P ∗n = P
∗
e +
βnµ4
µ3 (βnµ4 + µ2)
A∗e (B.58)
A∗g =
µ5
µ5 + βgµ7
A∗e (B.59)
P ∗g =
µ6
βgµ8 + µ6
P ∗e (B.60)
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Which gives the following steady-state transport by the ENTs;
j¯An = −
βnµ2µ4
βnµ4 + µ2
A∗e (B.61)
j¯Pn =
βnµ3µ4
βnµ4 + µ2
A∗e (B.62)
j¯Ag = −
βgµ5µ7
µ5 + βgµ7
A∗e (B.63)
j¯Pg = −
βgµ6µ8
βgµ8 + µ6
P ∗e (B.64)
So the steady-state extracellular concentration are determined by two ODEs;
0 = D∇2A∗e − µ1A∗e +
1
α
(
j¯An + j¯
A
g
)
+
S
α
δ (r) (B.65)
0 = D∇2A∗e + µ1A∗e +
1
α
(
j¯Pn + j¯
P
g
)
(B.66)
Which can be rearranged as follows;
0 = ∇2A∗e −
A∗e
λ2
+
S
αD
δ (r) (B.67)
0 = ∇2P ∗e +
A∗e
κ21
− P
∗
e
κ22
(B.68)
Where;
λ =
√
D
(
µ1 +
1
α
(
βnµ2µ4
βnµ4 + µ2
+
βgµ5µ7
µ5 + βgµ7
))−1
(B.69)
κ1 =
√
D
(
µ1 +
1
α
βnµ3µ4
βnµ4 + µ2
)−1
(B.70)
κ2 =
√
Dα
βgµ8 + µ6
βgµ6µ8
(B.71)
Solutions in spherical coordinates are found by using the boundary condition
A∗e(r) → 0 as r → ∞ and by using the divergence theorem to equate the
surface integrated of the ODE with the volume integral of the source term as
the radium of the volume goes to zero. The same approach yields a solutions
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Figure B.1: The low concentration limit provides a good approximation
for a wide range of sources because the concentration is rapidly dimin-
ished by diffusion. Examples of relatively; a) large source (10, 000zmol/s) and
b) small source (1, 000zmol/s) are shown with enlargements close (blue box) and
far (red box) from the source. The radius at which the concentration reaches IC50
is indicated with an arrow labelled r50. Contour plots show the inhibitory concen-
tration of 20%, 40%, 60% and 80% of A1R, with scale arrow of 50µm. c) Shows
how the maximum distance at which the concentration exceeds the IC50 increases
with the source intensity in the low concentration limit (solid lines) for each of the
models. The dashed show the numerical solution are almost identical to the low
concentration limit.
for Pe, as follows;
A∗e(r) =
S
4piDαr
exp
(
− r
λ
)
(B.72)
P ∗e (r) =
Sκ22λ
2
4piDακ21
(
κ22 − λ2
)
r
(
exp
(
− r
κ2
)
− exp
(
− r
λ
))
(B.73)
These solutions (Figure B.1a,b) are obtained from the general solution,
which has the form;
Ae(r) = K1
e−
r
λ
r
+K2
e
r
λ
r
(B.74)
lim
r→∞Ae(r) = 0 (B.75)
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So
Ae(r) = K1
e−
r
λ
r
(B.76)
Then by considering an integral of a sphere about the source of radius ep-
silon; ∫ ∫ ∫
V
dV Ae =
∫ ∫ ∫
V
dV
F
Dα
δ(r) (B.77)
by the Divergence theorem;
4pi
[
r2∇ ·Ae(r)
]
0
= − F
Dα
(B.78)
4Kpie−

λ
(
1− 
λ
)
= − F
Dα
(B.79)
Taking the limit → 0
K =
F
4piDα
(B.80)
The range of influence (r50), characterised by the distance where the con-
centration exceeds the IC50, is determined as;
F
4piαDr50
exp
(
−r50
λ
)
= IC50 (B.81)
r50
λ
exp
(
−r50
λ
)
=
F
4piαDλIC50
(B.82)
Let z = r50λ then;
zez =
F
4piαDλIC50
(B.83)
r50 =
1
λ
W
(
F
4piαDλIC50
)
(B.84)
Where W is the product-log function (Figure B.1c). The low concentration
limit for the other models are determined by removing the terms for the
appropriate clearance mechanisms and provides a good approximation for a
wide range of source terms Figure B.1c.
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B.4 High concentration limit
A similar limit can be found for high extracellular concentration of adeno-
sine. In this case
∂Ae
∂t
= D∇2Ae − V1 − 1
α
(
φAn + φ
A
g
)
+
S(t, r)
α
(B.85)
φAn = V2
1
Ae
[
K2K3 +K2 (Pe + Pn) + 2K3An −K3Ae
K3Ae
]
+O
(
1
A2e
)
(B.86)
φAn = V5
1
Ae
[
K5K6 +K5 (Pe + Pg) + 2K6Ag −K6Ae
K3Ae
]
+O
(
1
A2e
)
(B.87)
If the concentration of the breakdown products is far lower than that of
extracellular adenosine then the transport occurs at its maximum velocity
and the model IV is;
∂Ae
∂t
= D∇2Ae − Vmax + S(t, r)
α
(B.88)
Vmax = V1 +
1
α
(V2 + V5) (B.89)
Where V2 is the maximum uptake by neurons and V5 is the maximum uptake
by glia (these terms can be removed to given the maximum velocity in
models I, II and III). If the concentration of breakdown products is also
high, this approximation is invalid as transport between the intracellular
and extracellular space will be far slower.
B.5 Solution for the diffusion model
For model zero, where only diffusion is included the solution for a constant
point source F [zmol/s] is found in the same way as the solution of the low
concentration limit (section B.3. The general solution is;
Ae(r) =
K
r
(B.90)
By integrating over a small sphere about the origin;∫ ∫ ∫
V
dV Ae =
∫ ∫ ∫
V
dV
F
Dα
δ(r) (B.91)
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Using the divergence theorem on the left-hand side
lim
→0
4pi
[
r2∇ ·Ae(r)
]
0
=
F
Dα
(B.92)
4piK =
F
Dα
(B.93)
Ae(r) =
F
4piDαr
(B.94)
For a brief point source at the origin, the solution to the diffusion equation
in spherical coordinates is given by;
Ae(t, r) =
F0 exp
(
− r24Dt
)
√
6piα (Dt)
3
2
(B.95)
So the peak concentration at r = 0 has the form;
Ae(t, 0) =
F0√
6piα (Dt)
3
2
(B.96)
t50 =
F
2
3
0(
6piD3α2IC250
) 1
3
(B.97)
Which gives the scaling t50 ∼F
2
3
0 observed (Figure 3.9o).
B.6 Intracellular steady-state concentrations
B.6.1 Neuronal intracellular steady-state
Suppose the extracellular concentration is fixed by altering the source in-
tensity and glial metabolism. Then the neuronal steady state solution is
determined from the extracellular concentration of adenosine Ae and its
breakdown products Pe by solving a cubic. Using the equation for the
steady state of intracellular breakdown products, allows Pn to be written in
terms of An
0 = − K2V3 (Pn − Pe)
K2K3 +K2 (Pe + Pn) +K3 (Ae +An)
+ βn
V4An
K4 +An
(B.98)
Pn =
q0A
2
n + q1An + q2
q3An + q4
(B.99)
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Where
q0 = βnK3V4 (B.100)
q1 = K2V3Pe + βnV4 (K2K3 +K2Pe +K3Ae) (B.101)
q2 = K2K4V3Pe (B.102)
q3 = K2V3 − βnK2V4 (B.103)
q4 = K2K4V3 (B.104)
Then by substituting into the equation for the steady state of neuronal
adenosine, the neuronal concentration of adenosine is given by roots of the
cubic;
0 =
K2V3 (An −Ae)
K2K3 +K2 (Pe + Pn) +K3 (Ae +An)
+ βn
V4An
K4 +An
(B.105)
0 = b3A
3
n + b2A
2
n + b1An + b0 (B.106)
Where
b3 = K2K3 (V2V3 + βnV4 (V3 − V2)) (B.107)
b2 = K2K3V2V3 (2K4 −Ae)
+ βnK2V4 (K3V2 (Ae −K4) + V3 (K3 (K2 +K4 +Ae) + 2K2Pe))
(B.108)
b1 = K2K4 (K3V2V3 (K4 +Ae − 2)
+βnV3 (K2 (K3 + 2Pe) +K3V4 (V2 + V3)Ae))
(B.109)
b0 = −K2K3K24V2V3Ae (B.110)
Numerical evaluation of this solution for a physiological range of extracellu-
lar concentrations, shows three real solutions, one positive and two negative.
As the discriminant is always greater than zero for any extracellular concen-
tration (with parameters given in Table 2.3 and Table 2.2), by considering
the sum and product of the roots, it is clear that there is only one positive
root for all extracellular concentrations. The product of the roots is given
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by;
−b0
b3
=
K24V2V3
V2V3 + βnV4 (V3 − V2)Ae (B.111)
≈ 1300Ae (B.112)
Notice that the denominator is positive for the parameters for the rat cortex,
and will be non-negative provided;
V3 ≥ βnV4 (B.113)
Or if
V3 < βnV4 (B.114)
V2 ≥ βnV3V4
βnV4 − V3 (B.115)
The parameters used have V2 = V3 so as Ae ≥ 0 there could either be one
positive and two negative roots or three positive roots. The sum of the roots
is;
−b2
b3
=
K3V2V3 (Ae − 2K4)− βnV4 (K3V2 (Ae −K4) + V3 (K3 (Ae +K2 +K4) + 2K2Pe))
K3V4 (V2V3 + βn (V3 − V2))
(B.116)
≈ −12A− 13P − 100 < 0 (B.117)
The sum of the roots must be negative, so there cannot be three positive
roots, therefore there must always be one positive and two negative roots
with the parameters values found for the rat cortex. The parameters found
for the rat cortex give b3 > 0, instead if b3 < 0 then (B.111) is negative so
there is either one negative and two positive roots or three negative roots,
if additionally K3 >
βnV4 (V2 + V3)
V2V3
then (B.116) is positive, so there must
be one negative and two positive roots.
There is a bifurcation at b3 = 0 where the intracellular steady state are roots
of a quadratic rather than a cubic and the value of b3 depend on the bal-
ance between adenosine transport V2 and intracellular ADA V4, these vary
considerably with species brain region, e.g. no intracellular ADA observed
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red in the hippocampus (Yamamoto et al. 1987), ENT also varies between
brain regions e.g. Western blots show around a 10% decrease in ENT1 and
a 150% in ENT2 in the rat hypothalamus compared to the cortex (Alanko
et al. 2006).
Numerical solutions for the intracellular concentrations are found with 100nM
of extracellular adenosine and 100nM of breakdown products over a range
of V2 and V4 (Figure B.2), similar results are found for equal concentra-
tion of adenosine and breakdown products and with more adenosine then
breakdown products. The stability of these steady states are determined
by evaluating eigenvalues of model II (section B.7). There is only one non-
negative solution for both adenosine and the breakdown products and it
is stable, the unstable solution (Figure B.2a,b) has positive adenosine but
negative breakdown products, whereas the unstable solution (Figure B.2c,d)
has positive breakdown products by negative adenosine. Notice when b3 = 0
(shown by the contour) the solutions are equal. There is a third solution of
the cubic, where both adenosine and the breakdown products are negative,
such that the denominators of both the terms for the transports and for
ADA are zero. The neuronal steady-state has only one valid solution and it
is stable, regardless of the balance between transport and metabolism.
B.6.2 Glial intracellular steady-state
The glial intracellular steady-state concentration can be determined, again
by fixing the extracellular concentrations and solving the intracellular steady-
state. It can be shown that there is at most one steady-state solution for
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Figure B.2: The steady-state neuronal concentrations for a range of
transport and V2 and metabolism V4 maximum velocities show there
is only one valid stable solution. With 100µM extracellular adenosine and
100µM extracellular breakdown products. The neuronal adenosine concentrations
a), c) and breakdown product concentrations b), d) are shown for two solutions
of (Eq. B.106), with a contour b3 = 0 where the two solutions are equal. Labels
indicate the stability of the regions determined by the eigenvalues of model II.
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the intracellular concentration.
0 = r3AgPg + r2P
2
g + r1Pg + r0 (B.118)
r3 = βgµ8K6 (B.119)
r2 = βgµ8K5 (B.120)
r1 = βgµ8K6Ae +K5 (V6 + βgµ8 (K6 + Pe)) (B.121)
r0 = −K5V6Pe (B.122)
0 = c3AgPg + c2A
2
g + c1Ag + c0 (B.123)
c3 = −βgK5V7 (B.124)
c2 = K6 (βgV7 + V5) (B.125)
c1 = K6K7V5 + βgK5 (K6 + PE)V7 +K6 (βgV7 − V5)Ae (B.126)
c0 = −K6K7V5Ae (B.127)
By equating (Eq. B.118) and (Eq. B.123) the glial adenosine steady-state
concentration is given by the roots of a quadratic for some concentration of
the breakdown products;
0 =
c2
c3
A2g +
c1
c3
Ag + f(Pg) (B.128)
The sum of the roots is given by −c1
c2
< 0 as c1 and c2 are positive as
βgV7 > V5 for the rat cortex, this means that for any f (Pg) there is at
most one positive solution for the steady-state concentration of adenosine.
Conversely Pg can be expressed as a quadratic of the form;
0 =
r2
r3
P 2g +
r1
r3
Ag + f(Ag) (B.129)
The sum of the roots is given by −r1
r2
< 0 as r1 and r2 are positive, so for
any steady-state concentration of adenosine, there is at most one positive
solution for the steady-state concentration of the breakdown products.
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Substitution of (Eq. B.118) into (Eq. B.123) yields a quartic in Ag;
0 = a4A
4
g + a3A
3
g + a2A
2
g + a1A
1
g + a0 (B.130)
a4 = β
2
gK
2
5K6µ
2
8V5 (B.131)
a3 = βgK5K6µ8 [2K5V5V6 + βgK5V6V7
+βgµ8V5 (3AeK6 −K6K7 + 2K5 (K6 + Pe))]
(B.132)
a2 = K6
[
2A2eβ
2
gK
2
6µ
2
8V5
+AeβgK6µ8 (βgµ8 (−2K6K7 + 3K5 (K6 + Pe))V5 + 3K5V5V6 + βgK5V6V7)
+K5
[
V5
(
β2gµ
2
8 (K6 + Pe) (−K6K7 +K5 (K6 + Pe)) + βgK6 (2K5 −K7)µ8V6 +K5V 26
)
+βgK5V6 (βgK6µ8 + V6)V7]]
(B.133)
a1 = K5PeV6 [−2K6 (AeβgK6µ8 +K5 (βgµ8 (K6 + Pe) + V6)) (V5 + βgV7)
+βgK6µ8 (K6K7V5 + βgK5 (K6 + Pe)V7 +AeK6 (−V5 + βgV7))]
(B.134)
a0 = K
2
5K6P
2
e V
2
6 (V5 + βgV7) (B.135)
Numerically evaluating the discriminant suggests it is positive for any ex-
tracellular concentration (for the parameters of the rat cortex), so there are
four distinct real solutions.
The product of the roots
a4
a0
is positive as both a4 and a0 are positive, while
the sum of the roots −a3
a4
is negative as a3 is also positive (for the parameters
of the rat cortex). So there must be two positive and two negative roots.
Therefore there is exactly one solution of (Eq. B.118) and (Eq. B.123) where
both Ag and Pg are positive. The stability of the solution is determined by
considering the eigenvalues for model III, which are all negative so it is a
stable solution (section B.7).
B.7 Stability of the steady-state solutions
The simplest case to consider is that of a constant uniform of intensity C
[nM/s]. The concentration of breakdown products in models I and II clearly
diverge, however there is still a steady-state solution for the extracellular
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Figure B.3: For constant uniform source in models I and II, the ex-
tracellular adenosine concentration reaches a steady-state (A∗e) but the
breakdown products accumulate indefinitely. a) shows the steady-state ex-
tracellular adenosine concentration resulting from a given source intensity. With
example phase portraits for a source of b) 5nM/s c) 25nM/s and d) 50nM/s. In
each case there is a steady-state solution of extracellular adenosine (Ae), but not
for the breakdown products (Pe).
adenosine, shown by the phase portraits (Figure B.3).
The models with the parameters for the rat cortex (Table 2.3 and Table 2.2)
have only one steady-state solution (section B.6) and it is stable. The solu-
tion of characteristic equation for the Jacobian about the steady-state can
be found algebraically, however the resulting expression for the eigenvalues
for model II-IV are uninformative, (as roots of a 4th-6th order polynomial).
Instead the numerical values of the eigenvalues are determined for the model
with the current parameter values.
In this case model I and II are equivalent and have eigenvalue;
τ1 = − V1K1
(K1 +A∗e)
2 (B.136)
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In general the eigenvalues, (Figure B.4) are obtained from the Jacobian;
Nd = (K2K3 +K3 (A
∗
e +A
∗
n) +K2 (P
∗
e + P
∗
n))
2 (B.137)
Gd =
(
K5K6 +K6
(
A∗e +A
∗
g
)
+K5
(
P ∗e + P
∗
g
))2
(B.138)
µ1 =
V1K1
(K1 +A∗)2
(B.139)
µ2a = K3V2
2A∗nK3 +K2K3 +K2 (P ∗e + P ∗n)
Nd
(B.140)
µ2b = K3V2
2A∗eK3 +K2K3 +K2 (P ∗e + P ∗n)
Nd
(B.141)
µ2p = K2K3V2
A∗e −A∗n
Nd
(B.142)
µ3p = V3K2
2P ∗nK2 +K2K3 +K3 (A∗e +A∗n)
Nd
(B.143)
µ3q = V3K2
2P ∗eK2 +K2K3 +K3 (A∗e +A∗n)
Nd
(B.144)
µ3a = K2K3V3
P ∗e − P ∗n
Nd
(B.145)
µ4 =
V4K4
(K4 +A∗n)
2 (B.146)
µ5a = K6V5
2A∗gK6 +K5K6 +K5
(
P ∗e + P ∗g
)
Gd
(B.147)
µ5c = V5K6
2A∗eK6 +K5K6 +K5
(
P ∗e + P ∗g
)
Gd
(B.148)
µ5p = K5K6V5
A∗e −A∗g
Gd
(B.149)
µ6p = V6K5
2P ∗gK5 +K5K6 +K6
(
A∗e +A∗g
)
Gd
(B.150)
µ6q = V6K5
2P ∗eK5 +K5K6 +K6
(
A∗e +A∗g
)
Gd
(B.151)
µ6a = K5K6V6
P ∗e − P ∗g
Gd
(B.152)
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Model
τ1 τ2 τ3 τ4 τ5 τ6
(min−1) (min−1) (min−1) (min−1) (min−1) (min−1)
I) Extracellular only 1.06
II) Extracellular & neuronal 1.06
III) Extracellular & glial
Slow Removal µ8 = 5×10−4/s 0.011 2.32 3.62 96.53
Fast Removal µ8 = 5/s 0.022 0.039 1.61 5.04
IV) Extracellular, neuronal & glial
Slow Removal µ8 = 5×10−4/s 0.0044 2.63 5.17 28.01 30.82 96.54
Fast Removal µ8 = 5/s 0.38 5.17 27.91 30.81 96.54 302.31
Table B.1: All models have a stable steady-state solution. Decay rates at
which small perturbations form the low concentration limit will decay to the stable
steady-state solution.
J =

−µ1 − µ2aα − µ5aα µ5pα + µ2pα µ2bα µ2pα µ5cα µ5pα
µ1 +
µ3a
α +
µ6a
α −µ3pα − µ6pα µ3aα µ3qα µ6aα µ6qα
µ2a
βn
−µ2pβn −µ4 −
µ2b
βn
−µ2pβn 0 0
−µ3aβn
µ3p
βn
µ4 − µ3aβn −
µ3q
βn
0 0
µ5a
βg
−µ5pβg 0 0 −µ7 −
µ5c
βg
−µ5pβg
−µ6aβg
µ6p
βg
0 0 −µ6aβg −
µ6q
βg
− µ8

(B.153)
Where the values of µi depend on the steady state concentrations and are
given by equations (Eq. B.139)-(Eq. B.152). In the low concentration limit
this is given by (Eq. B.154) which gives the eigenvalues in Table B.1.
J =

−µ1 − µ2α − µ5α 0 µ2α 0 µ5α 0
µ1 −µ3α − µ6α 0 µ3α 0 µ6α
µ2
βn
0 −µ4 − µ2βn 0 0 0
0 µ3βn µ4 −
µ3
βn
0 0
µ5
βg
0 0 0 −µ7 − µ5βg 0
0 µ6βg 0 0 0 −
µ6
βg
− µ8

(B.154)
Where the values of µi =
Vi
Ki
.
B.8 Model sensitivity
The local sensitivity is determined for by taking the partial derivative of the
state of the model with respect to each parameter in turn. For a constant
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Figure B.4: All the eigenvalues are negative and tend towards zero as the
source intensity increases. The eigenvalues of a) models I and II, b) model III
c) model IV. The dashed lines show the eigenvalues for slow removal of breakdown
products in glia (µ8 = 5× 10−4/s) while solid lines show the eigenvalues with fast
removal (µ8 = 5/s)
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Figure B.5: The slowest decay rate for each model tends to zero as the
source intensity increases and overwhelms the clearance mechanisms.
The dashed lines for models III and IV indicate the slowest decay rate with slow
breakdown products in glia (µ8 = 5×10−4/s) while solid lines correspond with fast
removal (µ8 = 5/s)
uniform source the derivative of steady-state adenosine with respect to each
parameter is shown in (Figure B.6) and (Figure B.7). For model I these are;∣∣∣∣∂A∗e∂V1
∣∣∣∣ = αCK1αV1 − C (B.155)∣∣∣∣ ∂A∗e∂K1
∣∣∣∣ = CαV1 − C (B.156)
where C [µM/s] is the source. Like the steady-state extracellular concen-
tration of adenosine, the senility of parameters V1 (Eq. B.155) and K1
(Eq. B.156) diverges when the source intensity is greater than the max-
imum removal velocity. They increase monotonically with the adenosine
concentration (Figure B.6a,e) and the sensitivities are greater for model I
than models III and IV (for the same source) as there are no other clearance
mechanisms. However a larger source is required in models III and IV to
achieve the same adenosine tone, so models III and IV are more sensitive to
changes in V1 at a given steady-state adenosine concentration. Local sensi-
tivity of the parameters in models III and IV are determined for the PDE
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for Ae as follows;
∂Ae
∂t
=
JAn (Ae, An, Pe, Pn) + J
A
g (Ae, Ag, Pe, Pg
α
− V1
K1 +Ae
+
C
α
(B.157)
∣∣∣∣∂A∗e∂pi
∣∣∣∣ =
∣∣∣∣∣∣∣∣
∂
∂p1
∂Ae
∂t
∂
∂Ae
∂Ae
∂t
∣∣∣∣∣∣∣∣ (B.158)
where pi is the parameter being considered. In model IV the neuronal trans-
port of breakdown products (Figure B.6c,g) are the most sensitive parame-
ters, as the breakdown products from the neurons need to be transported to
the extracellular space so they can be removed by glia. The steady-state is
less sensitive to changes in the parameters for transport of adenosine (Figure
B.6b,f) and the neuronal metabolism by ADA (Figure B.6d,h). The sensi-
tivities reach a peak value and then decline for increasing adenosine tone,
this is because the intracellular neuronal concentration of adenosine reaches
a peak as the transporters saturate. There is greater sensitivity for the max-
imum velocity of breakdown products in glia V6 than adenosine transport V5
(Figure B.6i,j), as the primary role of glia in the steady-state arising from
a uniform source, is the removal of breakdown products. The sensitivity
to the unsaturating removal rate µ8 is relatively small except for model IV
with slow removal, where the accumulation of breakdown products inhibits
transport (Figure B.6l).
While the volume fractions were used in determining the correct MM param-
eters for the relative concentration (Table 2.3), here the MM parameters are
fixed and the changes in volume fraction only influence transport between
intracellular and extracellular space. The neuronal volume fraction βn is
the least sensitive volume fraction (Figure B.7b), as the steady-state is pri-
marily determined by the removal of breakdown products by glia. With
slow removal of breakdown products µ8 = 5× 10−4/s the steady-state is far
less senility to changes in the glial volume fraction βg (Figure B.7c), as the
clearance of breakdown products limited by the slow removal rather than
transporters.
The same local sensitivity analysis can be applied to steady-state resulting
from a constant point source in the low concentration limit, which provides
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Figure B.6: The adenosine tone in model IV is most sensitive to changes
in neuronal transport of breakdown products. Because the adenosine tone
is dependant on neuronally derived breakdown products being removed by glia.
Sensitivity of parameters for; a), e) ecto-ADA, b), f) neuronal adenosine transport,
c), g) neuronal transport of breakdown products, d), h) neuronal ADA, i),m) glial
adenosine transport, j), n) glial transport of breakdown products, k), o) glial ADK
and l) unsaturating removal of breakdown products in glia. The dashed lines show
the sensitivity for slow removal of breakdown products in glia (µ8 = 5 × 10−4/s)
while solid lines show the sensitivity with fast removal (µ8 = 5/s)
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Figure B.7: The adenosine tone is more sensitive to the extracellular
or glial volume fraction than the neuronal volume fraction. Sensitivity of
the adenosine tone to volume fraction; a) extracellular, b) neuronal, c) glial. The
dashed lines show the sensitivity for slow removal of breakdown products in glia
(µ8 = 5×10−4/s) while solid lines show the sensitivity with fast removal (µ8 = 5/s)
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a good approximation for a range of source intensities because of rapid dif-
fusion in the ECS (section 3.2). The characteristic length scale is a function
of the parameters λ(p), so the local sensitivity of the range of influence is
given by;
∂Ae(r50)
∂pi
=
(
W
(
F
4piDαIC50λ(p)
)2 ∂λ(p)
∂pi
)(
1 +W
(
F
4piDαIC50λ(p)
))−1
(B.159)
=
r50
∂λ(p)
∂pi
λ(p) + r50
(B.160)
Where pi is one of the clearance parameters IC50 is the concentration that
will halve an EPSP. The sensitivities increase monotonically with source in-
tensity (Figure B.8). To determine the sensitivity to the diffusion coefficient,
the
∂Ae(r50)
∂D
=
W
(
F
4piαIC50λ
)(
∂λ
∂D
DW
(
F
4piαIC50λ
)
− λ
)
D
(
1 +W
(
F
4piαIC50
)) (B.161)
=
r50
(
∂λ
∂D
D
λ(p)
r50 − λ
)
D (λ(p) + r50)
(B.162)
The models are far more sensitive to changes in the ECS volume fraction
(α) than either the neuronal or glial volume fraction (Figure B.8i,m,n). This
is because the amount of adenosine required to reach the IC50 is inversely
proportional ECS volume fraction. The sensitivity is greater for changes
in neuronal volume fraction than glial volume fraction consistent with the
dominant role of neuronal uptake in adenosine clearance clearance. Similarly
model IV is more sensitive to changes in neuronal adenosine transport than
any of the other clearance mechanisms (Figure B.8b).
B.9 Biosensor analytic solutions
The single enzyme biosensor model (Eq. B.165), let at(r) = A(r) − A∗
where A∗ is has steady-state concentration in tissue. Then the solution has
the form;
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Figure B.8: Sensitivity of the range of influence (r50) of low concentration
limit for a constant point source. Sensitivity to changes in the; a) maximum
velocity of ecto-ADA, b) maximum velocity of neuronal adenosine transporters,
c) maximum velocity of neuronal ADA, d) MM constant of ecto-ADA, e) MM
constant of neuronal adenosine transporters, f) MM constant of neuronal ADA, g)
maximum velocity of glial adenosine transporters, h) maximum velocity of ADK,
i) ECS volume fraction, j) MM constant of glial adenosine transporters, k) MM
constant of ADK, l) diffusion coefficient, m) neuronal volume fraction, n) glial
volume fraction.
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a(r) = b1K0 (cr) + b2I0 (cr) rt ≤ r (B.163)
lim
r→∞ a(r) = 0 (B.164)
So b2 = 0 and c is given by (Eq. 4.58). Then the steady-state solution has
the form;
A(r) =

b4I0 (κr) + b5K0 (κr) rb ≤ r < rf
b2 log (r) + b3 rf ≤ r ≤ rt
b1K0 (cr) +A
∗ rt ≤ r
(B.165)
Where κ is given by (Eq. 4.54). The constants b1 to b5 are found by applying
the boundary (Eq. 4.15) and continuity conditions (Eq. 4.3-4.6) to give the
analytic steady-state solution for the idealised biosensor (Eq. 4.61). The
solution for the electroactive product (H) is obtained by rearranging the
solution for the analyte in the enzyme layer;
0 = Db∇2A(r)− vbA(r) (B.166)
vbA(r) = Db∇2A(r) (B.167)
Substituting into (Eq. 4.16);
0 = Dh∇2
(
H(r) +
Db
Dh
A(r)
)
(B.168)
Let P (r) = H(r) + DbDhA(r) then the solution has the form;
P (r) = b6 log(r) + b7 (B.169)
So;
H(r) = b6 log(r) + b7 − Db
Dh
A(r) (B.170)
The constants b6 and b7 are determined by applying the boundary conditions
(Eqs. 4.17, 4.18) to give the solution (Eq. 4.65). A similar approach is used
for the two-enzyme biosensor and the three-enzyme biosensor.
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Appendix C
Code
C.1 Adenosine clearance from a point source
The following C code is used to compute a numerical solution for a brief
point source of adenosine and provides the concentration profiles (Figure
3.9) and totals amounts (Figure 3.10) of adenosine and breakdown products
in tissue. Similar code is used for the steady-state solution to a constant
point source and the bath applied case.
#include <stdio.h>
#include <stdlib.h>
#include <math.h>
5
/*macros*/
#define SQ(x) ((x)*(x))
#define CU(x) ((x)*(x)*(x))
#define MAX(a,b) ((a)>(b)?(a):(b))
10 #define MIN(a,b) ((a)<(b)?(a):(b))
/*trapezoid rule for integration*/
#define TRAP(xc,xp,Ac,Ap) 2.*M PI*((xc)−(xp))*(SQ(xc)*(Ac) + SQ(xp)*(Ap))
15
/*state vectors*/
/*extracellular adenosine*/
#define AOLD(i) A[j%2][i]
#define ANEW(i) A[(j+1)%2][i]
20
/*neuronal adenosine*/
#define BOLD(i) B[j%2][i]
#define BNEW(i) B[(j+1)%2][i]
25 /*glial adenosine*/
#define COLD(i) C[j%2][i]
#define CNEW(i) C[(j+1)%2][i]
/*extracellular break-down products*/
30 #define POLD(i) P[j%2][i]
#define PNEW(i) P[(j+1)%2][i]
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/*neuronal break-down products*/
#define QOLD(i) Q[j%2][i]
35 #define QNEW(i) Q[(j+1)%2][i]
/*glial break-down products*/
#define ROLD(i) R[j%2][i]
#define RNEW(i) R[(j+1)%2][i]
40
/*additional vectors*/
/*loss due to ADK*/
#define LOLD(i) L[j%2][i]
#define LNEW(i) L[(j+1)%2][i]
45
/*loss due to removal of break-down products*/
#define SOLD(i) S[j%2][i]
#define SNEW(i) S[(j+1)%2][i]
50 /*proportion of bound A1R*/
#define TOLD(i) Theta[j%2][i]
#define TNEW(i) Theta[(j+1)%2][i]
55 /*ENTs*/
#define TransAn(A,B,P,Q) (V2*(B−A)/(K2*(1. + (P+Q)/K3) + (A+B)))
#define TransPn(A,B,P,Q) (V3*(Q−P)/(K3*(1. + (A+B)/K2) + (P+Q)))
#define TransAg(A,C,P,R) (V5*(C−A)/(K5*(1. + (P+R)/K6) + (A+R)))
#define TransPg(A,C,P,R) (V6*(R−P)/(K6*(1. + (A+C)/K5) + (P+R)))
60
/*Diffusion*/
#define RK4DIFFBULK(A,Ap,Am,x,xn,xp)
(D*dt/(x*SQ(dx)))*(Ap*xn −2.*x*A + Am*xp) SQ
#define RK4DIFF(A,Ap,Am,x)
65 (i>0?RK4DIFFBULK(A,Ap,Am,x,(x+dx),(x−dx)):(2.*D*dt*(Ap−A)/(SQ(dx))))
/*d/dt macros for*/
/*extracellular adenosine*/
#define RK4A(A,B,C,P,Q,R,Ap,Am,x) (RK4DIFF((A),(Ap),(Am),(x)) \
70 + dt*(−V1*((A)/(K1+(A))) \
+ (1./alpha)*TransAn((A),(B),(P),(Q)) \
+ (1./alpha)*TransAg((A),(C),(P),(R))))
/*neuronal adenosine*/
75 #define RK4B(A,B,C,P,Q,R) dt*(−V4*(B)/((B)+K4) \
− (1./betan)*TransAn((A),(B),(P),(Q)))
/*glial adenosine*/
#define RK4C(A,B,C,P,Q,R) dt*(−V7*(C)/(K7+(C)) \
80 − (1./betag)*TransAg((A),(C),(P),(R)))
/*extracellular break-down products*/
#define RK4P(A,B,C,P,Q,R,Pp,Pm,x) (RK4DIFF((P),(Pp),(Pm),(x)) \
+ dt*( V1*((A)/(K1+(A))) \
85 + (1./alpha)*TransPn((A),(B),(P),(Q)) \
+ (1./alpha)*TransPg((A),(C),(P),(R))))
/*neuronal break-down products*/
#define RK4Q(A,B,C,P,Q,R) dt*(V4*(B)/((B)+K4) \
90 − (1./betan)*TransPn((A),(B),(P),(Q)))
/*glial break-down products*/
#define RK4R(A,B,C,P,Q,R) −dt*(mu8*R + (1./betag)*TransPg((A),(C),(P),(R)))
95 /*loss due to ADK*/
#define RK4L(A,B,C,P,Q,R) (dt*V7*(C)/(K7 + (C)))
/*loss due to removal of break-down products*/
#define RK4S(A,B,C,P,Q,R) dt*mu8*R
100
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/*proportion of bound A1R*/
#define RK4T(A,B,C,P,Q,R,T) dt*(kon*A*(1.−T)−koff*T)
105 /*RK4 update rule*/
#define RKSUM(x) (RK4[x][0] + 2.*RK4[x][1] + 2.*RK4[x][2] + RK4[x][3])/6.
/*macros for debugging used when compiled with -DDEBUG
110 * check for NaN or negative values which indicates a problem with the parameters provided
*/
#ifdef DEBUG
#define checkNAN(A,B,P,Q,C,R,L) \
if (isnan(A)| |isnan(B)| |isnan(P)| |isnan(Q)| |isnan(C)| |isnan(R)| |isnan(L))
115 {
fprintf(stderr,"Warning: NaNs in solution at r=%le t=%le time-step %le\n",x[i],t,dt); \
fprintf(stderr,"%le\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\n",x[i],A,B,P,Q,C,R,L); \
return −1; \
}
120 #define checkNEG(A,B,P,Q,C,R,L)
if (A<0| |B<0| |P<0| |Q<0| |C<0| |R<0| |M<0| |L<0) if
{
fprintf(stderr,"Warning: Negative solution at r=%le t=%le time-step %le\n",x[i],t,dt); \
fprintf(stderr,"%le\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\n",x[i],A,B,P,Q,C,R,L); \
125 fprintf(stderr,"Failed!\n"); \
return −2; \
}
#define check(A,B,P,Q,C,R,L) \
{ \
130 checkNAN(A,B,P,Q,C,R,L); \
checkNEG(A,B,P,Q,C,R,L); \
}
#define DPRINT(str,fmt) fprintf(stderr,str,fmt);
#else
135 #define check(A,B,P,Q,C,R,L) {}
#define DPRINT(str,fmt) {}
#endif
140
/* global variables */
double Rmin, /*radius of the source in the ECS*/
Rmax, /*boundary far from the source*/
145 minStep, /*time step*/
/*model parameters (see chapter 2)*/
V1,V2,V3,V4,V5,V6,V7,mu8,kon,koff,
K1,K2,K3,K4,K5,K6,K7,K8,alpha,betan,betag,F,D,IC50;
150 int N, /*number of grid points*/
MidStep, /*number of subdivision of Rmin*/
printStep, /*number of grid points to skip when printing output*/
printTimeStep;/*number of time steps to skip when printing output*/
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/*forward time centred space RK4 method*/
double FTCS(FILE* out, FILE* outREM, FILE* outIC50) FTCS
{
double dx=Rmin/MidStep; /*space step size*/
160 double dt = minStep; /*time step size*/
double ret=0; /*return value*/
double t=0; /*time*/
int i,j; /*indices*/
double tA=0,tB=0,tP=0,tQ=0,tC=0,tR=0,tL=0,tS=0;
165 /*totals in tissue*/
double Kd=koff/kon, Occ=IC50/(Kd+IC50);
/*parameters of the A1R*/
int maxR=0; /*maxim distance where A(r)>IC50*/
int Profile[10]; /*profiles*/
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/*peak adenosine at each grid point (Figure 3.9 c,e,i,k) */
double *peakA = (double*) calloc(N+1,sizeof (double*));
double *peakT = (double*) calloc(N+1,sizeof (double*));
175 /*signal duration at each grid point (Figure 3.9 d,f,j,l) */
double *peakTa = (double*) calloc(N+1,sizeof (double*));
double *peakAa = (double*) calloc(N+1,sizeof (double*));
/*time to reach peak at each grid point*/
180 double *peakAt = (double*) calloc(N+1,sizeof (double*));
double *peakTt = (double*) calloc(N+1,sizeof (double*));
/*allocate vectors*/
double** A = (double**) malloc(2*sizeof (double*));
185 A[0] = (double*)calloc(N+1,sizeof (double));
A[1] = (double*)calloc(N+1,sizeof (double));
double** B = (double**) malloc(2*sizeof (double*));
B[0] = (double*)calloc(N+1,sizeof (double));
B[1] = (double*)calloc(N+1,sizeof (double));
190 double** P = (double**) malloc(2*sizeof (double*));
P[0] = (double*)calloc(N+1,sizeof (double));
P[1] = (double*)calloc(N+1,sizeof (double));
double** Q = (double**) malloc(2*sizeof (double*));
Q[0] = (double*)calloc(N+1,sizeof (double));
195 Q[1] = (double*)calloc(N+1,sizeof (double));
double** R = (double**) malloc(2*sizeof (double*));
R[0] = (double*)calloc(N+1,sizeof (double));
R[1] = (double*)calloc(N+1,sizeof (double));
double** C = (double**) malloc(2*sizeof (double*));
200 C[0] = (double*)calloc(N+1,sizeof (double));
C[1] = (double*)calloc(N+1,sizeof (double));
double** L = (double**) malloc(2*sizeof (double*));
L[0] = (double*)calloc(N+1,sizeof (double));
L[1] = (double*)calloc(N+1,sizeof (double));
205 double** S = (double**) malloc(2*sizeof (double*));
S[0] = (double*)calloc(N+1,sizeof (double));
S[1] = (double*)calloc(N+1,sizeof (double));
double *x = (double*)malloc((N+1)*sizeof (double));
double **RK4 = (double**)malloc(10*sizeof (double));
210 double** Theta = (double**) malloc(2*sizeof (double*));
Theta[0] = (double*)calloc(N+1,sizeof (double));
Theta[1] = (double*)calloc(N+1,sizeof (double));
for(i=0;i<9;i++)
RK4[i] = (double*)malloc(4*sizeof (double));
215
/*initialize grid and profile points*/
x[0] = dx;
for(i=1;i<=N;i++)
{
220 x[i] = x[i−1]+dx;
if (x[i]<=5e−6)
Profile[0]=i;
if (x[i]<=10e−6)
Profile[1]=i;
225 if (x[i]<=15e−6)
Profile[2]=i;
if (x[i]<=20e−6)
Profile[3]=i;
if (x[i]<=25e−6)
230 Profile[4]=i;
if (x[i]<=30e−6)
Profile[5]=i;
if (x[i]<=40e−6)
Profile[6]=i;
235 if (x[i]<=50e−6)
Profile[7]=i;
if (x[i]<=75e−6)
Profile[8]=i;
159
if (x[i]<=100e−6)
240 Profile[9]=i;
}
DPRINT("Sampling at %le (%i) %le (%i) %le (%i) %le (%i)\n",
x[Profile[0]],Profile[0],x[Profile[1]],Profile[1],x[Profile[2]],Profile[2],x[Profile[3]],Profile[3]);
245
/*integral source over volume of ECS Rmin^3*/
double source = (3.*F*1e−18/(4.*M PI*alpha*CU(Rmin)))/(1 + 3./((double)MidStep*2.) + 1./(2.*SQ((double)MidStep)));
for(i=0;i<MidStep;i++)
{
250 A[0][i]=source;
}
fprintf(outREM,"%le\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20le\n",t,F*1e−18,tB,tP,tQ,tC,tR,tL,tS);
for(j=0;t<60;j++)
{
255 /*Neumann BC with imaginary point at -dx*/
for(i=0;i<N;i++)
{
/*RK4 method - step 1*/
260 RK4[0][0] = RK4A(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i),
AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][0] = RK4B(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
RK4[2][0] = RK4C(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
RK4[3][0] = RK4P(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i),
265 POLD(i+1),POLD(i−1),x[i]);
RK4[4][0] = RK4Q(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
RK4[5][0] = RK4R(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
RK4[6][0] = RK4L(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
RK4[7][0] = RK4T(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i),
270 TOLD(i));
RK4[8][0] = RK4S(AOLD(i),BOLD(i),COLD(i),POLD(i),QOLD(i),ROLD(i));
/*RK4 method - step 2*/
RK4[0][1] = RK4A(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
275 COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.,
AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][1] = RK4B(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
280 QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.);
RK4[2][1] = RK4C(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.);
RK4[3][1] = RK4P(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
285 COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.,
POLD(i+1),POLD(i−1),x[i]);
RK4[4][1] = RK4Q(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
290 QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2);
RK4[5][1] = RK4R(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.);
RK4[6][1] = RK4L(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
295 COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.);
RK4[7][1] = RK4T(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.,
300 TOLD(i)+RK4[7][0]/2.);
RK4[8][1] = RK4S(AOLD(i)+RK4[0][0]/2.,BOLD(i)+RK4[1][0]/2.,
COLD(i)+RK4[2][0]/2.,POLD(i)+RK4[3][0]/2.,
QOLD(i)+RK4[4][0]/2.,ROLD(i)+RK4[5][0]/2.);
305 /*RK4 method - step 3*/
RK4[0][2] = RK4A(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
160
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.,
AOLD(i+1),AOLD(i−1),x[i]);
310 RK4[1][2] = RK4B(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
RK4[2][2] = RK4C(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
315 QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
RK4[3][2] = RK4P(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.,
POLD(i+1),POLD(i−1),x[i]);
320 RK4[4][2] = RK4Q(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
RK4[5][2] = RK4R(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
325 QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
RK4[6][2] = RK4L(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
RK4[7][2] = RK4T(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
330 COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.,
TOLD(i)+RK4[7][1]/2.);
RK4[8][2] = RK4S(AOLD(i)+RK4[0][1]/2.,BOLD(i)+RK4[1][1]/2.,
COLD(i)+RK4[2][1]/2.,POLD(i)+RK4[3][1]/2.,
335 QOLD(i)+RK4[4][1]/2.,ROLD(i)+RK4[5][1]/2.);
/*RK4 method - step 4*/
RK4[0][3] = RK4A(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
340 COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2],
AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][3] = RK4B(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
345 QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
RK4[2][3] = RK4C(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
RK4[3][3] = RK4P(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
350 COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2],
POLD(i+1),POLD(i−1),x[i]);
RK4[4][3] = RK4Q(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
355 QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
RK4[5][3] = RK4R(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
RK4[6][3] = RK4L(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
360 COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
RK4[7][3] = RK4T(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2],
365 TOLD(i)+RK4[7][2]);
RK4[8][3] = RK4S(AOLD(i)+RK4[0][2],BOLD(i)+RK4[1][2],
COLD(i)+RK4[2][2],POLD(i)+RK4[3][2],
QOLD(i)+RK4[4][2],ROLD(i)+RK4[5][2]);
370 /*RK4 method - sum terms*//
BNEW(i) = BOLD(i) + RKSUM(1);
CNEW(i) = COLD(i) + RKSUM(2);
QNEW(i) = QOLD(i) + RKSUM(4);
RNEW(i) = ROLD(i) + RKSUM(5);
375 ANEW(i) = AOLD(i) + RKSUM(0);
PNEW(i) = POLD(i) + RKSUM(3);
161
LNEW(i) = LOLD(i) + RKSUM(6);
TNEW(i) = MIN(1.,TOLD(i) + RKSUM(7));
SNEW(i) = SOLD(i) + RKSUM(8);
380
check(A,B,P,Q,C,R,L);
/*peak adenosine at grid point x[i]*/
385 if (ANEW(i)>peakA[i])
{
peakA[i] = ANEW(i);
peakAt[i] = t+dt;
}
390
/*peak inhibition at grid point x[i]*/
if (TNEW(i)>peakT[i])
{
peakT[i] = TNEW(i);
395 peakTt[i] = t+dt;
}
/*duration above IC50 at grid point x[i]*/
if (ANEW(i)>=IC50)
400 peakAa[i] += dt;
/*duration above 50% inhibition at grid point x[i]*/
if (TNEW(i)>=Occ)
peakTa[i] += dt;
405
if (j%printTimeStep==0)
{
/*integrate to find total amounts*/
410 if (i==0)
{
tA = TRAP(x[0],0,ANEW(0),0);
tB = TRAP(x[0],0,BNEW(0),0);
tC = TRAP(x[0],0,CNEW(0),0);
415 tP = TRAP(x[0],0,PNEW(0),0);
tQ = TRAP(x[0],0,QNEW(0),0);
tR = TRAP(x[0],0,RNEW(0),0);
tL = TRAP(x[0],0,LNEW(0),0);
tS = TRAP(x[0],0,SNEW(0),0);
420
}
else
{
tA += TRAP(x[i],x[i−1],ANEW(i),ANEW(i−1));
425 tB += TRAP(x[i],x[i−1],BNEW(i),BNEW(i−1));
tC += TRAP(x[i],x[i−1],CNEW(i),CNEW(i−1));
tP += TRAP(x[i],x[i−1],PNEW(i),PNEW(i−1));
tQ += TRAP(x[i],x[i−1],QNEW(i),QNEW(i−1));
tR += TRAP(x[i],x[i−1],RNEW(i),RNEW(i−1));
430 tL += TRAP(x[i],x[i−1],LNEW(i),LNEW(i−1));
tS += TRAP(x[i],x[i−1],SNEW(i),SNEW(i−1));
}
}
435
/*stop iteration if all states at x[i] are zero*/
if (ANEW(i) ==0 && BNEW(i)==0 && CNEW(i) == 0 && PNEW(i)==0 && QNEW(i)==0 && RNEW(i)==0)
{
break;
440 }
}
t+=dt;
445
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if (j%printTimeStep==0)
{
tA*=alpha;tP*=alpha; /*scale extracellular totals*/
tB*=betan;tQ*=betan; /*scale neuronal totals*/
450 tC*=betag;tR*=betag; /*scale glial totals*/
tL*=betag;tS*=betag; /*scale removal totals*/
/*write the profiles and totals*/
fprintf(outREM,"%le\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20le\n",t,tA,tB,tP,tQ,tC,tR,tL,tS);
455 fprintf(out,"%le",t);
for(i=0;i<10;i++)
fprintf(out,"\t%le\t%le\t%le",ANEW(Profile[i]),PNEW(Profile[i]),TNEW(Profile[i]));
fprintf(out,"\n");
}
460
ret = x[maxR];
}
465 DPRINT("%le\t%le\t%i\n",ret,t,maxR);
/*write peaks and durations to file*/
for(i=0;i<N;i++)
{
470 fprintf(outIC50,"%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\t%1.20e\n",
x[i],peakA[i],peakAt[i],peakAa[i],peakT[i],peakTt[i],peakTa[i]);
}
475 /*free allocated memory*/
free(A[0]);
free(A[1]);
free(A);
free(B[0]);
480 free(B[1]);
free(B);
free(P[0]);
free(P[1]);
free(P);
485 free(Q[0]);
free(Q[1]);
free(Q);
free(C[0]);
free(C[1]);
490 free(C);
free(R[0]);
free(R[1]);
free(R);
free(L[0]);
495 free(L[1]);
free(L);
free(S[0]);
free(S[1]);
free(S);
500 free(x);
return ret;
}
505
/*Read parameters from file*/
int readParameters(char *filename) readParameters
{
510 FILE *pf;
pf = fopen(filename,"r");
if (pf==NULL)
return −1;
if (fscanf(pf,"MidStep=%i\n",&MidStep)<0)
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515 return −2;
if (fscanf(pf,"N=%i\n",&N)<0)
return −2;
if (fscanf(pf,"minStep=%le\n",&minStep)<0)
return −2;
520 if (fscanf(pf,"PrintStep=%i\n",&printStep)<0)
return −2;
if (fscanf(pf,"PrintTimeStep=%i\n",&printTimeStep)<0)
return −2;
if (fscanf(pf,"V1=%lf\n",&V1)<0)
525 return −2;
if (fscanf(pf,"V2=%lf\n",&V2)<0)
return −2;
if (fscanf(pf,"V3=%lf\n",&V3)<0)
return −2;
530 if (fscanf(pf,"V4=%lf\n",&V4)<0)
return −2;
if (fscanf(pf,"V5=%lf\n",&V5)<0)
return −2;
if (fscanf(pf,"V6=%lf\n",&V6)<0)
535 return −2;
if (fscanf(pf,"V7=%lf\n",&V7)<0)
return −2;
if (fscanf(pf,"V8=%lf\n",&V8)<0)
return −2;
540 if (fscanf(pf,"V9=%lf\n",&V9)<0)
return −2;
if (fscanf(pf,"mu8=%lf\n",&mu8)<0)
return −2;
if (fscanf(pf,"K1=%lf\n",&K1)<0)
545 return −2;
if (fscanf(pf,"K2=%lf\n",&K2)<0)
return −2;
if (fscanf(pf,"K3=%lf\n",&K3)<0)
return −2;
550 if (fscanf(pf,"K4=%lf\n",&K4)<0)
return −2;
if (fscanf(pf,"K5=%lf\n",&K5)<0)
return −2;
if (fscanf(pf,"K6=%lf\n",&K6)<0)
555 return −2;
if (fscanf(pf,"K7=%lf\n",&K7)<0)
return −2;
if (fscanf(pf,"K8=%lf\n",&K8)<0)
return −2;
560 if (fscanf(pf,"D=%le\n",&D)<0)
return −2;
if (fscanf(pf,"alpha=%lf\n",&alpha)<0)
return −2;
if (fscanf(pf,"betan=%lf\n",&betan)<0)
565 return −2;
if (fscanf(pf,"betag=%lf\n",&betag)<0)
return −2;
if (fscanf(pf,"F=%lf\n",&F)<0)
return −2;
570 if (fscanf(pf,"IC50=%lf\n",&IC50)<0)
return −2;
if (fscanf(pf,"kon=%lf\n",&kon)<0)
return −2;
if (fscanf(pf,"koff=%lf\n",&koff)<0)
575 return −2;
Rmin=pow(3./(4.*M PI*alpha),1./3.)*1e−6;
return 0;
}
580
/*echo parameters*/
int printParameters(FILE *fp) printParameters
{
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fprintf(fp,"\nRmin=%le\n",Rmin);
585 fprintf(fp,"Rmax=%le\n",(double)N*Rmin/(double)MidStep);
fprintf(fp,"N=%i\n",N);
fprintf(fp,"minStep=%le\n",minStep);
fprintf(fp,"PrintStep=%i\n",printStep);
fprintf(fp,"PrintTimeStep=%i\n",printTimeStep);
590 fprintf(fp,"V1=%le\n",V1);
fprintf(fp,"V2=%le\n",V2);
fprintf(fp,"V3=%le\n",V3);
fprintf(fp,"V4=%le\n",V4);
fprintf(fp,"V5=%le\n",V5);
595 fprintf(fp,"V6=%le\n",V6);
fprintf(fp,"V7=%le\n",V7);
fprintf(fp,"mu8=%le\n",mu8);
fprintf(fp,"K1=%le\n",K1);
fprintf(fp,"K2=%le\n",K2);
600 fprintf(fp,"K3=%le\n",K3);
fprintf(fp,"K4=%le\n",K4);
fprintf(fp,"K5=%le\n",K5);
fprintf(fp,"K6=%le\n",K6);
fprintf(fp,"K7=%le\n",K7);
605 fprintf(fp,"K8=%le\n",K8);
fprintf(fp,"D=%le\n",D);
fprintf(fp,"alpha=%lf\n",alpha);
fprintf(fp,"betan=%lf\n",betan);
fprintf(fp,"betag=%lf\n",betag);
610 fprintf(fp,"IC50=%lf\n",IC50);
fprintf(fp,"koff=%lf\n",koff);
fprintf(fp,"kon=%lf\n",kon);
fprintf(fp,"F=%le\n",F);
ﬄush(fp);
615 return 0;
}
int main(int argc, char** argv) main
{
620 FILE *outIC50, *outTRACE,*outREM;
int err;
if (argc<5)
{
fprintf(stderr, "Insufficient arguments.\n"
625 "REQUIRED:\t parameterfile ouputIC50 outTRACE outREM F\n");
return −1;
}
/*open the parameter file and read the parameters*/
err=readParameters(argv[1]);
630 if (err==−1)
{
fprintf(stderr,"Failed to open file %s.\n",argv[1]);
return −1;
}
635 else if (err==−2)
{
fprintf(stderr,"Failed to read a parameter from %s.\n",argv[1]);
return −1;
}
640
/*open the output file for the peaks and durations*/
outIC50 = fopen(argv[2],"a");
if (outIC50 == NULL)
{
645 fprintf(stderr,"Failed to open file %s.\n",argv[2]);
return −1;
}
/*open the output file for the profiles*/
650 outTRACE = fopen(argv[3],"w");
if (outTRACE == NULL)
{
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fprintf(stderr,"Failed to open file %s.\n",argv[3]);
return −1;
655 }
/*open the output file for the totals*/
outREM = fopen(argv[4],"w");
if (outTRACE == NULL)
660 {
fprintf(stderr,"Failed to open file %s.\n",argv[4]);
return −1;
}
/*set the source intensity [zmol]*/
665 F=atof(argv[5]);
printParameters(stderr);
/*Call FTCS method*/
FTCS(outTRACE,outREM,outIC50);
670 /*close all the files*/
ﬄush(outIC50);
ﬄush(outTRACE);
fclose(outIC50);
fclose(outTRACE);
675 ﬄush(outREM);
fclose(outREM);
return 0;
}
C.2 Model of an idealised biosensor
The following C code provides a numeric solution for the PDEs (Eq. B.165)
and (Eq. 4.16) using the Runge-Kutta method (RK4). The parameters are
read from a parameter file and the solution is used to calculate the gradient
of electroactive product at biosensor, which is scaled to give the signal (Eq.
4.23) (Figure 4.7). In addition to the gradient profiles of the analyte and
product are output at regular time intervals, specified in the parameters file.
#include <stdio.h>
#include <stdlib.h>
#include <math.h>
5 /*simple macros*/
#define SQ(x) ((x)*(x))
#define MAX(a,b) ((a)>(b)?(a):(b))
#define MIN(a,b) ((a)<(b)?(a):(b))
10 /*access arrays representing the analyte and product*/
#define AOLD(i) A[j%2][i]
#define ANEW(i) A[(j+1)%2][i]
#define POLD(i) P[j%2][i]
#define PNEW(i) P[(j+1)%2][i]
15
/*Macros for the RK4 steps given the state (A) at position (x) and at x+dx (Ap) and x-dx (Am)*/
/*reaction-diffusion in tissue*/
166
#define STEPA0(A,Ap,Am,x) dt*( \
20 (D/SQ(lambda))*((Ap −2.*A + Am)/(SQ(dx)) + (Ap − Am)/(2.*dx*x)) \ SQ
− Vt*(A−A0))
/*diffusion in the free region*/
#define STEPA1(A,Ap,Am,x) dt*( \
25 D*((Ap −2.*A + Am)/(SQ(dx)) + (Ap − Am)/(2.*dx*x)))
/*reaction-diffusion in the enzyme-layer*/
#define STEPA2(A,Ap,Am,x) dt*( \
(D /SQ(mu))*( (Ap −2.*A + Am)/(SQ(dx)) + (Ap − Am)/(2.*dx*x)) − (Vb*A))
30
/*reaction-diffusion of the electroactive product*/
#define STEPP2(P,Pp,Pm,x,A) dt*( \
(Dh/SQ(mu))*( (Pp −2.*P + Pm)/(SQ(dx)) + (Pp − Pm)/(2.*dx*x)) + (Vb*A))
35 #define RKSUM(x) (RK4[x][0] + 2.*RK4[x][1] + 2.*RK4[x][2] + RK4[x][3])/6.
/*When compiled with -DDEBUG check for negative or NaN state variables
* that usually occur if the is a problem with the parameters*/
40 #ifdef DEBUG
#define checkNAN(A) if (isnan(A)){ \
fprintf(stderr,"Warning: NaNs in solution"); \
fprintf(stderr,"\nx=%le t=%le timestep %le\n",x[i],t,dt); \
return −1;}
45 #define checkNEG(A) if (A<0){ \
fprintf(stderr,"Warning: Negative solution"); \
fprintf(stderr,"\nx=%le t=%le timestep %le\n",x[i],t,dt); \
return −2;}
#define checkS(X) {checkNAN(X);}
50 #define check(A) {checkS(A);}
#else
#define checkS(X) {}
#define check(A) {}
#endif
55
/*
* Global variables
60 */
double dx1,dx2,dx, /*step sizes close to the biosensor and in tissue*/
Vt, /*tissue rate (vt)*/
D, /*analyte free diffusion coefficient (Df )*/
Dh, /*product free diffusion coefficient*/
65 R3, /*outer edge of the solution*/
R2, /*boundary between tissue and the free region (rt)*/
R1, /*boundary between the free region and enzyme layer (rf )*/
R0, /*radius of the biosensor core (rb)*/
lambda, /*tissue tortuosity (Dt = D/λ
2)*/
70 mu, /*enzyme-layer tortuosity (Db = D/µ2)*/
Vb, /*reaction rate in enzyme later*/
dt, /*time step*/
T, /*maximum solution time*/
A0, /*tissue steady-state concentration without the biosensor*/
75 alphaB, /*enzyme layer porosity (αb)*/
alphaT; /*tissue porosity (αt)*/
int N, /*number of grid points*/
printStep, /*number of gird points to skip when writing output*/
80 printTimeStep, /*number of time steps to skip when writing output*/
I0, /*grid point corresponding to R1*/
I1; /*grid point corresponding to R2*/
unsigned char CAL; /*flag indicates solve for calibration case*/
85 /*solve numerically using Forward-Time Central-Space method*/
int FTCS(FILE* outProfile, FILE* outSensor, FILE* outFinal) FTCS
{
167
double t=0, /*time*/
maxdiff=0; /*difference in continuity conditions*/
90 int I0, /*grid point corresponding to R1*/
A0E, /*fake grid point I0+1 used for continuity conditions*/
A1S, /*fake grid point I0+2 used for continuity conditions*/
I1, /*grid point corresponding to R2*/
A1E, /*fake grid point I1+1 used for continuity conditions*/
95 A2S; /*fake grid point I1+2 used for continuity conditions*/
/*indices*/
unsigned int i,j,k;
unsigned char DMG = R1<R2; /*flag if problem includes a free region*/
unsigned char LAST; /*continuity conditions unchanged in an iteration*/
100
/*arrays for the analyte and product*/
double** A = (double**) malloc(2*sizeof (double*));
A[0] = (double*)calloc(N+1,sizeof (double));
A[1] = (double*)calloc(N+1,sizeof (double));
105 double** P = (double**) malloc(2*sizeof (double*));
P[0] = (double*)calloc(N+1,sizeof (double));
P[1] = (double*)calloc(N+1,sizeof (double));
/*array of grid points*/
110 double *x = (double*)malloc((N+1)*sizeof (double));
/*array to store RK4 terms*/
double **RK4 = (double**)malloc(2*sizeof (double));
for(i=0;i<2;i++)
115 RK4[i] = (double*)malloc(4*sizeof (double));
/*initialise grid*/
dx=dx1;
x[0] = R0−dx;
120 if (CAL)
{
for(i=1;i<=N;i++)
{
x[i]=x[i−1]+dx;
125 if (x[i]<=R1 && x[i]+dx>R1)
{
I0=i;
x[i+1]=x[i];i++;I1=i;
break;
130 }
}
A[0][I1]=alphaB*A0;
A[1][I1]=alphaB*A0;
}
135 else
{
if (DMG)
{
for(i=1;i<=N;i++)
140 {
x[i] = x[i−1]+dx;
if (x[i]<=R1 && x[i]+dx>R1)
{
I0=i;
145 x[i+1]=x[i];i++;A0E=i;
x[i+1]=x[i];i++;A1S=i;
}
if (x[i]<=R2 && x[i]+dx>R2)
{
150 I1=i;
x[i+1]=x[i];i++;A1E=i;
x[i+1]=x[i];i++;A2S=i;
A[0][i]=A0;A[1][i]=A0;
dx=dx2;
155 }
if (x[i]>R2)
168
{
A[0][i]=A0;
A[1][i]=A0;
160 }
}
}
else
{
165 for(i=1;i<=N;i++)
{
x[i] = x[i−1]+dx;
if (x[i]<=R1 && x[i]+dx>R1)
{
170 I0=i;
x[i+1]=x[i];i++;A0E=i;
x[i+1]=x[i];i++;A1S=i;
dx=dx2;
}
175 if (x[i]>R1)
{
A[0][i]=A0;
A[1][i]=A0;
}
180 }
A2S=A1S;
}
}
185
for(j=0;t<T;j++)
{
for(k=0,LAST=1;LAST| |maxdiff>0;k++)
190 {
/*solve once after the continuity conditions are unchanged*/
if (k>0 && maxdiff==0)
LAST=0;
else
195 LAST=1;
dx=dx1; /*use the smaller step size for solving near the biosensor*/
for(i=1;i<=I0;i++)
{
200 /*RK4 method for analyte and product in the enzyme layer*/
RK4[0][0] = STEPA2(AOLD(i),AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][0] = STEPP2(POLD(i),POLD(i+1),POLD(i−1),x[i],AOLD(i));
RK4[0][1] = STEPA2(AOLD(i)+RK4[0][0]/2.,AOLD(i+1),AOLD(i−1),x[i]);
205 RK4[1][1] = STEPP2(POLD(i)+RK4[1][0]/2.,POLD(i+1),POLD(i−1),x[i],AOLD(i)+RK4[0][0]/2.);
RK4[0][2] = STEPA2(AOLD(i)+RK4[0][1]/2.,AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][2] = STEPP2(POLD(i)+RK4[1][1]/2.,POLD(i+1),POLD(i−1),x[i],AOLD(i)+RK4[0][1]/2.);
210 RK4[0][3] = STEPA2(AOLD(i)+RK4[0][2],AOLD(i+1),AOLD(i−1),x[i]);
RK4[1][3] = STEPP2(POLD(i)+RK4[1][2],POLD(i+1),POLD(i−1),x[i],AOLD(i)+RK4[0][2]);
ANEW(i) = AOLD(i) + RKSUM(0);
PNEW(i) = POLD(i) + RKSUM(1);
215
/*check solution if complied with -DDEBUG*/
check(ANEW(i));
check(PNEW(i));
220 }
/*if solving for calibration then apply the boundary conditions*/
if (CAL)
{
ANEW(I0)=A0*alphaB;
225 PNEW(I0)=0;
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ANEW(0)=ANEW(1); /*Neumann boundary for analyte at the core*/
PNEW(1)=0; /*x[1]=R0*/
}
else
230 {
if (DMG)
{
/*if there is a free region solve for it using RK4 method*/
for(i=A1S+1;i<=I1;i++)
235 {
RK4[0][0] = STEPA1(AOLD(i),AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][1] = STEPA1(AOLD(i)+RK4[0][0]/2.,AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][2] = STEPA1(AOLD(i)+RK4[0][1]/2.,AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][3] = STEPA1(AOLD(i)+RK4[0][2],AOLD(i+1),AOLD(i−1),x[i]);
240
ANEW(i) = AOLD(i) + RKSUM(0);
checkS(ANEW(i));
}
}
245 dx=dx2; /*using the larger step size*/
/*solve for tissue using the RK4 method*/
for(i=A2S+1;i<N;i++)
{
250 RK4[0][0] = STEPA0(AOLD(i),AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][1] = STEPA0(AOLD(i)+RK4[0][0]/2.,AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][2] = STEPA0(AOLD(i)+RK4[0][1]/2.,AOLD(i+1),AOLD(i−1),x[i]);
RK4[0][3] = STEPA0(AOLD(i)+RK4[0][2],AOLD(i+1),AOLD(i−1),x[i]);
255 ANEW(i) = AOLD(i) + RKSUM(0);
checkS(ANEW(i));
}
/*apply the boundary conditons*/
ANEW(0) = ANEW(1);
260 PNEW(1) = 0;
ANEW(N) = ANEW(N−1);
PNEW(I0) = 0;
if (DMG)
265 {
/*continuity between the enzyme-layer and free-region
* using 5 point stencils for the gradient*/
ANEW(A1S) = AOLD(I0)/alphaB;
ANEW(A0E) = ((18.*AOLD(I0−1) − 6.*AOLD(I0−2) +
270 AOLD(I0−3) −10.*AOLD(I0)) +
SQ(mu)*(48.*AOLD(A1S+1) −36.*AOLD(A1S+2)
+16.*AOLD(A1S+3) −3.*AOLD(A1S+4)−
25.*AOLD(A1S)))/3.;
275 /*continuity between the free-region and tissue using 5
* point stencils for the gradient*/
ANEW(A2S) = alphaT*AOLD(I1);
ANEW(A1E) = ((18.*AOLD(I1−1) − 6.*AOLD(I1−2) + AOLD(I1−3)
−10.*AOLD(I1)) + SQ(1./lambda)*(
280 48.*AOLD(A2S+1) −36.*AOLD(A2S+2)
+16.*AOLD(A2S+3) −3.*AOLD(A2S+4)
−25.*AOLD(A2S))*(dx1/dx2))/3.;
/*check how much continuity conditions have not changed*/
maxdiff = fabs(ANEW(A1S)−AOLD(A1S));
285 maxdiff +=fabs(ANEW(A0E)−AOLD(A0E));
maxdiff +=fabs(ANEW(A2S)−AOLD(A2S));
maxdiff +=fabs(ANEW(A1E)−AOLD(A1E));
/*update the fake grid points*/
AOLD(A1S) = ANEW(A1S);
290 AOLD(A0E) = ANEW(A0E);
AOLD(A2S) = ANEW(A2S);
AOLD(A1E) = ANEW(A1E);
}
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295 else
{
/*continuity between the enzyme-layer and tissue using 5
* point stencils for the gradient*/
ANEW(A1S) = alphaT*AOLD(I0)/alphaB;
300 ANEW(A0E) = ((18.*AOLD(I0−1) − 6.*AOLD(I0−2) + AOLD(I0−3)
−10.*AOLD(I0)) + SQ(mu/lambda)*(48.*AOLD(A1S+1)
−36.*AOLD(A1S+2) +16.*AOLD(A1S+3)
−3.*AOLD(A1S+4)
− 25.*AOLD(A1S))*(dx1/dx2))/3.;
305 /*check how much continuity conditions have not changed*/
maxdiff = fabs(ANEW(A1S)−AOLD(A1S));
maxdiff += fabs(ANEW(A0E)−AOLD(A0E));
/*update the fake grid points*/
AOLD(A1S) = ANEW(A1S);
310 AOLD(A0E) = ANEW(A0E);
}
/*check if the continuity conditions are converging in a
* reasonable number of iterations*/
315 if (k>100)
{
fprintf(stderr,"%i\tmaxdiff=%le (%i)\n",j,maxdiff,k);
}
}
320
}
t+=dt; /*update the time*/
if (j%printTimeStep==0)
325 {
/*initially write the grid being used (including fake points)*/
if (j==0)
{
fprintf(outProfile,"%le\t",t);
330 for(i=0;i<=I1;i++)
fprintf(outProfile,"%le\t",x[i]);
for(;i<=N;i+=printStep)
fprintf(outProfile,"%le\t",x[i]);
fprintf(outProfile,"\n");
335
}
/*output a profile of the solution at the current time*/
fprintf(outProfile,"%le\t",t);
340 for(i=0;i<=I1;i++)
fprintf(outProfile,"%1.20e\t",AOLD(i));
for(;i<=N;i+=printStep)
fprintf(outProfile,"%1.20e\t",AOLD(i));
fprintf(outProfile,"\n");
345
fprintf(outProfile,"%le\t",t);
for(i=0;i<=I1;i++)
fprintf(outProfile,"%1.20e\t",POLD(i));
350 for(;i<=N;i+=printStep)
fprintf(outProfile,"%1.20e\t",POLD(i));
fprintf(outProfile,"\n");
/*output the gradient of the electroactive product at the biosensor
355 * core*/
fprintf(outSensor,"%le\t%1.20e\t%1.20e\n",t,PNEW(2)/dx1);
}
}
360 /*output the profile at time T*/
for(i=0;i<N;i++)
{
fprintf(outFinal,"%1.20e\t%1.20e\t%1.20e\n",x[i],AOLD(i),POLD(i));
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365 }
/*free allocated memory*/
free(A[0]);
370 free(A[1]);
free(A);
free(P[0]);
free(P[1]);
free(P);
375 free(x);
free(RK4[0]);
free(RK4[1]);
free(RK4);
return 0;
380 }
/*load the parameter values from a file*/
385 int readParameters(char *filename) readParameters
{
FILE *pf;
pf = fopen(filename,"r");
if (pf==NULL)
390 return −1;
if (fscanf(pf,"dx1=%lf\n",&dx1)<0)
return −2;
if (fscanf(pf,"dx2=%lf\n",&dx2)<0)
return −2;
395 if (fscanf(pf,"T=%lf\n",&T)<0)
return −2;
if (fscanf(pf,"dt=%le\n",&dt)<0)
return −2;
if (fscanf(pf,"PrintStep=%i\n",&printStep)<0)
400 return −2;
if (fscanf(pf,"PrintTimeStep=%i\n",&printTimeStep)<0)
return −2;
if (fscanf(pf,"R3=%lf\n",&R3)<0)
return −2;
405 if (fscanf(pf,"R2=%lf\n",&R2)<0)
return −2;
if (fscanf(pf,"R1=%lf\n",&R1)<0)
return −2;
if (fscanf(pf,"R0=%lf\n",&R0)<0)
410 return −2;
if (fscanf(pf,"D=%lf\n",&D)<0)
return −2;
if (fscanf(pf,"Dh=%lf\n",&Dh)<0)
return −2;
415 if (fscanf(pf,"Lambda=%lf\n",&lambda)<0)
return −2;
if (fscanf(pf,"Mu=%lf\n",&mu)<0)
return −2;
if (fscanf(pf,"Vb=%lf\n",&Vb)<0)
420 return −2;
if (fscanf(pf,"Vt=%lf\n",&Vt)<0)
return −2;
if (fscanf(pf,"alphaB=%lf\n",&alphaB)<0)
return −2;
425 if (fscanf(pf,"alphaT=%lf\n",&alphaT)<0)
return −2;
N = (int)ceil((R3−R2)/dx2 + (R2/dx1));
N+=4; /*increase the number of grid point to include fake points for
continuity conditions*/
430 fclose(pf);
return 0;
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}435 /*echo parameter values*/
int printParameters(FILE *fp) printParameters
{
fprintf(fp,"N=%i\n",N);
fprintf(fp,"T=%lf\n",T);
440 fprintf(fp,"dx=%le\n",dx);
fprintf(fp,"dt=%le\n",dt);
fprintf(fp,"PrintStep=%i\n",printStep);
fprintf(fp,"PrintTimeStep=%i\n",printTimeStep);
fprintf(fp,"R3=%le\n",R3);
445 fprintf(fp,"R2=%le\n",R2);
fprintf(fp,"R1=%le\n",R1);
fprintf(fp,"R0=%le\n",R0);
fprintf(fp,"D=%le\n",D);
fprintf(fp,"Dh=%le\n",Dh);
450 fprintf(fp,"Lambda=%lf\n",lambda);
fprintf(fp,"Mu=%lf\n",mu);
fprintf(fp,"Vb=%lf\n",Vb);
fprintf(fp,"Vt=%lf\n",Vt);
fprintf(fp,"A*=%lf\n",A0);
455 fprintf(fp,"alphaB=%lf\n",alphaB);
fprintf(fp,"alphaT=%lf\n",alphaT);
ﬄush(fp);
return 0;
}
460
int main(int argc, char** argv) main
{
FILE *outProfile, *outSensor,*outFinal;
int err;
465 if (argc<6)
{
fprintf(stderr, "Insufficient arguments.\n"
"REQUIRED:\t parameterFile, profileOutput sensorOutput"
" finalProfile A0 calibrationFlag\n");
470 return −1;
}
err=readParamters(argv[1]);
if (err==−1)
{
475 fprintf(stderr,"Failed to open file %s.\n",argv[1]);
return −1;
}
else if (err==−2)
{
480 fprintf(stderr,"Failed to read a parameter from %s.\n",argv[1]);
return −1;
}
dx=MIN(dx1,dx2);
485 if (D*dt/SQ(dx)>0.5 | | D*dt/SQ(lambda*dx)>0.5 | | MAX(D,Dh)*dt/SQ(mu*dx)>0.5)
{
fprintf(stderr,
"Error: Parameters are unstable\nD*dt/SQ(dx)>0.5\n(%le %le %le)\n",
D*dt/SQ(dx), D*dt/SQ(lambda*dx),D*dt/SQ(lambda*dx));
490 return −1;
}
outProfile = fopen(argv[2],"w");
if (outProfile == NULL)
{
495 fprintf(stderr,"Failed to open file %s.\n",argv[2]);
return −1;
}
outSensor = fopen(argv[3],"w");
if (outSensor == NULL)
500 {
fprintf(stderr,"Failed to open file %s.\n",argv[3]);
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return −1;
}
outFinal = fopen(argv[4],"w");
505 if (outFinal == NULL)
{
fprintf(stderr,"Failed to open file %s.\n",argv[4]);
return −1;
}
510
A0=atof(argv[5]);
CAL=atoi(argv[6]);
printParameters(stderr);
515
/*Call the actual method*/
err = FTCS(outProfile,outSensor,outFinal);
fprintf(stderr, "Function returned %i",err);
ﬄush(outProfile);
520 ﬄush(outSensor);
ﬄush(outFinal);
fclose(outProfile);
fclose(outSensor);
fclose(outFinal);
525 return 0;
}
C.3 Model of a biosensor in vivo
The Alternating Direction Implicit (ADI) method is applied to the problem
of a biosensor in 3 dimensions, the code provided is for the in vivo model
(Figure 4.1d), a similar approach is used to the in vitro model (Figure 4.1c).
The GNU Scientific Library is used to solve the tridiagonal system, first
for a system where the radial direction is taken implicit, then for a system
where the vertical direction is taken implicit. The code provides output at
intervals specified in a parameters file, with the gradient at the core (Figure
4.14f) and profiles of the total concentrations of analyte and product (Figure
4.14g,h,k,j).
#include <stdio.h>
#include <stdlib.h>
#include <math.h>
#include <gsl/gsl linalg.h>
5 #include <gsl/gsl vector.h>
#include <gsl/gsl errno.h>
#include <zlib.h>
#include <string.h>
#include <assert.h>
10
/*simple macros*/
#define SQ(x) ((x)*(x))
#define MAX(a,b) ((a)>(b)?(a):(b))
174
15
#define AOLD(i,k) A[0][i][k]
#define ANEW(i,k) A[1][i][k]
#define POLD(i,k) P[1][i][k]
#define PNEW(i,k) P[1][i][k]
20
/*wrappers for functions that give a detailed error messages,
* used when compiled with -DDEBUG*/
#ifdef DEBUG
#define DBPRINT(x) fprintf(stderr,"%s",x)
25
#define GSL V SET(vec,idx,val) {lineno= LINE ; \
gsl vector set(vec,idx,val);}
#define GSL V GET(vec,idx) my vector get(vec,idx, LINE )
30 #else
#define DBPRINT(x) {}
#define GSL V SET(vec,idx,val) gsl vector set(vec,idx,val)
#define GSL V GET(vec,idx) gsl vector get(vec,idx)
#endif
35
/*wrappers for functions that check memory is successfully allocated*/
#define SCALLOC(n,sz) safe calloc(n,sz, LINE )
#define SMALLOC(sz) safe malloc(sz, LINE )
40
/*report and error using the scientific library (gsl)*/
#define ERR REP(x) {lineno= LINE ; \
if (x!=0){ \ if
fprintf(stderr, "GSL error: %s\n\tin %s at (%d)\n", \
45 gsl strerror(x), FILE , LINE ); \
return −1;}}
/*report and error using the compression library (zlib)*/
#define ERR ZLIB(x) {if (x<0){ \
fprintf(stderr, \ fprintf
50 "Zlib error %s:%d: %s returned a bad status of %d.\n", \
FILE , LINE ,#x, x); \
exit(x);}}
/*constants used when compressing output*/
55 #define CHUNK 32768
#define windowBits 15
#define GZIP ENCODING 16
#define MESG SIZE 16384
60
/*
* Global variables
65 */
double dx,dz, /*grid step sizes*/
dt, /*time step*/
depth, /*depth of the solution*/
70 length, /*length of the biosensor core (lb)*/
width, /*thickness of the enzyme-layer (w)*/
dmg, /*thickness of the free-region (d)*/
T, /*duration of the solution*/
R0, /*radius of the biosensor core (rb)*/
75 R1, /*boundary between the enzyme-layer and free-region (rf )*/
R2, /*boundary between the free-region and tissue (rt)*/
R3, /*maximum radius of the solution*/
80 Pz, /*length of the plastic sheath inserted into tissue (lp)*/
Cz, /*depth of the biosensor core (lp + lb)*/
Ez, /*depth of the enzyme layer (lp + lb + w))*/
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Fz, /*depth of the free-region (lp + lb + w + d))*/
D, /*analyte free-diffusion coefficient (Dg)*/
85 Dp, /*product free-diffusion coefficient)*/
lambda, /*tissue tortuosity (Dt = D/λ
2)*/
mu, /*product tortuosity (Db = D/µ
2)*/
Vt, /*tissue reaction rate (vt)*/
Vb, /*enzyme-layer reaction rate (vb)*/
90 A0, /*steady-state tissue concentration (A∗)*/
alphaT, /*tissue porosity (αt)*/
alphaB; /*enzyme-layer porosity (αb)*/
int N,M, /*number of grid points in the r and z direction*/
95 I0, /*column number of grid corresponding to R0*/
I1, /*column number of grid corresponding to R1*/
K0, /*row number of grid corresponding to the base of the plastic
sheath*/
K1, /*row number of grid corresponding to the base of the
100 biosensor core*/
K2, /*row number of grid corresponding to the base of the
free-region*/
K3, /*row number of grid corresponding to the base of the
enzyme layer*/
105 lineno; /*line number reported in debug messages*/
int printSensorStep, /*frequency of output to sensor file*/
printTimeStep; /*frequency of output of profile files*/
110 /*array used for writing compressed output*/
unsigned char zout[CHUNK];
typedef struct zfile
{
115 FILE* file;
z stream stream;
}zfile;
120 /*function reports an error with in the scientific library (gsl)*/
void errHandler (const char * reason, const char * file, int line, errHandler
int gsl errno)
{
fprintf(stderr,"GSL Error occurred: %s \t(%s)\nFile: %s at %d [from %d]\n",
125 reason,gsl strerror(gsl errno),file,line,lineno);
exit(−1);
}
/*wrapper for calloc function that checks memory has been allocated*/
130 void* safe calloc(size t nmemb, size t size, int line) safe calloc
{
void* ptr = calloc(nmemb,size);
if (ptr==NULL)
{
135 fprintf(stderr,"Error occurred: calloc failed at line %d\n",line);
}
return ptr;
}
/*wrapper for malloc function that checks memory has been allocated*/
140 void* safe malloc(size t size, int line) safe malloc
{
void* ptr = malloc(size);
if (ptr==NULL)
{
145 fprintf(stderr,"Error occurred: malloc failed at line %d\n",line);
}
return ptr;
}
150
/*function initialised stream for compressed output*/
176
int zstream init(z stream * strm) zstream init
{
strm−>zalloc = Z NULL;
155 strm−>zfree = Z NULL;
strm−>opaque = Z NULL;
ERR ZLIB(deflateInit2(strm, Z DEFAULT COMPRESSION, Z DEFLATED,
windowBits | GZIP ENCODING, 8, Z DEFAULT STRATEGY));
return 0;
160 }
/*function opens a file for compressed output*/
zfile* zfopen(const char * name) zfopen
{
165 zfile* zf = (zfile*)SCALLOC(1,sizeof (struct zfile));
zf−>file = fopen(name,"w");
if (zf−>file == NULL)
{
fprintf(stderr,"Failed to create file %s.\n",name);
170 exit(−1);
}
zstream init(&zf−>stream);
return zf;
}
175
/*function writes compressed output*/
int zprint(zfile* F, char * msg) zprint
{
F−>stream.next in = (unsigned char*)msg;
180 int have;
F−>stream.avail in = strlen(msg);
do {
F−>stream.avail out = CHUNK;
185 F−>stream.next out = zout;
ERR ZLIB(deflate(&F−>stream, Z NO FLUSH));
have = CHUNK − F−>stream.avail out;
fwrite(zout, sizeof (char), have, F−>file);
}
190 while (F−>stream.avail out == 0);
bzero(msg,MESG SIZE*sizeof (unsigned char));
return 0;
}
195
/*function closes file used for compressed output*/
int zfclose(zfile* F, char* msg) zfclose
{
int flag;
200 int have;
F−>stream.avail in = strlen(msg);
do {
F−>stream.avail out = CHUNK;
F−>stream.next out = zout;
205 flag = deflate(&F−>stream, Z FINISH);
ERR ZLIB(flag)
have = CHUNK − F−>stream.avail out;
fwrite(zout, sizeof (char), have, F−>file);
}
210 while (F−>stream.avail out == 0 && flag == Z OK);
ﬄush(F−>file);
fclose(F−>file);
deflateEnd(&F−>stream);
free(F);
215 bzero(msg,MESG SIZE*sizeof (unsigned char));
return 0;
}
/*function wrapper for gsl vector get that checks for NaN, only used when
220 * compiled with -DDEBUG*/
177
double my vector get(gsl vector* v, int idx,int lineno) my vector get
{
double ret = gsl vector get(v,idx);
if (isnan(ret))
225 {
fprintf(stderr,"Error: %ith value is NaN at %d\n",idx,lineno);
exit(−1);
}
return ret;
230 }
/*function computes the solution and writes the sensor output (outSensor) and
* a series of profiles to files that start with file name*/
int solver(FILE* outSensor, char* filename) solver
235 {
/*set a function for reporting GSL errors*/
gsl set error handler(&errHandler);
double t=0, /*time*/
240 cb=Vb*SQ(mu*dx)/D, /*enzyme-layer reaction*/
ct=Vt*SQ(lambda*dx)/D; /*tissue reaction*/
unsigned int i,j,k; /*indices*/
245 int IC, /*column number of fake grid points for boundary condition at
* biosensor core (rb)*/
A0E,A1S, /*column numbers of fake grid points for continuity conditions
* at the edge of the enzyme-layer (rf )*/
A1E,A2S, /*column numbers of fake grid points for continuity conditions
250 * at the edge of the free-region (rt)*/
EzE,FzS, /*row numbers of fake grid points for continuity conditions at
* the edge of the enzyme-layer (lp + lb + w)*/
FzE,TzS; /*row numbers of fake grid points for continuity conditions at
* the edge of the free region (lp + lb + w + d)*/
255
/*file names for writing profiles of the analyte and product*/
char* fname = (char*)SCALLOC((strlen(filename)+35),sizeof (char));
/*buffer for writing compressed output*/
260 char* msg = (unsigned char*)SCALLOC(MESG SIZE,sizeof (unsigned char*));
/*zip file pointer for compressed output*/
zfile* zf;
/*grids for the analyte and product*/
265 double*** A = (double***)SMALLOC(2*sizeof (double**));
double*** P = (double***)SMALLOC(2*sizeof (double**));
for(j=0;j<2;j++)
{
A[j] = (double**)SMALLOC((N+1)*sizeof (double*));
270 for(i=0;i<=N;i++)
A[j][i] = (double*)SCALLOC(M+1,sizeof (double));
}
double *z = (double*)SMALLOC((M+1)*sizeof (double));
double *x = (double*)SMALLOC((N+1)*sizeof (double));
275
/*set the spatial directions, including fake points for the boundaries
* between regions*/
z[0] = −dz/2.;
280 for(k=1;k<=M;k++)
{
z[k]=z[k−1]+dz;
if (z[k]<=Pz && z[k]+dz>Pz)
{
285 K0=k;
}
if (z[k]<=Cz && z[k]+dz>Cz)
{
K1=k;
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290 }
if (z[k]<=Ez && z[k]+dz>Ez)
{
K2=k;
z[k+1]=z[k];k++;EzE=k;
295 FzS=k+1;
}
if (z[k]<=Fz && z[k]+dz>Fz)
{
K3=k;
300 z[k+1]=z[k];k++;FzE=k;
TzS=k+1;
}
}
x[0] = −dx/2.;
305 unsigned char DMG = R1<R2;
unsigned char LAST;
for(i=1;i<=N;i++)
{
x[i] = x[i−1]+dx;
310 if (x[i]<=R0 && x[i]+dx>R0)
{
IC=i;
}
if (x[i]<=R1 && x[i]+dx>R1)
315 {
I0=i;
x[i+1]=x[i];i++;A0E=i;
A1S=i+1;
}
320 if (x[i]<=R2 && x[i]+dx>R2)
{
I1=i;
x[i+1]=x[i];i++;A1E=i;
A2S=i+1;
325 }
}
/*set the initial conditions*/
for(i=0;i<=N;i++)
330 {
for(k=0;k<=M;k++)
{
A[0][i][k]=0;
A[1][i][k]=0;
335 }
}
for(i=A2S;i<=N;i++)
{
for(k=0;k<=M;k++)
340 {
A[0][i][k]=A0;
A[1][i][k]=A0;
}
}
345 for(k=TzS;k<=M;k++)
{
for(i=1;i<=N;i++)
{
A[0][i][k]=A0;
350 A[1][i][k]=A0;
}
}
int Wx = I0+1, /*reduced grid directions for electroactive product*/
Wz = K2+1; /*which is limited to the enzyme layer*/
355 for(j=0;j<2;j++)
{
P[j] = (double**)SMALLOC((Wx+1)*sizeof (double*));
for(i=0;i<=Wx;i++)
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P[j][i] = (double*)SCALLOC(Wz+1,sizeof (double));
360 }
for(j=0;j<2;j++)
{
for(i=0;i<=Wx;i++)
{
365 for(k=0;k<=Wz;k++)
P[j][i][k]=0;
}
}
fprintf(stderr,"R2=x[%i]=%e (%i %i) R1=x[%i]=%e (%i %i) R0=x[%i]=%e\n",I1,x[I1],A0E,A1S,I0,x[I0],A1E,A2S,IC,x[IC]);
370 fprintf(stderr,"K3=z[%i]=%e (%i %i) K2=z[%i]=%e (%i %i) K1=z[%i]=%e K0=z[%i]=%e\n",K3,z[K3],FzE,TzS,K2,z[K2],EzE,FzS,K1,z[K1],K0,z[K0]);
/*allocate vectors used to form and solve the tridiagonal system
*vectors for the radial direction*/
gsl vector* MrDiag = gsl vector alloc(N+1);
375 gsl vector* MrUpper = gsl vector alloc(N);
gsl vector* MrLower = gsl vector alloc(N);
gsl vector* bk = gsl vector alloc(N+1);
gsl vector* MrDiagP = gsl vector alloc(N+1);
gsl vector* MrUpperP = gsl vector alloc(N);
380 gsl vector* MrLowerP = gsl vector alloc(N);
gsl vector* bkP = gsl vector alloc(N+1);
gsl vector* MrDiagE = gsl vector alloc(N+1);
gsl vector* MrUpperE = gsl vector alloc(N);
gsl vector* MrLowerE = gsl vector alloc(N);
385 gsl vector* bkE = gsl vector alloc(N+1);
gsl vector* MrDiagT = gsl vector alloc(N+1);
gsl vector* MrUpperT = gsl vector alloc(N);
gsl vector* MrLowerT = gsl vector alloc(N);
gsl vector* bkT = gsl vector alloc(N+1);
390 gsl vector* MrDiagF = gsl vector alloc(N+1);
gsl vector* MrUpperF = gsl vector alloc(N);
gsl vector* MrLowerF = gsl vector alloc(N);
gsl vector* bkF = gsl vector alloc(N+1);
gsl vector* xk = gsl vector alloc(N+1);
395
/*vectors for the vertical direction*/
gsl vector* MzDiagF = gsl vector alloc(M+1);
gsl vector* MzUpperF = gsl vector alloc(M);
gsl vector* MzLowerF = gsl vector alloc(M);
400 gsl vector* biF = gsl vector alloc(M+1);
gsl vector* MzDiagE = gsl vector alloc(M+1);
gsl vector* MzUpperE = gsl vector alloc(M);
gsl vector* MzLowerE = gsl vector alloc(M);
gsl vector* biE = gsl vector alloc(M+1);
405 gsl vector* MzDiagB = gsl vector alloc(M+1);
gsl vector* MzUpperB = gsl vector alloc(M);
gsl vector* MzLowerB = gsl vector alloc(M);
gsl vector* biB = gsl vector alloc(M+1);
gsl vector* MzDiagT = gsl vector alloc(M+1);
410 gsl vector* MzUpperT = gsl vector alloc(M);
gsl vector* MzLowerT = gsl vector alloc(M);
gsl vector* biT = gsl vector alloc(M+1);
gsl vector* xi = gsl vector alloc(M+1);
415 /*vectors for the product in the radial direction*/
gsl vector* PrDiag = gsl vector alloc(Wx+1);
gsl vector* PrUpper = gsl vector alloc(Wx);
gsl vector* PrLower = gsl vector alloc(Wx);
gsl vector* bPk = gsl vector alloc(Wx+1);
420 gsl vector* PrDiagC = gsl vector alloc(Wx+1);
gsl vector* PrUpperC = gsl vector alloc(Wx);
gsl vector* PrLowerC = gsl vector alloc(Wx);
gsl vector* bPkC = gsl vector alloc(Wx+1);
gsl vector* xPk = gsl vector alloc(Wx+1);
425
/*vectors for the product in the vertical direction*/
gsl vector* PzDiag = gsl vector alloc(Wz+1);
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gsl vector* PzUpper = gsl vector alloc(Wz);
gsl vector* PzLower = gsl vector alloc(Wz);
430 gsl vector* bPi = gsl vector alloc(Wz+1);
gsl vector* PzDiagP = gsl vector alloc(Wz+1);
gsl vector* PzUpperP = gsl vector alloc(Wz);
gsl vector* PzLowerP = gsl vector alloc(Wz);
gsl vector* bPiP = gsl vector alloc(Wz+1);
435 gsl vector* xPi = gsl vector alloc(Wz+1);
/*
*
440 *
* Create Vectors
*
*
*/
445
/*
*
* Tri-diagonal system for the analyte in the radial direction
* There are 5 different cases depending on the depth there are;
450 * 1) biosensor core followed by the enzyme-layer, free-region and tissue
* 2) plastic sheath followed by the free-region and the tissue
* 3) enzyme-layer followed by free-region and tissue
* 4) free-region followed by tissue
* 5) tissue
455 *
* Vectors for the RHS of the tri-diagonal system are created in turn with
* the corresponding boundary and continuity conditions.
*/
460 /*
* Core—-Enzyme—-Free—Tissue
*/
/*Zero in core*/
for(i=0;i<IC−1;i++)
465 {
GSL V SET(MrDiag,i,1);
GSL V SET(MrUpper,i,0);
GSL V SET(MrLower,i,0);
}
470
/*Zero flux at core*/
GSL V SET(MrDiag,IC−1,1);
GSL V SET(MrUpper,IC−1,−1);
475 for(i=IC;i<=I0;i++)
{
GSL V SET(MrDiag,i,1.+(D*dt/(2.*SQ(mu*dx)))*(2.+cb));
GSL V SET(MrUpper,i,−(D*dt/(2.*SQ(mu*dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLower,i−1,−(D*dt/(2.*SQ(mu*dx)))*(1.−(dx/2.*x[i])));
480 }
/*Continuity condition are not time dependant*/
GSL V SET(MrDiag,A0E,−1);
GSL V SET(MrUpper,A0E,SQ(mu));
485 GSL V SET(MrLower,A0E−1,1.−SQ(mu)/alphaB);
GSL V SET(MrDiag,A1S,1.+(D*dt/(2.*SQ(dx)))*(2.
+(SQ(mu)/(alphaB−SQ(mu)))*(1.−(dx/2.*x[A1S]))));
GSL V SET(MrUpper,A1S,−(D*dt/(2.*SQ(dx))));
490 GSL V SET(MrLower,A1S−1, −(D*dt/(2.*SQ(dx)))*
(1./(alphaB−SQ(mu)))*(1.−(dx/2.*x[A1S])));
for(i=A1S+1;i<=I1;i++)
495 {
GSL V SET(MrDiag,i,1.+2.*(D*dt/(2.*SQ(dx))));
181
GSL V SET(MrUpper,i,−(D*dt/(2.*SQ(dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLower,i−1,−(D*dt/(2.*SQ(dx)))*(1.−(dx/2.*x[i])));
}
500
GSL V SET(MrDiag,A1E,−1);
GSL V SET(MrUpper,A1E,1./SQ(lambda));
GSL V SET(MrLower,A1E−1,1.−alphaT/SQ(lambda));
505 GSL V SET(MrDiag,A2S, 1+(D*dt/(2.*SQ(dx*lambda)))*
(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MrUpper,A2S, −(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[A2S])));
GSL V SET(MrLower,A2S−1, −(D*dt/(2.*SQ(dx*lambda)))*
(1.−(dx/2.*x[A2S]))*alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
510
for(i=A2S+1;i<N;i++)
{
GSL V SET(MrDiag,i,1+(D*dt/(2.*SQ(dx*lambda)))*(2.+ct));
GSL V SET(MrUpper,i,−(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[i])));
515 GSL V SET(MrLower,i−1,−(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[i])));
}
GSL V SET(MrLower,N−1,0);
GSL V SET(MrDiag,N,1);
520
for(i=0;i<IC;i++)
GSL V SET(bk,i,0); /*Zero in core*/
GSL V SET(bk,A0E,0); /*Continuity conditions*/
525 GSL V SET(bk,A1E,0);
GSL V SET(bk,N,A0); /*Zero flux*/
DBPRINT("Created vectors for first row:\tCore---Enzyme---Free---Tissue\n");
530 /*
* Plastic—Free—-Tissue
*/
/*Zero in plastic*/
for(i=0;i<=I0;i++)
535 {
GSL V SET(MrDiagP,i,1);
GSL V SET(MrUpperP,i,0);
GSL V SET(MrLowerP,i,0);
}
540
/*Zero flux at the boundary with the plastic sheath*/
GSL V SET(MrDiagP,A0E,1);
GSL V SET(MrUpperP,A0E,−1);
545 for(i=A1S;i<=I1;i++)
{
GSL V SET(MrDiagP,i,1.+2.*(D*dt/(2.*SQ(dx))));
GSL V SET(MrUpperP,i,−(D*dt/(2.*SQ(dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLowerP,i−1,−(D*dt/(2.*SQ(dx)))*(1.−(dx/2.*x[i])));
550 }
GSL V SET(MrDiagP,A1E,−1);
GSL V SET(MrUpperP,A1E,1./SQ(lambda));
GSL V SET(MrLowerP,A1E−1,1.−alphaT/SQ(lambda));
555 GSL V SET(MrDiagP,A2S, 1+(D*dt/(2.*SQ(dx*lambda)))*
(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MrUpperP,A2S, −(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[A2S])));
GSL V SET(MrLowerP,A2S−1, −(D*dt/(2.*SQ(dx*lambda)))*
(1.−(dx/2.*x[A2S]))*alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
560
for(i=A2S+1;i<N;i++)
{
GSL V SET(MrDiagP,i,1.+(D*dt/(2.*SQ(dx*lambda)))*(2.+ct));
GSL V SET(MrUpperP,i,−(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[i])));
565 GSL V SET(MrLowerP,i−1,−(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[i])));
182
}GSL V SET(MrLowerP,N−1,0);
GSL V SET(MrDiagP,N,1);
570
for(i=0;i<=I0;i++)
GSL V SET(bkP,i,0); /*Zero in plastic*/
GSL V SET(bkP,A0E,0); /*Continuity conditions*/
575 GSL V SET(bkP,A1E,0);
GSL V SET(bkP,N,A0); /*A(N)=A**/
DBPRINT("Created vectors for second row:\tPlastic---Free---Tissue\n");
580
/*
* Enzyme—-Free—Tissue
*/
/*Zero flux at zero*/
585 GSL V SET(MrDiagE,0,1);
GSL V SET(MrUpperE,0,−1);
for(i=1;i<=I0;i++)
{
590 GSL V SET(MrDiagE,i,1.+(D*dt/(2.*SQ(mu*dx)))*(2.+cb));
GSL V SET(MrUpperE,i,−(D*dt/(2.*SQ(mu*dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLowerE,i−1,−(D*dt/(2.*SQ(mu*dx)))*(1.−(dx/2.*x[i])));
}
595 /*Continuity condition are not time dependant*/
GSL V SET(MrDiagE,A0E,−1);
GSL V SET(MrUpperE,A0E,SQ(mu));
GSL V SET(MrLowerE,A0E−1,1.−SQ(mu)/alphaB);
600 GSL V SET(MrDiagE,A1S,1.+(D*dt/(2.*SQ(dx)))*(2.
+(SQ(mu)/(alphaB−SQ(mu)))*(1.−(dx/2.*x[A1S]))));
GSL V SET(MrUpperE,A1S,−(D*dt/(2.*SQ(dx))));
GSL V SET(MrLowerE,A1S−1, −(D*dt/(2.*SQ(dx)))*
(1./(alphaB−SQ(mu)))*(1.−(dx/2.*x[A1S])));
605
for(i=A1S+1;i<=I1;i++)
{
GSL V SET(MrDiagE,i,1.+2.*(D*dt/(2.*SQ(dx))));
610 GSL V SET(MrUpperE,i,−(D*dt/(2.*SQ(dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLowerE,i−1,−(D*dt/(2.*SQ(dx)))*(1.−(dx/2.*x[i])));
}
GSL V SET(MrDiagE,A1E,−1);
615 GSL V SET(MrUpperE,A1E,1./SQ(lambda));
GSL V SET(MrLowerE,A1E−1,1. − alphaT/SQ(lambda));
GSL V SET(MrDiagE,A2S, 1+(D*dt/(2.*SQ(dx*lambda)))*
(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT)));
620 GSL V SET(MrUpperE,A2S, −(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[A2S])));
GSL V SET(MrLowerE,A2S−1, −(D*dt/(2.*SQ(dx*lambda)))*
(1.−(dx/2.*x[A2S]))*alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
for(i=A2S+1;i<N;i++)
625 {
GSL V SET(MrDiagE,i,1.+(D*dt/(2.*SQ(dx*lambda)))*(2.+ct));
GSL V SET(MrUpperE,i,−(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLowerE,i−1,−(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[i])));
}
630
GSL V SET(MrLowerE,N−1,0);
GSL V SET(MrDiagE,N,1);
GSL V SET(bkE,0,0); /*Zero flux at zero*/
183
635 GSL V SET(bkE,A0E,0); /*Continuity conditions*/
GSL V SET(bkE,A1E,0);
GSL V SET(bkE,N,A0); /*A(N)=A* */
DBPRINT("Created vectors for third row:\tEnzyme---Free---Tissue\n");
640
/*
* Free—Tissue
*/
645 /*Zero flux at zero*/
GSL V SET(MrDiagF,0,1);
GSL V SET(MrUpperF,0,−1);
for(i=1;i<=I1;i++)
650 {
GSL V SET(MrDiagF,i,1.+2.*(D*dt/(2.*SQ(dx))));
GSL V SET(MrUpperF,i,−(D*dt/(2.*SQ(dx)))*(1.+(dx/2.*x[i])));
GSL V SET(MrLowerF,i−1,−(D*dt/(2.*SQ(dx)))*(1.−(dx/2.*x[i])));
}
655
/*Bridge over the fake grid point*/
GSL V SET(MrDiagF,I0,1.+(3.+(dx/2.*x[I0]))*(D*dt/(2.*SQ(dx))));
GSL V SET(MrUpperF,I0,−2.*(D*dt/(2.*SQ(dx)))*(1.+(dx/2.*x[I0])));
GSL V SET(MrDiagF,A0E,−1);
660 GSL V SET(MrUpperF,A0E,0.5);
GSL V SET(MrLowerF,A0E−1,0.5);
GSL V SET(MrDiagF,A1S,1.+(3.−(dx/2.*x[A1S]))*(D*dt/(2.*SQ(dx))));
GSL V SET(MrLowerF,A1S−1,−2.*(D*dt/(2.*SQ(dx)))*(1.−(dx/2.*x[A1S])));
665
GSL V SET(MrDiagF,A1E,−1);
GSL V SET(MrUpperF,A1E,1./SQ(lambda));
GSL V SET(MrLowerF,A1E−1,1. − alphaT/SQ(lambda));
670 GSL V SET(MrDiagF,A2S, 1+(D*dt/(2.*SQ(dx*lambda)))*
(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MrUpperF,A2S, −(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[A2S])));
GSL V SET(MrLowerF,A2S−1, −(D*dt/(2.*SQ(dx*lambda)))*
(1.−(dx/2.*x[A2S]))*alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
675
for(i=A2S+1;i<N;i++)
{
GSL V SET(MrDiagF,i,1+(D*dt/(2.*SQ(dx*lambda)))*(2.+ct));
GSL V SET(MrUpperF,i,−(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[i])));
680 GSL V SET(MrLowerF,i−1,−(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[i])));
}
GSL V SET(MrLowerF,N−1,0);
GSL V SET(MrDiagF,N,1);
685
GSL V SET(bkF,0,0); /*Zero flux at zero*/
GSL V SET(bkF,A0E,0); /*Continuity conditions*/
GSL V SET(bkF,A1E,0);
GSL V SET(bkF,N,A0); /*A(N)=A* */
690
DBPRINT("Created vectors for fourth row:\tFree---Tissue\n");
/*
* Tissue
695 */
/*Zero flux at zero*/
GSL V SET(MrDiagT,0,1);
GSL V SET(MrUpperT,0,−1);
700 for(i=1;i<N;i++)
{
GSL V SET(MrDiagT,i,1.+(D*dt/(2.*SQ(dx*lambda)))*(2.+ct));
GSL V SET(MrUpperT,i,−(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[i])));
184
GSL V SET(MrLowerT,i−1,−(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[i])));
705 }
/*Bridge over the extra points*/
GSL V SET(MrDiagT,I0,1.+(3.+ct+(dx/2.*x[I0]))*(D*dt/(2.*SQ(dx*lambda))));
GSL V SET(MrUpperT,I0,−2.*(D*dt/(2.*SQ(dx*lambda)))*(1.+(dx/2.*x[I0])));
710 GSL V SET(MrDiagT,A0E,−1);
GSL V SET(MrUpperT,A0E,0.5);
GSL V SET(MrLowerT,A0E−1,0.5);
GSL V SET(MrDiagT,A1S,1.+(3.+ct−(dx/2.*x[A1S]))*(D*dt/(2.*SQ(dx*lambda))));
GSL V SET(MrLowerT,A1S−1,−2.*(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[A1S])));
715
GSL V SET(MrDiagT,I1,1.+(3.+ct+dx/x[I1])*(D*dt/(2.*SQ(dx*lambda))));
GSL V SET(MrUpperT,I1,−2.*(D*dt/(2.*SQ(dx*lambda)))*(1.+dx/x[I1]));
GSL V SET(MrDiagT,A1E,−1);
GSL V SET(MrUpperT,A1E,0.5);
720 GSL V SET(MrLowerT,A1E−1,0.5);
GSL V SET(MrDiagT,A2S,1.+(3.+ct−(dx/2.*x[A2S]))*(D*dt/(2.*SQ(dx*lambda))));
GSL V SET(MrLowerT,A2S−1,−2.*(D*dt/(2.*SQ(dx*lambda)))*(1.−(dx/2.*x[A2S])));
725 GSL V SET(MrLowerT,N−1,0); /*Zero flux*/
GSL V SET(MrDiagT,N,1);
GSL V SET(bkT,0,0); /*Zero flux at 0*/
GSL V SET(bkT,A0E,0); /*Continuity conditions*/
730 GSL V SET(bkT,A1E,0);
GSL V SET(bkT,N,A0); /*A(N)=A* */
DBPRINT("Created vectors for fifth row:\tTissue\n");
735 /*
*
* Tri-diagonal system for the product in the radial direction
* As the product is limited to the enzyme layer, there are only 2 cases;
* 1) biosensor core followed by the enzyme-layer
740 * 2) enzyme layer
*
* Vectors for the RHS of the tri-diagonal system are created in turn with
* the corresponding boundary and continuity conditions.
*/
745
/*
* Core—Enzyme
*/
for(i=0;i<IC;i++)
750 {
GSL V SET(PrDiagC,i,1);
GSL V SET(PrUpperC,i,0);
GSL V SET(PrLowerC,i,0);
}
755
GSL V SET(PrDiagC,IC,1); /*BC - zero at core */
GSL V SET(PrUpperC,IC,0);
for(i=IC+1;i<Wx;i++)
760 {
GSL V SET(PrDiagC,i,1.+2.*(Dp*dt/(2.*SQ(dx*mu))));
GSL V SET(PrUpperC,i,−(Dp*dt/(2.*SQ(dx*mu)))*(1.+(dx/2.*x[i])));
GSL V SET(PrLowerC,i−1,−(Dp*dt/(2.*SQ(dx*mu)))*(1.−(dx/2.*x[i])));
}
765
GSL V SET(PrDiagC,Wx,1); /*BC - zero at free-region*/
GSL V SET(PrLowerC,Wx−1,0);
for(i=0;i<=IC;i++)
770 {
GSL V SET(bPkC,i,0);
}
185
GSL V SET(bPkC,Wx,0);
775
/*
* Enzyme
*/
for(i=1;i<Wx;i++)
780 {
GSL V SET(PrDiag,i,1.+2.*(Dp*dt/(2.*SQ(dx*mu))));
GSL V SET(PrUpper,i,−(Dp*dt/(2.*SQ(dx*mu)))*(1.+(dx/2.*x[i])));
GSL V SET(PrLower,i−1,−(Dp*dt/(2.*SQ(dx*mu)))*(1.−(dx/2.*x[i])));
}
785
GSL V SET(PrDiag,0,1); /*BC zero flux at r=0*/
GSL V SET(PrUpper,0,−1);
GSL V SET(PrDiag,Wx,1);
790 GSL V SET(PrLower,Wx−1,0);
GSL V SET(bPk,0,0);
GSL V SET(bPk,Wx,0);
795
/*
*
*
800 * Tridiagonal system for the vertical direction
*
* There are 4 cases to consider for columns in the system
* 1) Plastic sheath followed by biosensor core, enzyme-layer, free-region
* and tissue.
805 * 2) Plastic sheath followed by enzyme-layer, free-region and tissue.
* 3) Free region followed by tissue.
* 4) Tissue.
*
* Vectors for the RHS of the tri-diagonal system are created for each of
810 * these cases with the corresponding boundary and continuity conditions.
*/
/*
815 * Plastic—Core—Enzyme—Free—Tissue
*/
/*No analyte in plastic and core*/
for(k=0;k<K1;k++)
820 {
GSL V SET(MzDiagB,k,1);
GSL V SET(MzUpperB,k,0);
GSL V SET(MzLowerB,k,0);
}
825
/*Zero flux at core*/
GSL V SET(MzDiagB,K1,1);
GSL V SET(MzUpperB,K1,−1);
830 for(k=K1+1;k<=K2;k++)
{
GSL V SET(MzDiagB, k, 1.+2.*(D*dt/(2.*SQ(dz*mu))));
GSL V SET(MzUpperB,k, −(D*dt/(2.*SQ(dz*mu))));
GSL V SET(MzLowerB,k−1,−(D*dt/(2.*SQ(dz*mu))));
835 }
GSL V SET(MzDiagB,EzE,−1);
GSL V SET(MzUpperB,EzE,SQ(mu));
GSL V SET(MzLowerB,EzE−1,1.−SQ(mu)/alphaB);
840
GSL V SET(MzDiagB,FzS, 1.+(D*dt/(2.*SQ(dz)))*(2.+SQ(mu)/(alphaB−SQ(mu))));
186
GSL V SET(MzUpperB,FzS, −(D*dt/(2.*SQ(dz))));
GSL V SET(MzLowerB,FzS−1,−(D*dt/(2.*SQ(dz)))*(SQ(mu)/(alphaB−SQ(mu))));
845 for(k=FzS+1;k<=K3;k++)
{
GSL V SET(MzDiagB, k, 1.+2.*(D*dt/(2.*SQ(dz))));
GSL V SET(MzUpperB,k, −(D*dt/(2.*SQ(dz))));
GSL V SET(MzLowerB,k−1,−(D*dt/(2.*SQ(dz))));
850 }
GSL V SET(MzDiagB,FzE,−1);
GSL V SET(MzUpperB,FzE,1./SQ(lambda));
GSL V SET(MzLowerB,FzE−1,1.−alphaT/SQ(lambda));
855
GSL V SET(MzDiagB,TzS, 1.+(D*dt/(2.*SQ(dz*lambda)))*
(2.+alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MzUpperB,TzS, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerB,TzS−1,−(D*dt/(2.*SQ(dz*lambda)))*
860 alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
for(k=TzS+1;k<M;k++)
{
GSL V SET(MzDiagB, k, 1.+2.*(D*dt/(2.*SQ(dz*lambda))));
865 GSL V SET(MzUpperB,k, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerB,k−1,−(D*dt/(2.*SQ(dz*lambda))));
}
870 /*A=A* at lower boundary*/
GSL V SET(MzDiagB,M,1);
GSL V SET(MzLowerB,M−1,0);
for(k=0;k<=K1;k++)
875 {
GSL V SET(biB,k,0);
}
GSL V SET(biB,EzE,0);
GSL V SET(biB,FzE,0);
880 GSL V SET(biB,M,A0);
DBPRINT("Created vectors for first column:\t"
"Plastic---Core---Enzyme---Free---Tissue\n");
885
/*
* Plastic—Enzyme—Free—Tissue
*/
890 /*Zero in plastic*/
for(k=0;k<K0;k++)
{
GSL V SET(MzDiagE,k,1);
GSL V SET(MzUpperE,k,0);
895 GSL V SET(MzLowerE,k,0);
}
/*Zero flux at plastic*/
GSL V SET(MzDiagE,K0,1);
900 GSL V SET(MzUpperE,K0,−1);
for(k=K0+1;k<=K2;k++)
{
GSL V SET(MzDiagE, k, 1.+2.*(D*dt/(2.*SQ(dz*mu))));
905 GSL V SET(MzUpperE,k, −(D*dt/(2.*SQ(dz*mu))));
GSL V SET(MzLowerE,k−1,−(D*dt/(2.*SQ(dz*mu))));
}
GSL V SET(MzDiagE,EzE,−1);
910 GSL V SET(MzUpperE,EzE,SQ(mu));
187
GSL V SET(MzLowerE,EzE−1,1.−SQ(mu)/alphaB);
GSL V SET(MzDiagE,FzS, 1.+(D*dt/(2.*SQ(dz)))*(2.+SQ(mu)/(alphaB−SQ(mu))));
GSL V SET(MzUpperE,FzS, −(D*dt/(2.*SQ(dz))));
915 GSL V SET(MzLowerE,FzS−1,−(D*dt/(2.*SQ(dz)))*SQ(mu)/(alphaB−SQ(mu)));
for(k=FzS+1;k<M;k++)
{
920 GSL V SET(MzDiagE, k, 1.+2.*(D*dt/(2.*SQ(dz))));
GSL V SET(MzUpperE,k, −(D*dt/(2.*SQ(dz))));
GSL V SET(MzLowerE,k−1,−(D*dt/(2.*SQ(dz))));
}
925 GSL V SET(MzDiagE,FzE,−1);
GSL V SET(MzUpperE,FzE,1./SQ(lambda));
GSL V SET(MzLowerE,FzE−1,1.−alphaT/SQ(lambda));
GSL V SET(MzDiagE,TzS, 1.+(D*dt/(2.*SQ(dz*lambda)))*
930 (2.+alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MzUpperE,TzS, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerE,TzS−1,−(D*dt/(2.*SQ(dz*lambda)))*
alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
935 for(k=TzS+1;k<M;k++)
{
GSL V SET(MzDiagE, k, 1.+2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzUpperE,k, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerE,k−1,−(D*dt/(2.*SQ(dz*lambda))));
940 }
/* A* at lower boundary*/
GSL V SET(MzDiagE,M,1);
GSL V SET(MzLowerE,M−1,0);
945
for(k=0;k<=K0;k++)
{
GSL V SET(biE,k,0);
}
950 GSL V SET(biE,EzE,0);
GSL V SET(biE,FzE,0);
GSL V SET(biE,M,A0);
DBPRINT("Created vectors for second column:\tEnzyme---Free---Tissue\n");
955
/*
* Free—Tissue
*/
960
/*Zero flux at surface*/
GSL V SET(MzDiagF,0,1);
GSL V SET(MzUpperF,0,−1);
965 for(k=1;k<=K3;k++)
{
GSL V SET(MzDiagF, k, 1.+2.*(D*dt/(2.*SQ(dz))));
GSL V SET(MzUpperF,k, −(D*dt/(2.*SQ(dz))));
GSL V SET(MzLowerF,k−1,−(D*dt/(2.*SQ(dz))));
970 }
/*Bridge over extra point*/
GSL V SET(MzDiagF, K2, 1.+3.*(D*dt/(2.*SQ(dz))));
GSL V SET(MzUpperF,K2,−2.*(D*dt/(2.*SQ(dz))));
975 GSL V SET(MzDiagF,EzE,−1);
GSL V SET(MzUpperF,EzE,0.5);
GSL V SET(MzLowerF,EzE−1,0.5);
GSL V SET(MzDiagF, FzS, 1.+3.*(D*dt/(2.*SQ(dz))));
GSL V SET(MzLowerF,FzS−1, −2.*(D*dt/(2.*SQ(dz))));
188
980
GSL V SET(MzDiagF,FzE,−1);
GSL V SET(MzUpperF,FzE,1./SQ(lambda));
GSL V SET(MzLowerF,FzE−1,1.−alphaT/SQ(lambda));
985 GSL V SET(MzDiagF,TzS, 1.+(D*dt/(2.*SQ(dz*lambda)))*
(2.+alphaT/(SQ(lambda)−alphaT)));
GSL V SET(MzUpperF,TzS, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerF,TzS−1,−(D*dt/(2.*SQ(dz*lambda)))*
alphaT*SQ(lambda)/(SQ(lambda)−alphaT));
990
for(k=TzS+1;k<M;k++)
{
GSL V SET(MzDiagF, k, 1.+2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzUpperF,k, −(D*dt/(2.*SQ(dz*lambda))));
995 GSL V SET(MzLowerF,k−1,−(D*dt/(2.*SQ(dz*lambda))));
}
/* A* at lower boundary*/
GSL V SET(MzDiagF,M,1);
1000 GSL V SET(MzLowerF,M−1,0);
GSL V SET(biF,0,0);
GSL V SET(biF,EzE,0);
GSL V SET(biF,FzE,0);
1005 GSL V SET(biF,M,A0);
DBPRINT("Created vectors for third column:\tFree---Tissue\n");
1010 /*
* Tissue
*/
/*Zero flux at surface*/
1015 GSL V SET(MzDiagT,0,1);
GSL V SET(MzUpperT,0,−1);
for(k=1;k<M;k++)
{
1020 GSL V SET(MzDiagT, k, 1.+2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzUpperT,k, −(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerT,k−1,−(D*dt/(2.*SQ(dz*lambda))));
}
1025 /*Bridge over extra points*/
GSL V SET(MzDiagT, K2, 1.+3.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzUpperT,K2, −2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzDiagT,EzE,−1);
GSL V SET(MzUpperT,EzE,0.5);
1030 GSL V SET(MzLowerT,EzE−1,0.5);
GSL V SET(MzDiagT, FzS, 1.+3.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzLowerT,FzS−1, −2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzDiagT, K3, 1.+3.*(D*dt/(2.*SQ(dz*lambda))));
1035 GSL V SET(MzUpperT,K3, −2.*(D*dt/(2.*SQ(dz*lambda))));
GSL V SET(MzDiagT,FzE,−1);
GSL V SET(MzUpperT,FzE,0.5);
GSL V SET(MzLowerT,FzE−1,0.5);
GSL V SET(MzDiagT, TzS, 1.+3.*(D*dt/(2.*SQ(dz*lambda))));
1040 GSL V SET(MzLowerT,TzS−1, −2.*(D*dt/(2.*SQ(dz*lambda))));
/* A* flux lower boundary*/
GSL V SET(MzDiagT,M,1);
1045 GSL V SET(MzLowerT,M−1,0);
GSL V SET(biT,0,0);
GSL V SET(biT,EzE,0);
189
GSL V SET(biT,FzE,0);
1050 GSL V SET(biT,M,A0);
DBPRINT("Created vectors for forth column:\tTissue\n");
/*
1055 *
* Tri-diagonal system for the product in the vertical direction
* As the product is limited to the enzyme layer, there are only 2 cases;
* 1) plastic sheath followed by the biosensor core and the enzyme-layer.
* 2) plastic sheath followed by the enzyme layer.
1060 *
* Vectors for the RHS of the tri-diagonal system are created in turn with
* the corresponding boundary and continuity conditions.
*/
1065 /*
* Plastic–Core–Enzyme
*/
for(k=0;k<K1;k++)
{
1070 GSL V SET(PzDiag,k,1);
GSL V SET(PzUpper,k,0);
GSL V SET(PzLower,k,0);
}
GSL V SET(PzDiag,K1,1);
1075 GSL V SET(PzUpper,K1,0);
for(k=K1+1;k<Wz;k++)
{
GSL V SET(PzDiag,k,1.+2.*(Dp*dt/(2.*SQ(dz*mu))));
1080 GSL V SET(PzUpper,k,−(Dp*dt/(2.*SQ(dz*mu))));
GSL V SET(PzLower,k−1,−(Dp*dt/(2.*SQ(dz*mu))));
}
GSL V SET(PzDiag,Wz,1);
GSL V SET(PzLower,Wz−1,0);
1085
for(k=0;k<=K1;k++)
{
GSL V SET(bPi,k,0);
}
1090 GSL V SET(bPi,Wz,0);
/*
* Plastic–Enzyme
1095 */
for(k=0;k<K0;k++)
{
GSL V SET(PzDiagP,k,1);
GSL V SET(PzUpperP,k,0);
1100 GSL V SET(PzLowerP,k,0);
}
GSL V SET(PzDiagP,K0,1);
GSL V SET(PzUpperP,K0,0);
1105 for(k=K0+1;k<Wz;k++)
{
GSL V SET(PzDiagP,k,1.+2.*(Dp*dt/(2.*SQ(dz*mu))));
GSL V SET(PzUpperP,k,−(Dp*dt/(2.*SQ(dz*mu))));
GSL V SET(PzLowerP,k−1,−(Dp*dt/(2.*SQ(dz*mu))));
1110 }
GSL V SET(PzDiagP,Wz,1);
GSL V SET(PzLowerP,Wz−1,0);
for(k=0;k<=K0;k++)
1115 {
GSL V SET(bPiP,k,0);
}
190
GSL V SET(bPiP,Wz,0);
1120
for(j=0;t<T;j++)
{
1125 /*
* Alternating direction implicit method, first solve in the radially
* For each of 5 cases decried above, create a corresponding LHS and
* use the Gnu Scientific Library function gsl linalg solve tridiag
* to calculate the solution
1130 */
/*
* Plastic–Free–Tissue
*/
1135 for(k=1;k<=K0;k++)
{
for(i=A1S;i<=I1;i++)
GSL V SET(bkP,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
1140 for(i=A2S;i<N;i++)
GSL V SET(bkP,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagP,MrUpperP,MrLowerP,bkP,xk));
1145
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
/*
1150 * Core—Enzyme—Free—Tissue
*/
for(k=K0+1;k<K1;k++)
{
for(i=IC;i<=I0;i++)
1155 GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(mu*dz)))*
(AOLD(i,k+1)−2.*AOLD(i,k)+AOLD(i,k−1)));
for(i=A1S;i<=I1;i++)
GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
1160 for(i=A2S;i<N;i++)
GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
1165 ERR REP(gsl linalg solve tridiag(MrDiag,MrUpper,MrLower,bk,xk));
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
1170 /*zero flux at plastic sheath*/
for(i=1;i<=I0;i++)
ANEW(i,K0)=ANEW(i,K0+1);
/*bridge over fake points*/
k=K1;
1175 {
for(i=IC;i<=I0;i++)
GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(mu*dz)))*
(AOLD(i,k+1)−2.*AOLD(i,k)+AOLD(i,k−1)));
for(i=A1S;i<=I1;i++)
1180 GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−3.*AOLD(i,k)+2.*AOLD(i,k+1)));
for(i=A2S;i<N;i++)
GSL V SET(bk,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−3.*AOLD(i,k)+2.*AOLD(i,k+1))+dt*Vt*A0/2.);
1185
191
ERR REP(gsl linalg solve tridiag(MrDiag,MrUpper,MrLower,bk,xk));
for(i=0;i<N;i++)
1190 ANEW(i,k) = GSL V GET(xk,i);
}
/*
* Enzyme—Free—Tissue
1195 */
for(k=K1+1;k<K2;k++)
{
for(i=1;i<=I0;i++)
GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(mu*dz)))*
1200 (AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A1S;i<=I1;i++)
GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A2S;i<N;i++)
1205 GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagE,MrUpperE,MrLowerE,bkE,xk));
1210 for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
/*bridge over fake points*/
k=K2;
1215 {
for(i=1;i<=I0;i++)
GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(mu*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A1S;i<=I1;i++)
1220 GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−3.*AOLD(i,k)+2.*AOLD(i,k+1)));
for(i=A2S;i<N;i++)
GSL V SET(bkE,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−3.*AOLD(i,k)+2.*AOLD(i,k+1))+dt*Vt*A0/2.);
1225
ERR REP(gsl linalg solve tridiag(MrDiagE,MrUpperE,MrLowerE,bkE,xk));
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
1230 }
/*
* Free—Tissue
*/
1235 /*apply continuity conditions*/
k=FzS;
{
for(i=1;i<=I0;i++)
GSL V SET(bkF,i,AOLD(i,k) +
1240 (D*dt/(2.*SQ(mu*dz)))*(AOLD(i,k−1)*(1./(alphaB−SQ(mu)))
− (2.+SQ(mu)/(alphaB−SQ(mu)))*AOLD(i,k) + AOLD(i,k+1)));
for(i=A1S;i<=I1;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(2.*AOLD(i,k−1)−3.*AOLD(i,k)+AOLD(i,k+1)));
1245 for(i=A2S;i<N;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(2.*AOLD(i,k−1)−3.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagF,MrUpperF,MrLowerF,bkF,xk));
1250
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
for(k=FzS+1;k<=K3;k++)
1255 {
192
for(i=1;i<=I0;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A1S;i<=I1;i++)
1260 GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A2S;i<N;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
1265
ERR REP(gsl linalg solve tridiag(MrDiagF,MrUpperF,MrLowerF,bkF,xk));
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
1270 }
/*bridge over fake points*/
k=K3;
{
for(i=1;i<=I0;i++)
1275 GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
for(i=A1S;i<=I1;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1)));
1280 for(i=A2S;i<N;i++)
GSL V SET(bkF,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−3.*AOLD(i,k)+2.*AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagF,MrUpperF,MrLowerF,bkF,xk));
1285
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
1290 /*
* Tissue
*/
/*apply continuity conditions*/
k=TzS;
1295 {
for(i=1;i<=I0;i++)
GSL V SET(bkT,i,AOLD(i,k)+
(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)*alphaT*SQ(lambda)/(SQ(lambda)−alphaT)
1300 −(2.+alphaT/(SQ(lambda)−alphaT))*AOLD(i,k)
+ AOLD(i,k+1)) + dt*Vt*A0/2.);
for(i=A1S;i<=I1;i++)
GSL V SET(bkT,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(2.*AOLD(i,k−1)−3.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
1305 for(i=A2S;i<N;i++)
GSL V SET(bkT,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(2.*AOLD(i,k−1)−3.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagT,MrUpperT,MrLowerT,bkT,xk));
1310
for(i=0;i<N;i++)
ANEW(i,k) = GSL V GET(xk,i);
}
1315 for(k=TzS+1;k<M;k++)
{
for(i=1;i<=I0;i++)
GSL V SET(bkT,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
1320 for(i=A1S;i<=I1;i++)
GSL V SET(bkT,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
(AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
for(i=A2S;i<N;i++)
GSL V SET(bkT,i,AOLD(i,k)+(D*dt/(2.*SQ(lambda*dz)))*
193
1325 (AOLD(i,k−1)−2.*AOLD(i,k)+AOLD(i,k+1))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MrDiagT,MrUpperT,MrLowerT,bkT,xk));
for(i=0;i<N;i++)
1330 ANEW(i,k) = GSL V GET(xk,i);
}
/*
* Alternating direction implicit method, solve for the product in the
1335 * radial direction
*/
/*
* Core—Enzyme
1340 */
for(k=K0+1;k<=K1;k++)
{
for(i=IC+1;i<Wx;i++)
GSL V SET(bPkC,i,POLD(i,k)+(Dp*dt/(2.*SQ(mu*dz)))*
1345 (POLD(i,k−1)−2.*POLD(i,k)+POLD(i,k+1))
+ Vb*dt*AOLD(i,k)/2.);
ERR REP(gsl linalg solve tridiag(PrDiagC,PrUpperC,PrLowerC,bPkC,
xPk));
1350
for(i=IC+1;i<Wx;i++)
PNEW(i,k) = GSL V GET(xPk,i);
}
1355
/*
* Enzyme
*/
for(k=K1;k<K2;k++)
1360 {
for(i=1;i<Wx;i++)
GSL V SET(bPk,i,POLD(i,k)+(Dp*dt/(2.*SQ(mu*dz)))*
(POLD(i,k−1)−2.*POLD(i,k)+POLD(i,k+1))
+ Vb*dt*AOLD(i,k)/2.);
1365
ERR REP(gsl linalg solve tridiag(PrDiag,PrUpper,PrLower,bPk,xPk));
for(i=1;i<Wx;i++)
PNEW(i,k) = GSL V GET(xPk,i);
1370 }
for(i=0;i<N;i++)
ANEW(i,0)=ANEW(i,1);
1375 for(k=0;k<M;k++)
ANEW(0,k)=ANEW(1,k);
/*
* Alternating direction implicit method, next solve in the vertical
1380 * direction using the solutions found for the radial direction.
* For each of 4 cases decried above, create a corresponding LHS and
* use the Gnu Scientific Library function gsl linalg solve tridiag
* to calculate the solution
*/
1385
/*
* Plastic—Core—Enzyme—Free—Tissue
*/
for(i=1;i<IC;i++)
1390 {
for(k=K1+1;k<=K2;k++)
GSL V SET(biB,k,ANEW(i,k)+(D*dt/(2.*SQ(mu*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
194
− (2.+cb)*ANEW(i,k)+ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
1395
for(k=FzS;k<=K3;k++)
GSL V SET(biB,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−2.*ANEW(i,k)
+ ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
1400
for(k=TzS;k<M;k++)
GSL V SET(biB,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(2.+ct)*ANEW(i,k)+ANEW(i−1,k)*
(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
1405
ERR REP(gsl linalg solve tridiag(MzDiagB,MzUpperB,MzLowerB,biB,xi));
for(k=0;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
1410 }
/*
* Plastic—Enzyme—Free—Tissue
*/
1415 for(i=IC;i<I0;i++)
{
for(k=K0+1;k<=K2;k++)
GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(mu*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(2.+cb)*ANEW(i,k)+ANEW(i−1,k)*
1420 (1.−(dx/2.*x[i]))));
for(k=FzS;k<=K3;k++)
GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−2.*ANEW(i,k)+ANEW(i−1,k)*
1425 (1.−(dx/2.*x[i]))));
for(k=TzS;k<M;k++)
GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(2.+ct)*ANEW(i,k)+ANEW(i−1,k)*
1430 (1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MzDiagE,MzUpperE,MzLowerE,biE,xi));
for(k=K0+1;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
1435 }
/*bridge over fake points*/
i=I0;
{
for(k=K0+1;k<=K2;k++)
1440 GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(mu*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(2.+cb)*ANEW(i,k)+ANEW(i−1,k)*
(1.−(dx/2.*x[i]))));
for(k=FzS;k<=K3;k++)
1445 GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
(2.*ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(3+(dx/2.*x[i]))*ANEW(i,k)
+ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
for(k=TzS;k<M;k++)
1450 GSL V SET(biE,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(2.*ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(3.+ct+(dx/2.*x[i]))*ANEW(i,k)+
ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MzDiagE,MzUpperE,MzLowerE,biE,xi));
1455 for(k=K0+1;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
}
1460 /*
* Free—Tissue
*/
195
/*apply continuity conditions*/
i=A1S;
1465 {
for(k=K0;k<=K2;k++)
GSL V SET(biF,k,ANEW(i,k) +
(D*dt/(2.*SQ(dx)))*(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
− (2.+(SQ(mu)/(alphaB−SQ(mu)))*(1.−(dx/2.*x[i])))*ANEW(i,k)
1470 + ANEW(i−1,k)*(1.−(dx/2.*x[i]))*(1./(alphaB−SQ(mu)))));
for(k=FzS;k<=K3;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*(ANEW(i+1,k)*
(1.+(dx/2.*x[i]))−(3.−(dx/2.*x[A1S]))*ANEW(i,k)+2.*ANEW(i−1,k)*
1475 (1.−(dx/2.*x[i]))));
for(k=TzS;k<M;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(3.+ct−(dx/2.*x[A1S]))*ANEW(i,k)
1480 + 2.*ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MzDiagF,MzUpperF,MzLowerF,biF,xi));
for(k=0;k<M;k++)
1485 AOLD(i,k) = GSL V GET(xi,k);
}
/*zero flux at plastic sheath*/
for(k=0;k<=K0;k++)
AOLD(A0E,k)=AOLD(A1S,k);
1490
for(i=A1S+1;i<I1;i++)
{
for(k=1;k<=K2;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
1495 (ANEW(i+1,k)*(1.+(dx/2.*x[i]))−2.*ANEW(i,k)
+ ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
for(k=FzS;k<=K3;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
1500 (ANEW(i+1,k)*(1.+(dx/2.*x[i]))−2.*ANEW(i,k)
+ ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
for(k=TzS;k<M;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
1505 (ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(2.+ct)*ANEW(i,k)
+ ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MzDiagF,MzUpperF,MzLowerF,biF,xi));
1510
for(k=0;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
}
/*bridge over fake points*/
1515 i=I1;
{
for(k=1;k<=K2;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−2.*ANEW(i,k)
1520 + ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
for(k=FzS;k<=K3;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(3.+(dx/2.*x[i]))*ANEW(i,k)
1525 + ANEW(i−1,k)*(1.−(dx/2.*x[i]))));
for(k=TzS;k<M;k++)
GSL V SET(biF,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(2.*ANEW(i+1,k)*(1.+(dx/2.*x[i]))−(3.+ct+(dx/2.*x[i]))*ANEW(i,k)
1530 +ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
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ERR REP(gsl linalg solve tridiag(MzDiagF,MzUpperF,MzLowerF,biF,xi));
1535
for(k=0;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
}
1540
/*
* Tissue
*/
/*apply continuity conditions*/
1545 i=A2S;
{
for(k=1;k<=K2;k++)
GSL V SET(biT,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
1550 −(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT))*ANEW(i,k)
+ANEW(i−1,k)*(1.−(dx/2.*x[i]))*
alphaT*SQ(lambda)/(SQ(lambda)−alphaT) + dt*Vt*A0/2.));
for(k=FzS;k<=K3;k++)
1555 GSL V SET(biT,k,ANEW(i,k)+(D*dt/(2.*SQ(lambda*dx)))*
(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
−(2.+ct+(1.−(dx/2.*x[A2S]))*alphaT/(SQ(lambda)−alphaT))*ANEW(i,k)
+ANEW(i−1,k)*(1.−(dx/2.*x[i]))*
alphaT*SQ(lambda)/(SQ(lambda)−alphaT) +dt*Vt*A0/2.));
1560
for(k=TzS;k<M;k++)
GSL V SET(biT,k,ANEW(i,k) +
(D*dt/(2.*SQ(lambda*dx)))*(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
− (3.+ct−(dx/2.*x[A2S]))*ANEW(i,k)+2.*ANEW(i−1,k)*(1.−(dx/2.*x[i])))
1565 + dt*Vt*A0/2.);
ERR REP(gsl linalg solve tridiag(MzDiagT,MzUpperT,MzLowerT,biT,xi));
for(k=0;k<M;k++)
1570 AOLD(i,k) = GSL V GET(xi,k);
}
for(i=A2S+1;i<N;i++)
{
1575 for(k=1;k<=K2;k++)
GSL V SET(biT,k,ANEW(i,k) +
(D*dt/(2.*SQ(lambda*dx)))*(ANEW(i+1,k)*(1.+(dx/2.*x[i]))
− (2.+ct)*ANEW(i,k)+ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
1580 for(k=FzS;k<=K3;k++)
GSL V SET(biT,k,ANEW(i,k) +
(D*dt/(2.*SQ(lambda*dx)))*(ANEW(i+1,k)*(1.+(dx/2.*x[i])) −
(2.+ct)*ANEW(i,k)+ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
1585 for(k=TzS;k<M;k++)
GSL V SET(biT,k,ANEW(i,k) +
(D*dt/(2.*SQ(lambda*dx)))*(ANEW(i+1,k)*(1.+(dx/2.*x[i])) −
(2.+ct)*ANEW(i,k)+ANEW(i−1,k)*(1.−(dx/2.*x[i])))+dt*Vt*A0/2.);
1590 ERR REP(gsl linalg solve tridiag(MzDiagT,MzUpperT,MzLowerT,biT,xi));
for(k=0;k<M;k++)
AOLD(i,k) = GSL V GET(xi,k);
}
1595 /*
* Alternating direction implicit method, solve for the product in
* the vertical direction using the solutions from the radial
* direction.
*/
1600
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/*
* Plastic—Core—Enzyme
*/
for(i=1;i<=IC;i++)
1605 {
for(k=K1+1;k<Wz;k++)
GSL V SET(bPi,k,PNEW(i,k) +
(Dp*dt/(2.*SQ(mu*dx)))*(PNEW(i+1,k)*(1.+(dx/2.*x[i])) −
2.*PNEW(i,k)+PNEW(i−1,k)*(1.−(dx/2.*x[i])))+Vb*dt*ANEW(i,k)/2.);
1610
ERR REP(gsl linalg solve tridiag(PzDiag,PzUpper,PzLower,bPi,xPi));
for(k=K1+1;k<Wz;k++)
POLD(i,k) = GSL V GET(xPi,k);
1615 }
/*
* Plastic—Enzyme
*/
1620 for(i=IC+1;i<I0;i++)
{
for(k=K0+1;k<Wz;k++)
GSL V SET(bPiP,k,PNEW(i,k) +
(Dp*dt/(2.*SQ(mu*dx)))*(PNEW(i+1,k)*(1.+(dx/2.*x[i])) −
1625 2.*PNEW(i,k)+PNEW(i−1,k)*(1.−(dx/2.*x[i])))+Vb*dt*ANEW(i,k)/2.);
ERR REP(gsl linalg solve tridiag(PzDiagP,PzUpperP,PzLowerP,bPiP,
xPi));
1630 for(k=K0+1;k<Wz;k++)
POLD(i,k) = GSL V GET(xPi,k);
}
/*Zero flux at r=0*/
1635 for(i=0;i<N;i++)
AOLD(i,0)=AOLD(i,1);
for(k=0;k<M;k++)
AOLD(0,k)=AOLD(1,k);
1640
/*Update the time*/
t+=dt;
/*write the gradient at the biosensor at time-steps specified in the
1645 * parameters file. */
if ((j+1)%printSensorStep==0)
{
fprintf(outSensor,"%le\t",t);
for(k=K0;k<=K1;k++)
1650 fprintf(outSensor,"%1.20e\t",POLD(IC+1,k)/dx);
fprintf(outSensor,"\n%le\t",t);
for(i=0;i<=IC;i++)
fprintf(outSensor,"%1.20e\t",POLD(i,K1+1)/dz);
fprintf(outSensor,"\n",t);
1655 }
/*write analyte and product profiles to compressed files*/
if ((j+1)%printTimeStep==0)
{
1660 sprintf(fname,"%s-%f-Analyte.txt.gz",filename,t);
zf = zfopen(fname);
for(k=0;k<=M;k++)
{
if (k==EzE | | k==FzE)
1665 continue;
for(i=0;i<=N;i++)
{
if (i==A0E| |i==A1E)
continue;
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1670 sprintf(msg + strlen(msg),"%1.20e\t",AOLD(i,k));
if (strlen(msg)>MESG SIZE−100)
zprint(zf,msg);
}
sprintf(msg + strlen(msg),"\n");
1675 }
zfclose(zf,msg);
sprintf(fname,"%s-%f-Product.txt.gz",filename,t);
1680 zf = zfopen(fname);
for(k=0;k<=Wz;k++)
{
if (k==EzE | | k==FzE)
continue;
1685 for(i=0;i<=Wx;i++)
{
if (i==A0E| |i==A1E)
continue;
sprintf(msg + strlen(msg),"%1.20e\t",POLD(i,k));
1690 if (strlen(msg)>MESG SIZE−100)
zprint(zf,msg);
}
sprintf(msg + strlen(msg),"\n");
}
1695 zfclose(zf,msg);
}
}
/*write the final analyte and product profiles*/
1700 sprintf(fname,"%sFinalAnalyte.txt.gz",filename);
zf = zfopen(fname);
for(k=0;k<=M;k++)
{
if (k==EzE | | k==FzE)
1705 continue;
for(i=0;i<=N;i++)
{
if (i==A0E| |i==A1E)
continue;
1710 sprintf(msg + strlen(msg),"%1.20e\t",AOLD(i,k));
if (strlen(msg)>MESG SIZE−100)
zprint(zf,msg);
}
sprintf(msg + strlen(msg),"\n");
1715 }
zfclose(zf,msg);
sprintf(fname,"%sFinalProduct.txt.gz",filename);
zf = zfopen(fname);
1720 for(k=0;k<=Wz;k++)
{
if (k==EzE | | k==FzE)
continue;
for(i=0;i<=Wx;i++)
1725 {
if (i==A0E| |i==A1E)
continue;
sprintf(msg + strlen(msg),"%1.20e\t",POLD(i,k));
if (strlen(msg)>MESG SIZE−100)
1730 zprint(zf,msg);
}
sprintf(msg + strlen(msg),"\n");
}
zfclose(zf,msg);
1735
/*free memory allocated for the grid*/
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for(j=1;j<2;j++)
1740 {
for(i=0;i<=Wx;i++)
{
free(A[j][i]);
}
1745 for(;i<=N;i++)
free(A[j][i]);
}
for(j=0;j<2;j++)
{
1750 free(A[j]);
}
free(A);
/*Free all GSL vectors*/
1755 gsl vector free(MrDiag);
gsl vector free(MrUpper);
gsl vector free(MrLower);
gsl vector free(bk);
gsl vector free(MrDiagP);
1760 gsl vector free(MrUpperP);
gsl vector free(MrLowerP);
gsl vector free(bkP);
gsl vector free(MrDiagE);
gsl vector free(MrUpperE);
1765 gsl vector free(MrLowerE);
gsl vector free(bkE);
gsl vector free(MrDiagT);
gsl vector free(MrUpperT);
gsl vector free(MrLowerT);
1770 gsl vector free(bkT);
gsl vector free(MrDiagF);
gsl vector free(MrUpperF);
gsl vector free(MrLowerF);
gsl vector free(bkF);
1775 gsl vector free(xk);
gsl vector free(MzDiagF);
gsl vector free(MzUpperF);
gsl vector free(MzLowerF);
gsl vector free(biF);
1780 gsl vector free(MzDiagE);
gsl vector free(MzUpperE);
gsl vector free(MzLowerE);
gsl vector free(biE);
gsl vector free(MzDiagB);
1785 gsl vector free(MzUpperB);
gsl vector free(MzLowerB);
gsl vector free(biB);
gsl vector free(MzDiagT);
gsl vector free(MzUpperT);
1790 gsl vector free(MzLowerT);
gsl vector free(biT);
gsl vector free(xi);
gsl vector free(PzDiag);
gsl vector free(PzUpper);
1795 gsl vector free(PzLower);
gsl vector free(bPi);
gsl vector free(PzDiagP);
gsl vector free(PzUpperP);
gsl vector free(PzLowerP);
1800 gsl vector free(bPiP);
gsl vector free(xPi);
gsl vector free(PrDiag);
gsl vector free(PrUpper);
gsl vector free(PrLower);
1805 gsl vector free(bPk);
gsl vector free(PrDiagC);
gsl vector free(PrUpperC);
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gsl vector free(PrLowerC);
gsl vector free(bPkC);
1810 gsl vector free(xPk);
return 0;
}
1815
/*load the parameter values from a file*/
int readParameters(char *filename) readParameters
{
FILE *pf;
1820 pf = fopen(filename,"r");
if (pf==NULL)
return −1;
if (fscanf(pf,"dx=%lf\n",&dx)<0)
return −2;
1825 if (fscanf(pf,"dz=%lf\n",&dz)<0)
return −2;
if (fscanf(pf,"T=%lf\n",&T)<0)
return −2;
if (fscanf(pf,"dt=%le\n",&dt)<0)
1830 return −2;
if (fscanf(pf,"PrintProfileTimeStep=%i\n",&printTimeStep)<0)
return −2;
if (fscanf(pf,"PrintSensorTimeStep=%i\n",&printSensorStep)<0)
return −2;
1835 if (fscanf(pf,"Rb=%lf\n",&R0)<0)
return −2;
if (fscanf(pf,"w=%lf\n",&width)<0)
return −2;
if (fscanf(pf,"d=%lf\n",&dmg)<0)
1840 return −2;
if (fscanf(pf,"R3=%lf\n",&R3)<0)
return −2;
if (fscanf(pf,"depth=%lf\n",&depth)<0)
return −2;
1845 if (fscanf(pf,"inserted=%lf\n",&Pz)<0)
return −2;
if (fscanf(pf,"length=%lf\n",&length)<0)
return −2;
if (fscanf(pf,"D=%lf\n",&D)<0)
1850 return −2;
if (fscanf(pf,"Dp=%lf\n",&Dp)<0)
return −2;
if (fscanf(pf,"Lambda=%lf\n",&lambda)<0)
return −2;
1855 if (fscanf(pf,"Mu=%lf\n",&mu)<0)
return −2;
if (fscanf(pf,"Vb=%lf\n",&Vb)<0)
return −2;
if (fscanf(pf,"Vt=%lf\n",&Vt)<0)
1860 return −2;
if (fscanf(pf,"alphaB=%lf\n",&alphaB)<0)
return −2;
if (fscanf(pf,"alphaT=%lf\n",&alphaT)<0)
return −2;
1865
/*grid sizes including fake points for boundary and continuity conditions */
N = (int)ceil(R3/dx)+3;
M = (int)ceil(depth/dz)+4;
1870 /*boundaries between regions*/
R1=R0+width;
R2=R1+dmg;
Cz=Pz+length;
Ez=Cz+width;
1875 Fz=Ez+dmg;
fclose(pf);
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return 0;
}
1880 /*echo parameter values*/
int printParameters(FILE *fp) printParameters
{
fprintf(fp,"N=%i\n",N);
fprintf(fp,"M=%i\n",M);
1885 fprintf(fp,"T=%lf\n",T);
fprintf(fp,"dx=%le\n",dx);
fprintf(fp,"dz=%le\n",dx);
fprintf(fp,"dt=%le\n",dt);
fprintf(fp,"PrintProfileTimeStep=%i\n",printTimeStep);
1890 fprintf(fp,"PrintSensorTimeStep=%i\n",printSensorStep);
fprintf(fp,"Rb=%le\n",R0);
fprintf(fp,"w=%le\n",width);
fprintf(fp,"d=%le\n",dmg);
fprintf(fp,"R3=%le\n",R3);
1895 fprintf(fp,"depth=%le\n",depth);
fprintf(fp,"inserted=%le\n",Pz);
fprintf(fp,"length=%le\n",length);
fprintf(fp,"depth=%le\n",depth);
fprintf(fp,"D=%le\n",D);
1900 fprintf(fp,"Dp=%le\n",Dp);
fprintf(fp,"Lambda=%lf\n",lambda);
fprintf(fp,"Mu=%lf\n",mu);
fprintf(fp,"Vb=%lf\n",Vb);
fprintf(fp,"Vt=%lf\n",Vt);
1905 fprintf(fp,"A*=%lf\n",A0);
fprintf(fp,"alphaB=%lf\n",alphaB);
fprintf(fp,"alphaT=%lf\n",alphaT);
ﬄush(fp);
return 0;
1910 }
int main(int argc, char** argv) main
{
1915 FILE *outProfile, *outSensor,*outFinal;
int err;
if (argc<4)
{
fprintf(stderr, "Insufficient arguments.\n REQUIRED:\t parameterFile, sensorOutput profilePrefix A0 \n");
1920 return −1;
}
err=readParameters(argv[1]);
if (err==−1)
{
1925 fprintf(stderr,"Failed to open file %s.\n",argv[1]);
return −1;
}
else if (err==−2)
{
1930 fprintf(stderr,"Failed to read a parameter from %s.\n",argv[1]);
return −1;
}
if (D*dt/SQ(dx)>0.5 | | D*dt/SQ(lambda*dx)>0.5 | | MAX(D,Dp)*dt/SQ(mu*dx)>0.5)
1935 {
fprintf(stderr,
"Warning: Parameter give large CLT: \nD*dt/SQ(dx)>0.5\n(%le %le %le)\n",
D*dt/SQ(dx), D*dt/SQ(lambda*dx),D*dt/SQ(lambda*dx));
}
1940 outSensor = fopen(argv[2],"w");
if (outSensor == NULL)
{
fprintf(stderr,"Failed to open file %s.\n",argv[3]);
return −1;
1945 }
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A0=atof(argv[4]);
printParameters(stderr);
1950 /*Call the actual method*/
err = solver(outSensor,argv[3]);
fprintf(stderr, "Function returned: %i\n",err);
ﬄush(outSensor);
fclose(outSensor);
1955 return 0;
}
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